

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Prescription Medication Use According to Body Weight Classification for a Large Employer in the United States

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024078
Article Type:	Research
Date Submitted by the Author:	11-May-2018
Complete List of Authors:	Merrill, Ray; Brigham Young University, Public Health Fowers, Rylan; Brigham Young University
Keywords:	health risks, screening, prescription medication, health risk appraisal, body mass index, pharmaceutical costs

SCHOLARONE™
Manuscripts

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 Prescription Medication Use According to Body Weight Classification for a Large Employer in
16
17 the United States
18

19
20 Ray M. Merrill, PhD, MPH, Rylan P. Fowers, BS
21

22
23 Department of Public Health, College of Life Sciences, Brigham Young University
24
25
26
27
28
29
30
31

32 Corresponding Author:
33

34 Ray M. Merrill
35

36 Department of Public Health
37

38 2063 Life Sciences Building
39

40 Provo, Utah 84602
41

42 Email: Ray_Merrill@byu.edu
43

44 Telephone: 801-422-9788
45

46 Fax: 801-422-9363
47
48
49

50 Keywords: body mass index, obesity, prevention, pharmaceuticals, screening.
51

52 Word count: 2892
53
54
55
56
57
58
59
60

Objectives To identify the extent that body mass index is associated with the frequency and cost of 32 selected prescribed medications.

Methods Retrospective analysis of prescription medication use among 2531 workers employed all four academic years for a large employer in the United States, 2011-2014. Pharmaceutical and other data were available on each employee.

Results Those completing wellness screening were more likely women and younger. They were also significantly more likely to file a pharmaceutical claim each year. Higher body weight was significantly associated with a greater number of prescription claims for 11 of 32 (overweight vs. normal weight) and 21 of 32 (obese vs. normal weight) medications. The strongest positive association between body weight and prescription medications was for diabetes, high cholesterol, high blood pressure, and edema. Higher body weight was associated with less prescription medication for birth control, herpes, and osteoporosis. Pharmaceutical costs tend to increase with weight. For example, annual total cost for obese compared with normal weight individuals was significantly higher for acid reflux, anticonvulsants, asthma, depression, diabetes, edema, high blood pressure, muscle spasms, nausea/vomiting, opioids, statins, and thyroid, but significantly lower for birth control, herpes, and osteoporosis.

Conclusions This study shows an association between BMI and pharmaceutical costs for a large employer.

Strengths and limitations of this study

- Research has shown that obesity increases the use and cost for medications related to the cardiovascular system, gastrointestinal system, respiratory system, central nervous system, endocrine system, and more. The current study assessed the association between body mass index, primarily obesity, and several types of prescription

1
2
3 medication, more than previously considered.

- 4
5
6 • Some associations previously observed were confirmed, but a few were not found to be
7
8 significant in our study. Some new associations were identified, which were not
9
10 previously considered, including three in which obesity was associated with lower use
11
12 and cost of medication.
13
14
15 • The study design did not allow us to determine whether heavier weight led to
16
17 medication use or medication use led to greater weight.
18
19
20 • The study population and patterns of prescription drug use may limit generalization of
21
22 the results.
23
24

25 26 **Introduction**

27
28 Many companies offer wellness screening programs such as biometric screenings and health risk
29
30 assessments (questionnaires that ask about lifestyle, physical, and psychological health) to their
31
32 employees. The 2016 Employer Health Benefits Survey found that among large firms (200 or
33
34 more employees) in the United States, 59% offered health risk assessment (of which 32% had an
35
36 incentive component) and 53% offered biometric screening (of which 31% included an incentive
37
38 component).¹ These programs are intended to promote a greater sense of personal responsibility
39
40 for lifestyle choices, identify the need for health behavior change, reduce future health problems,
41
42 encourage patient management of existing health problems, decrease worker absenteeism, and
43
44 improve job satisfaction and worker productivity.²⁻⁷
45
46
47
48

49
50 Pharmaceuticals are often useful for preventing and managing health problems. For
51
52 example, antihypertensive medication, or statins, are useful in preventing cardiovascular
53
54 disease;⁸⁻¹⁰ multivitamins or folic acid for preventing congenital abnormalities;¹¹ aspirin and
55
56
57
58
59
60

1
2
3 non-steroidal anti-inflammatory for preventing colorectal cancer;¹² bronchodilators, steroids,
4 and anti-inflammatories for managing asthma;¹³ and nonsteroidal anti-Inflammatory drugs,
5 steroids, analgesics, and immunosuppressive drugs for managing arthritis.¹⁴ Consequently,
6
7 wellness screening may actually increase use of prescription medication.¹⁵ In addition to the
8
9 benefits of managing existing health problems, longer-term pharmaceutical costs associated with
10
11 more serious health problems may be avoided.
12
13
14
15

16
17 Although obesity is associated with increased risk for various chronic health conditions
18 and poorer health-related quality of life,^{16,17} only in the last 15 years or so has its impact on
19
20 healthcare expenditures been assessed.¹⁸ Further, only a small number of studies have explored
21
22 the association between body weight and prescription drug use. A study conducted in England
23
24 found that overweight and obese individuals were more likely to receive medication for the
25
26 cardiovascular system; gastrointestinal system; respiratory system; central nervous system;
27
28 endocrine system; gynecology/urinary disorders; musculoskeletal and joint disorders; infections;
29
30 eye, ear and oropharynx problems; and skin disorders.¹⁹ A study in Sweden showed that use and
31
32 cost of medication in general are significantly greater in obese individuals.²⁰ A study in the
33
34 United States found that obesity was responsible for \$7 billion in Medicare prescription drug
35
36 costs in 2006.²¹ Another study conducted in the United States identified increased medication use
37
38 during 1988 through 2012, with the increase most prominent among obese individuals.²² A large
39
40 cross-sectional study of 9789 adults in the National Health and Nutrition Examination Survey
41
42 (NHANES) found that obese individuals utilize several prescription drugs (e.g., hypertension,
43
44 lipid-lowering, and diabetes medications) more frequently than normal weight individuals.²³
45
46
47
48
49 Another study based on NHANES data found that while medication use increased over time for
50
51 obese compared with normal weight individuals ages 40 years and older, the increase was only
52
53
54
55
56
57
58
59
60

1
2
3 marginal for those aged 25-39 years.²⁴ One study found that obese individuals used more
4
5 analgesic, asthma, cardiovascular, diabetes, intranasal allergic rhinitis, thyroid, and ulcer
6
7 medications.²⁵
8
9

10 The purpose of this study is to identify the extent that body mass index is associated with
11
12 the frequency and total cost of 32 more commonly prescribed medications among employees.
13
14 These employees participated in wellness screening, which provided information about body
15
16 mass. Although studies have previously looked at the association between body mass index
17
18 (BMI) and prescription medications, we evaluate some drugs that have not been previously
19
20 considered, and the breadth of drugs covered is greater than in previous studies.
21
22
23
24
25

26 **Methods**

27
28 Analyses are based on employees of a large school district in the western United States involving
29
30 6 high schools, 8 junior high schools, and 31 elementary schools. The study involved the
31
32 academic years 2010-11, 2011-12, 2012-13, and 2013-14. Employees were offered wellness
33
34 screenings (personal health risk assessment and biometric evaluation) each fall. Pharmaceutical
35
36 claims data was also obtained for the employees in each academic year. Wellness screening and
37
38 pharmaceutical claims data were combined with an eligibility file of employees and assessed
39
40 within each academic year. The eligibility file contained information on current employment,
41
42 age, sex, and year.
43
44
45

46 **Wellness Screening**

47
48 Wellness screening consisted of a personal health risk assessment (HRA) and biometric
49
50 evaluation. All employees were offered wellness screening. Although participation was
51
52 voluntary, it was promoted through incentives. The HRA involved 36 questions. For the current
53
54
55
56
57
58
59
60

1
2
3 study, we only used information on self-rated health status, exercise, sleep, stress, fruit
4
5 consumption, vegetable consumption, and grain consumption. Self-rated health was based on the
6
7 question: “In general, how would you rate your overall health?” Participants responded on a
8
9 scale from 1 (low) to 10 (high). Exercise was based on the question: “During the past week, how
10
11 many days per week do you usually exercise?” Sleep was based on the question: “During the
12
13 past week, how many days did you get enough sleep so that you awoke feeling rested and
14
15 refreshed?” Stress was based on the question: “During the past 3 months, how often has your
16
17 normal daily routine been disrupted by stressful events? Fruit, vegetables, and grain
18
19 consumption, were determined as the number of servings per day.
20
21
22
23

24 Biometric screenings included measurements of body mass, blood pressure, cholesterol,
25
26 and glucose. They were provided at no cost to the employees and were made available to
27
28 employees on location or with a personal physician. A health nurse or physician assisted the
29
30 employee in interpreting their biometric measures. The current study only considers BMI.
31
32 Weight classifications are determined as follows: normal weight (BMI < 25), overweight (BMI
33
34 25-29), and obese (BMI 30+).
35
36
37

38 Pharmaceutical Claims Data

39
40
41 Pharmaceutical costs were adjusted to account for medical-cost inflation. Tom’s Medical-
42
43 Cost Inflation Calculator was used for this purpose. Annual average dollar (\$) pharmaceutical
44
45 cost and number of claims per eligible employee were obtained. In this study, cost represents the
46
47 amount paid by the company as well as copays by the employee.
48
49
50
51
52
53
54

55 Statistical Techniques

Counts, means, standard deviations, standard errors, and percentages were used to describe characteristics of the study population. Regression and Pearson's Correlation Coefficients were used to evaluate the association between selected variables. Because the use of pharmaceuticals tends to be greater in older employees and among women,^{26,27} we will adjust for these variables, along with year. Risk ratios were used to assess medication use for selected drugs according to weight classification. These ratios were adjusted using the Mantel-Haenszel method. Statistical significance was assessed using the p value and 95% confidence limits. Two-sided tests of significance were based on the 0.05 level against a null hypothesis of no association. Data was evaluated using the statistical software package PC-SAS (version 9.4; SAS Institute, Inc., 2014)

Results

In 2010-11, there were 3023 eligible employees, of which 2531 (83.72%) remained employed through the academic year 2013-14. The percentage of females was about the same for those remaining employed versus not, at about 73.2%. Mean age was 6.3 (SE = 0.2, $p < 0.0001$) years older for those continuously employed, averaging about 48.4 (SD = 10.4, range 18-78). The results of this study are based on those continuously employed over the four academic years.

Most employees participated in annual wellness screening (84.1% in 2010-11, 84.4% in 2011-12, 87.6% in 2012-13, and 80.7% in 2013-14). Women were 1.04 (95% CI 1.02- 1.06) times more likely than men to complete annual wellness screenings, after adjusting for age and year. Participants in wellness screening were significantly younger, on average (47.7 vs. 49.8, $p < 0.0001$), after adjusting for sex and year. Those participating in wellness screening filed more

1
2
3 pharmaceutical claims annually ($M = 10.6$ vs. 9.6 , $p = 0.0064$), but there was no significant
4
5 difference in mean annual total costs, after adjusting for age, sex, and year.
6
7

8 Participants in wellness screenings were asked how they would rate their overall health.
9
10 This variable was regressed on BMI, exercise, fruit, vegetables, grains, stress, sleep, age, sex,
11
12 and year. The variability in self-rated overall health was most strongly associated with BMI
13
14 (13.8% , $p < 0.0001$), followed by days exercised per week (8.6% , $p < 0.0001$), and days of
15
16 restful sleep per week (3.6% , $p < 0.0001$). Body mass was significantly correlated with exercise
17
18 ($r = -0.21$, $p < 0.0001$), fruit ($r = -0.04$, $p = 0.0146$), vegetables ($r = -0.05$, $p = 0.0013$), grains ($r =$
19
20 -0.05 , $p = 0.0030$), stress ($r = 0.05$, $p = 0.0014$), and sleep (-0.06 , $p < 0.0001$), after adjusting for
21
22 age, sex, and year.
23
24
25
26

27 The mean health rating was 8.4 for normal weight (BMI 18-24), 7.9 for overweight (BMI
28
29 25-29), and 7.1 for obese (BMI 30+), after adjusting for age, sex, and year. The percentage of
30
31 men and women in each of these BMI categories is presented in Table 1. Frequency and total
32
33 cost of pharmaceuticals increased with increasing weight for men and women. The distribution
34
35 of mean frequency and particularly total cost values are highly skewed, as indicated by their
36
37 comparison with the median scores.
38
39
40
41

42 The association between weight and annual frequency and total cost of pharmaceutical
43
44 claims is shown in Table 2. Overweight compared with normal weight participants were 1.10
45
46 times more likely to file 15 or more pharmaceutical claims per year versus no claims. Obese
47
48 compared with normal weight participants were 1.27 times more likely to file 15 or more
49
50 pharmaceutical claims per year versus no claims. Overweight compared with normal weight
51
52 participants were 1.08 times more likely to have annual pharmaceutical costs of \$1000 or more
53
54
55
56
57
58
59
60

1
2
3 per year than no costs. Obese compared with normal weight participants were 1.20 times more
4 likely to have annual pharmaceutical costs of \$1000 or more per year than no costs.
5
6
7

8 Overweight and obese individuals are significantly more likely to file a claim each year
9 for many types of medication (Table 3). Overweight individuals are significantly more likely
10 than normal weight individuals to file a claim for 11 of the 32 medications considered. Obese
11 individuals are more likely than normal weight individuals to file a claim for 21 of the selected
12 medications. The strongest positive association between weight and prescription medications is
13 for diabetes, high cholesterol, high blood pressure, and edema. Overweight individuals were less
14 likely to receive medication for birth control or osteoporosis. Higher body weight lowers the
15 need for medications associated birth control, herpes, and osteoporosis. For all prescription
16 medications, obese are 1.05 (95% CI 1.02-1.07) times more likely than normal weight
17 individuals to file a claim (population attributable fraction 3.77), adjusting for age, sex, and year.
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 We also report the population attributable fraction (population attributable risk percent)
33 in the table. For example, this statistic says that 3.78% of diabetes medication is attributed to
34 being overweight and 6.62% of diabetes medication is attributed with being obese. Where the
35 risk ratio is less than 1, we estimated the preventive fraction. For example, 15% more birth
36 control medication would have been prescribed in the absence of obesity. However, these
37 statistics imply a cause-and-effect association between exposure and disease.
38
39
40
41
42
43
44
45

46 Annual total cost for the selected medications according to weight classification is shown
47 in Table 4. Pharmaceutical cost tends to increase with weight. Overall, obese individuals have
48 significantly greater annual total cost than normal weight individuals. Annual total cost for obese
49 individuals is significantly greater than normal weight individuals for acid reflux,
50
51
52
53
54
55
56
57
58
59
60 anticonvulsants, asthma, depression, diabetes, edema, high blood pressure, muscle spasms,

1
2
3 nausea/vomiting, opioids, statins, and thyroid. Annual total cost for obese individuals is
4 significantly greater than overweight individuals for anticonvulsants, diabetes, high blood
5 pressure, inflammation, muscle spasms, and thyroid. On the other hand, annual total cost for
6 obese individuals is significantly lower than normal weight individuals for birth control, herpes,
7 and osteoporosis. Annual total cost for obese individuals is significantly lower than overweight
8 individuals for herpes. The average annual total cost for all prescription medications was 691.4
9 for normal weight, 843.2 for overweight, and 910.9 for obese, adjusting for age, sex and year.
10
11 The difference between normal weight and obese was significant ($p = 0.0208$).
12
13
14
15
16
17
18
19
20
21
22
23

24 Discussion

25
26 The current study identified the degree to which increasing body weight is associated
27 with frequency and cost of 32 types of medication. We found positive associations between body
28 weight and higher use of medications for treating acid reflux, arthritis, asthma, bacterial
29 infections, cardiovascular disease, blood coagulation, colds, flu, allergies, depression, diabetes,
30 edema, high blood pressure, inflammation, muscle spasms, pain, stomach acid, thyroid, and
31 ulcers. Other studies have identified a similar association between body weight and some of the
32 medications used to treat these conditions.^{19, 22, 23, 25} Obese individuals were also more likely to
33 be prescribed vitamins and minerals. We did not find an association between body weight and
34 increased use of medication for the bowel/rectum, skin, or urinary tract, which was counter to
35 that found in other studies.^{19, 28-30} We also assessed but did not find a significant association for
36 medications used to treat anxiety, fungus, seizures, or teeth and gums, although the number
37 receiving medication for teeth and gums were small. Finally, we assessed the association
38 between body weight and medications used to treat birth control, herpes, and osteoporosis, for
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 which significant negative associations were found. We are not aware of other studies that have
4
5 looked at the association between body weight and medications used for coagulation of blood,
6
7 colds, flu, depression, edema, birth control, herpes, or osteoporosis.
8
9

10 For those medications in which there was a significant positive or negative association
11
12 with body weight, some showed no significant association with annual total cost. This was the
13
14 case for bacterial infections, coagulation of blood, eye infection, and ulcers. This is likely due to
15
16 the high variability in the annual total cost data. For bacterial infections, the coefficient of
17
18 variation is 6.1 for normal weight, 14.4 for overweight, and 4.3 for obese; for coagulation of
19
20 blood the coefficient of variation is 29.7 for normal weight, 37.4 for overweight, and 11.6 for
21
22 obese; for eye infection, the coefficient of variation is 6.2 for normal weight, 4.8 for overweight,
23
24 and 5.1 for obese; and for ulcers, the coefficient of variation is 14.6 for normal weight, 20.6 for
25
26 overweight, and 10.8 for obese. In addition, the increased use of medication among those with
27
28 bacterial or eye infections was relatively small.
29
30
31
32
33

34 Increased use of medication for acid reflux or stomach acid among obese individuals is
35
36 consistent with previous research that showed greater reflux disease hospitalization rates with
37
38 higher BMI.^{31, 32} Another study found that higher BMI is associated with increased
39
40 gastroesophageal reflux in both normal and overweight individuals.³³ Greater weight can add
41
42 pressure to the stomach and diaphragm, thereby resulting in reflux. Further, increased use of
43
44 medication for nausea/vomiting among obese individuals is consistent with other research
45
46 associating increasing BMI with nausea/vomiting.³⁴
47
48
49

50 The positive association between being overweight or obese with increased use of
51
52 medication for ulcers is consistent with other research, particularly peptic (gastric and duodenal)
53
54 ulcers.^{35, 36} The mechanism to explain the association between obesity and peptic ulcer disease
55
56
57
58
59
60

1
2
3 remains unclear. Obesity is also associated with *Helicobacter pylori*, which has been linked with
4
5 gastric ulcers.³⁷
6
7

8 Overweight and obese individuals had a higher use of medication for inflammation.
9
10 Overweight and especially obese individuals are at greater risk for chronic inflammation, which
11
12 can compromise the immune system. As such, overweight and obese individuals are at greater
13
14 risk for infections.³⁸⁻⁴⁰ This is consistent with our results that show increased use of antibiotics
15
16 and medication for eye infections among obese individuals. However, research has shown that
17
18 antibiotics can also weaken the immune system,⁴¹ as well as lead to obesity.⁴² Some chronic
19
20 inflammatory diseases known to be associated with obesity in which we found a positive
21
22 association between obesity and medication included influenza,^{43, 44} heart disease,⁴⁵ diabetes,⁴⁶
23
24 allergies,⁴⁷⁻⁵⁰ asthma,⁵¹ edema,⁵²⁻⁵⁴ and arthritis.⁵⁵⁻⁵⁸ A compromised immune system may also
25
26 trigger autoimmune diseases, including rheumatoid arthritis and thyroid disease,⁵⁹ as indicated in
27
28 the current study.
29
30
31
32
33

34 Overweight and obese individuals were more likely to receive cold, flu, or allergy
35
36 medication. Obesity is associated with impaired immune response to influenza vaccination in
37
38 humans.⁶⁰ Because vaccination is less successful for obese individuals, a greater level of
39
40 medication may be sought for treating colds, flu, and allergies.
41
42
43

44 Overweight and obese individuals received higher levels of pain medication. Research
45
46 indicates that the nature of the relationship between higher BMI and pain is likely indirect.⁶¹ For
47
48 example, greater body weight is associated with osteoarthritis, which, in turn, leads to pain.⁶²
49
50 Being overweight or obese may result in greater risk for back pain, joint pain, and muscle
51
52 spasms.⁶³ One study also found that obese individuals were more sensitive than those of normal
53
54 weight to pressure pain.⁶⁴
55
56
57
58
59
60

1
2
3 We found that overweight and obese individuals were more likely to receive depression
4 medication than those of normal weight. This is consistent with previous research.⁶⁵⁻⁶⁸ The age-
5 adjusted percentage of adults in the United States ages 20 years and older who were obese was
6 43.2 for those with depression compared with 33.0 for those with no depression.⁶⁹ It may be that
7 higher use of prescription medication for depression among overweight and obese individuals is
8 because these people are more likely to experience other conditions related to depression, such as
9 heart disease and diabetes.⁷⁰⁻⁷²

10
11
12
13
14
15
16
17
18
19
20 Obese individuals filed more claims for vitamins and minerals. Previous research has
21 associated low vitamin B12 with being overweight or obesity.⁷³ Vitamin B assists the body in
22 metabolizing fats, carbohydrates, and protein, as well as helps with appetite control. Deficiency
23 in vitamin B can cause anemia or nervous conditions. Another study found that the prevalence of
24 vitamin D deficiency was 35% greater in obese individuals.⁷⁴ Vitamin D assists the body to
25 absorb calcium and promote bone growth, whereas deficiency causes soft bones and depression.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Among the vitamin or mineral claims filed in the current study, 8.0% involved vitamin B and
57.3% involved vitamin D.

References

1. 2016 Employer Health Benefits Survey. kff.org. <http://www.kff.org/health-costs/report/2016-employer-health-benefits-survey/>. Published September 14, 2016. Accessed February 21, 2018.
2. Chen L, Hannon PA, Laing SS, Kohn MJ, Clark K, Pritchard S, Harris JR. Perceived workplace health support is associated with employee productivity. *Am J Health Promot.* 2015;29(3):139-146.

- 1
2
3 3. Centers for Disease Control and Prevention. [cdc.gov](http://www.cdc.gov).
4
5 <http://www.cdc.gov/sustainability/worksitewellness/> Worksite wellness. Updated December
6
7 9, 2014. Accessed March 18, 2018.
8
9
- 10 4. Michaels CN, Greene AM. Worksite wellness: increasing adoption of workplace health
11
12 promotion programs. *Health Promot Pract*. 2013;14(4):473-479.
13
- 14 5. Witt LB, Olsen D, Ablah E. Motivating factors for small and mid-sized businesses to
15
16 implement worksite health promotion. *Health Promot Pract*. 2013;14(6), 876-884.
17
18
- 19 6. Niessen MA, Kraaijenhagen RA, Dijkgraaf MG, van Pelt D, van Kalken CK, Peek N. Impact
20
21 of a Web-based worksite health promotion program on absenteeism. *J Occup Environ Med*.
22
23 2012;54(4):404-408.
24
25
- 26 7. Kaspin LC, Gorman KM, Miller RM. Systematic review of employer-sponsored wellness
27
28 strategies and their economic and health-related outcomes. *Popul Health Manag*. 2013;16(1):
29
30 14-21.
31
32
- 33 8. Karmali KN, Lloyd-Jones DM, Berendsen M, et al. Drugs for primary prevention of
34
35 atherosclerotic cardiovascular disease: an overview of systematic reviews. *JAMA Cardiol*.
36
37 2016;1(3):341-349.
38
39
- 40 9. Fretheim A, Odgaard-Jensen, Brørs O, Madsen S, et al. Comparative effectiveness of
41
42 antihypertensive medication for primary prevention of cardiovascular disease: systematic
43
44 review and multiple treatments meta-analysis. *BMC Med*. 2012;10:33.
45
46
- 47 10. Taylor F, Huffman MD, Macedo A, et al. Statins for the primary prevention of
48
49 cardiovascular disease. *Cochrane*. 2013. [http://www.cochrane.org/CD004816/VASC_statins-](http://www.cochrane.org/CD004816/VASC_statins-primary-prevention-cardiovascular-disease)
50
51 [primary-prevention-cardiovascular-disease](http://www.cochrane.org/CD004816/VASC_statins-primary-prevention-cardiovascular-disease). Accessed February 21, 2018.
52
53
- 54 11. Czeizel AE. Birth defects are preventable. *Int J Med Sci*. 2005;2(3):91-92.
55
56
57
58
59
60

12. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. *Gastroenterology*. 2010;138(6):2029-2043.
13. Asthma. Mayo Clinic. <https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-treatment/drc-20369660>. Published March 9, 2018. Accessed February 24, 2018.
14. Arthritis. Mayo Clinic. <https://www.mayoclinic.org/diseases-conditions/arthritis/diagnosis-treatment/drc-20350777>. Published March 7, 2018. Accessed February 24, 2018.
15. Preventive Medicine Reports Paper
16. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic consequences of obesity. *Arch Intern Med*. 1999;119(18):2177-2183.
17. Pi-Sunyer X. The medical risks of obesity. *Postgrad Med*. 2009;121(6):21-33.
18. Arterburn DE, Maciejewski ML, Tsevat J. Impact of morbid obesity on medical expenditures in adults. *Int J Obes*. 2005;29(3):334-9.
19. Kinge JM, Morris S. Association between obesity and prescribed medication use in England. *Econ Hum Biol*. 2014;15:47-55.
20. Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. *Arch Intern Med*. 2002;162(18):2061-2069.
21. Finkelstein EA, Trogon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. *Health Aff*. 2009;28(5):w822-31.
22. Randhawa AK, Parikh JS, Kuk JL. Trends in medication use by body mass index and age between 1988 and 2012 in the United States. *PLoS One*. 2017 Sep 20;12(9):e0184089.
23. Kit BK, Ogden CL, Flegal KM. Prescription medication use among normal weight, overweight, and obese adults, United States, 2005-2008. *Ann Epidemiol*. 2012;22(2):112-9.

24. Jarrett B, Bloch GJ, Bennett D, Bleazard B, Hedges D. The influence of body mass index, age and gender on current illness: a cross-sectional study. *Int J Obes*. 2010;34(3):429-36.
25. Raebel MA, Malone DC, Conner DA, Xu S, Porter JA, Lanty FA. Health services use and health care costs of obese and nonobese individuals. *Arch Intern Med*. 2004;164(19):2135-40.
26. Metge C, Black C, Peterson S, Kozyrskyi AL. The population's use of pharmaceuticals. *Med Care*. 1999;37(6 Suppl):JS42-JS59.
27. Bertakis K, Azari R, Helms L, Callahan E, Robbins J. Gender differences in the utilization of health care services. *J Fam Pract*. 2000;49(2):147-152.
28. Ma Y, Yang Y, Wang F, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. *PLoS One* 2013;8(1):e53916.
29. Brown J, Wimpenny P, Maughan H. Skin problems in people with obesity. *Nurs Stand*. 2004;18(35):38-42.
30. Semins MJ, Shore AD, Makary MA, Weiner J, Matlaga BR. The impact of obesity on urinary tract infection risk. *Urology*. 2012;79(2):266-9.
31. Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup Study. First National Health and Nutrition Examination Survey. *Ann Epidemiol*. 1999;9(7):424-35.
32. Anggiansah R, Sweis R, Anggiansah A, Wong T, Cooper D, Fox M. The effects of obesity on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux disease. *Alim Pharmacol Ther*. 2013;37(5):555-563.

- 1
2
3 33. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Association between body
4 mass index and gastroesophageal reflux symptoms in both normal weight and overweight
5 women. *N Engl J Med*. 2006;354(22):2340-2348.
6
7
8
9
10 34. Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in
11 young adults: a birth cohort study. *Am J Gastroenterol* 2004;99(9):1807-1814.
12
13
14 35. Boylan MR, Khalili H, Huang ES, Chan AT. Measures of adiposity are associated with
15 increased risk of peptic ulcer. *Clin Gastroenterol Hepatol*. 2014 Oct;12(10):1688-1694.
16
17
18
19 36. Kim J, Kim KH, Lee BJ. Association of peptic ulcer disease with obesity, nutritional
20 components, and blood parameters in the Korean population. *PLoS One*. 2017;12(8):
21 e0183777.
22
23
24
25
26 37. Xu M, Liu L, Yuan B, Yin J, Lu Q. Association of obesity with *Helicobacter pylori* infection:
27 A retrospective study. *World J Gastroenterol* 2017;23(15):2750-2756.
28
29
30
31 38. Falagas ME, Kompoti M. Obesity and infection. *Lancet Infect Dis* 2006;6(7):438-46.
32
33
34 39. Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. *Int J Obes*.
35 2013;37:333-340.
36
37
38 40. Lübbecke A, Zingg M, Hoffmeyer P, et al. Body mass and weight thresholds for increased
39 prosthetic joint infection rates after primary total joint arthroplasty. *Acta Orthopaedica*.
40 2016;87(2):132-138
41
42
43
44 41. Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ. Antibiotic-induced
45 changes to the host metabolic environment inhibit drug efficacy and alter immune function.
46 *Cell Host & Microbe*. 2017;22(6):757-765.
47
48
49
50
51 42. Early G. Current Evidence regarding antibiotic exposure and childhood obesity: an
52 integrative review. *Ped Nurs*. 2017;43(4):169-174.
53
54
55
56
57
58
59
60

- 1
2
3 43. Bandaru P, Rajkumar H, Napanveettil G. The impact of obesity on immune response to
4 infection and vaccine: an insight into plausible mechanisms. *Endocrinol Metab Synd*
5 2013;2:2.
6
7
8
9
10 44. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during
11 influenza seasons in Ontario, Canada: a cohort study. *Clin Infect Dis*. 2011;53(5):413-421.
12
13
14 45. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease.
15 *Mediators Inflamm*. 2010;2010:535918.
16
17
18
19 46. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent
20 advances in the relationship between obesity, inflammation, and insulin resistance. *Eur*
21 *Cytokine Netw*. 2006;17(1):4-12.
22
23
24
25
26 47. Ciprandi G, Pistorio A, Tosca M, Ferraro MR, Cirillo I. Body mass index, respiratory
27 function and bronchial hyperactivity in allergic rhinitis and asthma. *Respir Med*
28 2009;103(2):289-295.
29
30
31
32
33 48. Gorgievska-Sukarovska B, Lipozencić J, Susac A. Obesity and allergic diseases. *Acta*
34 *Dermatovenerol Croat*. 2008;16(4):231-235.
35
36
37
38 49. Shah R, Yang Y. Health and economic burden of obesity in elderly individuals with asthma
39 in the United States. *Popul Health Manag* 2015;18(3):186-91.
40
41
42
43 50. Guo Y, Moon JY, Laurie CC, et al. Genetic Predisposition to Obesity is associated
44 with Asthma in US Hispanics/Latinos: Results from the Hispanic Community Health
45 Study/Study of Latinos. *Allergy*. 2018;doi: 10.1111/all.13450. [Epub ahead of print]
46
47
48
49 51. Rodriguez D. Obesity and Asthma – What’s the Connection.
50
51 <https://www.everydayhealth.com/asthma/obesity-connection.aspx>. Published August 28,
52 2013. Accessed April 12, 2018.
53
54
55
56
57
58
59
60

- 1
2
3 52. Greene, A.K., et al. Lower-Extremity Lymphedema and Elevated Body-Mass Index. *N Engl*
4
5 *J Med.* 2012;366:2136-2137.
6
7
8 53. Helyer, L.K., et al. Obesity is a risk factor for developing postoperative lymphedema in
9
10 breast cancer patients. *Breast J.* 2012;16(1):48-54.
11
12 54. Greene AK, Grant FD, Slavin SA, Maclellan RA. Obesity-induced lymphedema: clinical and
13
14 lymphoscintigraphic features. *Plast Reconstr Surg.* 2015;135(6):1715-1719.
15
16
17 55. King LK, March L, Anandacoomarasamy A. Obesity & osteoarthritis. *Indian J Med Res.*
18
19 2013;138(2):185-193.
20
21
22 56. Baodong Qin, Min Yang, Haitao Fu, et al. Body mass index and the risk of rheumatoid
23
24 arthritis: a systematic review and dose-response meta-analysis. *Arthritis Res Ther.*
25
26 2015;17(1):86.
27
28
29 57. Feng J, Chen Q, Yu F, et al. Body mass index and risk of rheumatoid arthritis: a meta-
30
31 analysis of observational studies. *Medicine.* 2016;95(8):e2859.
32
33
34 58. Albrecht K, Richter A, Callhoff J, et al. Body mass index distribution in rheumatoid arthritis:
35
36 a collaborative analysis from three large German rheumatoid arthritis databases. *Arthritis Res*
37
38 *Ther.* 2016;18:149.
39
40
41 59. Rodriguez D. How Your Immune System Worsens Arthritis. *EverydayHealth.com.*
42
43 <https://www.everydayhealth.com/arthritis/understanding/the-immune-system.aspx>. Published
44
45 August 1, 2012. Accessed April 11, 2018.
46
47
48 60. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response
49
50 to influenza vaccination in humans. *Int J Obes.* 2012;36(8):1072-1077.
51
52
53 61. Okifuji A, Hare BD. The association between chronic pain and obesity. *J Pain Res.*
54
55 2015;8:399-408.
56
57
58
59
60

- 1
2
3 62. Erdmann J. Osteoarthritis and Obesity. www.arthritis.org. [https://www.arthritis.org/living-](https://www.arthritis.org/living-with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php)
4 with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php. Accessed April
5 11, 2018.
6
7
8
9
10 63. American Obesity Association. Health effects of obesity. AOA Fact Sheets. 2002.
11
12 64. Tashani OA, Asitita R, Sharp D, Johnson MI. Body mass index and distribution of body fat
13 can influence sensory detection and pain sensitivity. *Eur J Pain* 2017;21(7):1186-1196.
14
15 65. Rathee N. Obesity and depression: Are they related? *Indian J Health Well*. 2017;8(12):1472-
16 1475.
17
18 66. Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH. Depression and anxiety among
19 US adults: associations with body mass index. *Int J Obesity*. 2009;33(2):257-266.
20
21 67. Onyike CU, Crum RM, Lee HB, Lyketsos DG, Eaton WW. Is obesity associated with major
22 depression? Results from the Third National Health and Nutrition Examination Survey. *Am J*
23 *Epidemiol*. 2003;158(12):1139-1147.
24
25 68. Petry NM, Barry D, Pietrzak RH, Wagner JA. Overweight and obesity are associated with
26 psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and
27 Related Conditions. *Psychosom Med*. 2008;70(3):288-297.
28
29 69. Pratt LA, Brody DJ. Depression and obesity in the U.S. adult household population, 2005-
30 2010. NCHS Data Brief, No. 167, October 2014.
31
32 70. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood
33 disorders and obesity related? A review for the mental health professional. *J Clin Psychiatry*
34 2004;65(5):634-651.
35
36 71. Ferraro KF, Su Y, Gretebeck RJ, Black DR, Badylak SF. Body mass index and disability in
37 adulthood: A 20-year panel study. *Am J Public Health*. 2002;92(5):834-840.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 72. Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. *J*
4
5 *Psychosom Res.* 2002;53(4):859-863.
6
7
8 73. Baltaci D, Kutlucan A, Turker Y, et al. Association of vitamin B12 with obesity, overweight,
9
10 insulin resistance and metabolic syndrome, and body fat composition; primary care-based
11
12 study. *Med Glas.* 2013;10(2):203-210.
13
14
15 74. Pereira-Santos M¹, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin D
16
17 deficiency: a systematic review and meta-analysis. *Obes Rev.* 2015;16(4):341-349.
18
19

20 Footnotes

21
22
23 Contributors: RMM conceived and designed the epidemiological study, contributed to
24
25 acquisition of data, analyzed and interpreted the data, and drafted the manuscript. RPF
26
27 interpreted the data, provided a literature review, and revised the manuscript. Both authors
28
29 critically revised the manuscript for important intellectual content. The manuscript has been read
30
31 and approved by both authors.
32
33

-
- 34
35 • Funding: The authors have not declared a specific grant for this research from any funding
36
37 agency in the public, commercial or not-for-profit sectors.
38
39
 - 40 • Competing interests: None declared.
41
42
 - 43 • Patient consent: Not required.
44
45
 - 46 • Ethics approval: Study approval was obtained from the institutional review board at Brigham
47
48 Young University (IRB E1 5259).
49
50
 - 51 • Provenance and peer review: Not commissioned; externally peer reviewed.
52
53
 - 54 • Data sharing statement: The data sets used and analyzed in the current study are available from
55
56 the corresponding author on reasonable request at: Ray_Merrill@byu.edu.
57
58

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Mean Frequency and Total Cost of Pharmaceuticals According to Classifications of Body Mass Index and Sex in Wellness Screening Participants

Weight	Men							Women						
	%	Frequency Mean	Pr > t	Median	Total Cost Mean	Pr > t	Median	%	Frequency Mean	Pr > t	Median	Total Cost Mean	Pr > t	Median
Normal weight BMI < 25	21.0	6.3	< .0001	2	744.3	0.7844	23.3	44.2	10.5	< .0001	7	900.0	0.0431	216.0
Overweight BMI 25-29	42.3	7.9	< .0001	4	746.5	0.7979	66.1	28.5	13.2	0.0003	8	1005.1	0.3032	255.7
Obese BMI 30+	36.6	10.2	0.0000	5	813.1	0.0000	81.6	27.2	15.0	0.0000	11	1137.3	0.0000	320.3
P value				< 0.001			< 0.001				< 0.001			< 0.0001

Means are adjusted for age and year. Differences in the median values were assessed for statistical significance using the median one-way analysis chi-square test.

Table 2. Frequency and Total Cost of Pharmaceutical Medication for Overweight and Obese Compared with Normal Weight
Participants in Wellness Screening

Frequency								Total Cost							
		Overweight vs Normal Weight			Obese vs Normal Weight					Overweight vs Normal Weight			Obese vs Normal Weight		
No.	%	Risk Ratio	95% LCL	95% UCL	Risk Ratio	95% LCL	95% UCL	\$	%	Risk Ratio	95% LCL	95% UCL	Risk Ratio	95% LCL	95% UCL
0	21.64	0.00			0.00			0	21.64	0.00			0.00		
1-4	20.62	0.96	0.89	1.05	0.94	0.85	1.02	1-99	21.33	0.97	0.89	1.05	0.99	0.91	1.07
5-9	17.14	0.92	0.84	1.01	0.94	0.85	1.03	100-499	25.31	0.99	0.93	1.07	1.10	1.03	1.18
10-14	13.03	1.06	0.94	1.18	1.17	1.05	1.31	500-999	11.67	1.05	0.93	1.18	1.21	1.07	1.36
15+	27.57	1.10	1.03	1.18	1.27	1.20	1.36	1000+	20.05	1.08	1.00	1.18	1.20	1.11	1.30

LCL: Lower Confidence Level; UCL: Upper Confidence Level. Risk ratios and confidence intervals adjusted for age, sex, and year.

Table 3. Medication Use According to Weight Classification in Wellness Screening Participants

Medication	%	Overweight vs Normal Weight			Population Attributable Fraction	Obese vs Normal Weight			Population Attributable Fraction
		Risk Ratio	95% LCL	95% UCL		Risk Ratio	95% LCL	95% UCL	
Acid Reflux	5.43	1.23	0.96	1.57		1.69	1.34	2.12	3.61
Antibiotic	20.98	1.03	0.93	1.15		1.16	1.04	1.29	3.25
Anticonvulsants	1.38	0.82	0.48	1.40		1.32	0.83	2.11	
Antifungal	4.94	0.82	0.64	1.05		1.23	0.99	1.54	
Anxiety	7.55	0.99	0.82	1.20		0.99	0.81	1.20	
Arthritis	10.98	1.07	0.90	1.26		1.52	1.31	1.77	5.40
Asthma	8.54	1.46	1.20	1.77	3.78	1.83	1.52	2.21	6.62
Birth Control	7.98	0.95	0.81	1.11		0.85	0.72	1.00	15.00*
Blood Thinner	1.15	1.84	0.94	3.61		4.24	2.30	7.81	3.59
Bowel/Rectum	2.95	0.85	0.62	1.19		0.93	0.68	1.29	
Cold/Flu/Allergy	17.75	1.20	1.06	1.35	3.43	1.34	1.19	1.51	5.69
Depression	17.78	1.21	1.07	1.36	3.60	1.36	1.21	1.53	6.02
Diabetes	6.03	2.48	1.84	3.34	8.19	5.34	4.07	7.01	20.74
Edema	5.03	1.58	1.21	2.07	2.83	2.74	2.15	3.48	8.05
Eye Infection	11.87	1.13	0.98	1.33	1.52	1.30	1.12	1.50	3.44
Herpes	5.99	1.07	0.89	1.29	0.42	0.57	0.45	0.72	43.00*
High Blood Pressure	16.02	1.71	1.48	1.99	10.21	2.66	2.32	3.05	21.01
Inflammation	4.51	1.32	1.02	1.73	1.42	1.40	1.08	1.83	1.77
Insomnia	3.99	1.05	0.82	1.36		1.01	0.78	1.32	
Muscle Spasms	4.31	1.40	1.06	1.85	1.69	1.83	1.40	2.41	3.45
Nausea/Vomiting	4.86	1.24	0.95	1.61		1.62	1.27	2.08	2.93
Opioids	16.79	1.18	1.03	1.35	2.93	1.61	1.42	1.82	9.29
Osteoporosis	1.08	0.94	0.60	1.50		0.50	0.29	0.89	50.00*
Pain – non opioid	2.15	1.08	0.71	1.61		1.65	1.14	2.39	1.38
Skin	6.86	0.91	0.74	1.12		0.97	0.79	1.19	
Statins	11.93	2.32	1.94	2.78	13.61	2.84	2.39	3.37	18.00
Stomach Acid	1.17	1.14	0.65	1.99		2.02	1.23	3.31	1.18
Teeth/Gums	0.43	1.80	0.73	4.44		1.40	0.53	3.67	
Thyroid	12.79	1.09	0.96	1.25		1.23	1.08	1.40	2.86
Ulcers	9.33	1.30	1.09	1.55	2.72	1.52	1.28	1.80	4.63
Urinary Tract Infection	3.23	0.98	0.73	1.31		1.14	0.86	1.51	
Vitamins/Minerals	2.98	0.84	0.54	1.31		1.49	1.01	2.19	1.44

Note: Risk ratios and confidence intervals adjusted for age, sex, and year.

*Preventive Fraction.

Table 4. Total Annual Cost for Selected Medications According to Weight Classification

	Normal	Overweight	Obese		Normal	Overweight	Obese
Medication	Mean	Mean	Mean	Medication	Mean	Mean	Mean
Acid Reflux	3.51	15.84	14.94	High Blood Pressure	11.5	40.0	55.4
p value	0.0029	0.3115	.	p value	<.0001	0.013	.
Antibiotic	12.20	15.34	13.09	Inflammation	8.25	13.61	5.66
p value	0.8280	0.5933	.	p value	0.4421	0.0210	.
Anticonvulsants	8.82	5.63	20.01	Insomnia	2.7	4.6	2.8
p value	0.0198	0.0034	.	p value	0.9644	0.3237	.
Antifungal	0.74	2.11	2.22	Muscle Spasms	0.1	0.4	3.9
p value	0.0628	0.8977	.	p value	0.0025	0.0172	.
Anxiety	1.2	1.6	1.1	Nausea/Vomiting	0.2	1.1	1.0
p value	0.7948	0.1226	.	p value	0.007	0.6432	0
Arthritis	139.2	126.4	125.2	Opioids	2.6	7.4	9.5
p value	0.7593	0.9788	.	p value	<0.0001	0.1618	.
Asthma	32.0	38.4	46.5	Osteoporosis	5.1	2.9	0.3
p value	0.0256	0.2263	.	p value	0.0505	0.2597	.
Birth Control	39.1	32.1	25.8	Pain – Non Opioid	3.16	2.03	0.38
p value	0.0005	0.1049	.	p value	0.1552	0.3440	.
Blood Thinner	8.03	14.90	12.23	Skin	6.08	4.69	4.91
p value	0.6338	0.7675	.	p value	0.3537	0.8636	.
Bowels/Rectum	21.6	25.1	20.8	Statins	7.9	23.9	31.2
p value	0.9168	0.5598	.	p value	<.0001	0.1066	.
Cold/Flu/Allergy	13.9	21.1	17.5	Stomach Infection	2.61	1.88	2.25
p value	0.1763	0.1818	.	p value	0.7248	0.4936	.
Depression	31.2	53.7	57.5	Teeth/Gums	0.04	0.04	0.02
p value	0.0009	0.6405	.	p value	0.4433	0.4458	.
Diabetes	24.1	55.5	130.7	Thyroid	5.9	7.6	10.1
p value	<.0001	<.0001	.	p value	0.0003	0.0356	.
Edema	0.6	3.0	3.4	Ulcers	0.6	6.8	4.0
p value	0.0006	0.6529	.	p value	0.1366	0.3589	.
Eye Infection	4.4	4.8	4.2	Urinary Tract Infection	1.49	0.95	1.71
p value	0.7459	0.6384	.	p value	0.7002	0.1915	.
Herpes	14.43	15.02	7.63	Vitamins/Minerals	0.3	1.5	0.9
p value	0.0145	0.0094	.	p value	0.251	0.3174	.

Means adjusted for age, sex, and year.

BMJ Open

To what extent does sex, age, and BMI impact medical and pharmacy costs? A retrospective cohort study involving employees in a large school district

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024078.R1
Article Type:	Research
Date Submitted by the Author:	21-Nov-2018
Complete List of Authors:	Merrill, Ray; Brigham Young University, Public Health Fowers, Rylan; Brigham Young University
Primary Subject Heading:	Pharmacology and therapeutics
Secondary Subject Heading:	Public health, Epidemiology
Keywords:	health risks, screening, prescription medication, health risk appraisal, body mass index, pharmaceutical costs

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 **To what extent does sex, age, and BMI impact medical and pharmacy costs? A**
16 **retrospective cohort study involving employees in a large school district**
17
18

19
20 Ray M. Merrill, PhD, MPH, Rylan P. Fowers, BS
21

22
23 Department of Public Health, College of Life Sciences, Brigham Young University
24
25
26
27
28
29
30
31

32 Corresponding Author:
33

34 Ray M. Merrill
35

36 Department of Public Health
37

38 2063 Life Sciences Building
39

40 Provo, Utah 84602
41

42 Email: Ray_Merrill@byu.edu
43

44 Telephone: 801-422-9788
45

46 Fax: 801-422-9363
47
48
49

50 Keywords: body mass index, obesity, prevention, pharmaceuticals, screening
51

52 Word count: 3527
53
54
55
56
57
58
59
60

1
2
3 **Objective** To identify the extent that sex, age, and body mass index (BMI) is associated with
4
5 medical and pharmacy costs.
6

7
8 **Design** Retrospective cohort.
9

10 **Setting** A school district in the Western United States involving 2531 workers continuously
11
12 employed during 2011-2014.
13

14 **Main outcome measures** Medical and pharmacy costs and BMI.
15

16
17 **Results** Approximately 84% of employees participated in the wellness screening. Participants
18
19 were 1.03 (95% CI 1.01- 1.06) times more likely to be women and younger (M = 47.8 vs. 49.8, p
20
21 < 0.001). Median medical and pharmacy costs were higher for women than men, increased with
22
23 age, and were greater in morbidly obese individuals (p < 0.001). Annual pharmacy claims were
24
25 18% more likely to be filed by women than men, 23% more likely filed by those aged ≥ 60 versus
26
27 <40 years, and 6% more likely filed by morbidly obese individuals than of normal weight (p <
28
29 0.001) individuals. Greater medical and pharmacy costs in older age were most pronounced in
30
31 underweight and morbidly obese groups. Higher use of medication among women than men was
32
33 primarily because of drugs involving birth control, osteoporosis, thyroid disease, and urinary
34
35 tract infection. Higher medication use in older age was primarily related to medications used to
36
37 treat gastrointestinal problems. Medication use was positively associated with BMI weight
38
39 classifications for most of the 32 drug types considered, with exceptions involving birth control,
40
41 herpes, and osteoporosis. A J-shape relationship was observed between BMI and medication use
42
43 for acne, antibiotic, cold/influenza/allergy, eye infection, edema, muscle spasms, pain, and
44
45 ulcers.
46
47
48
49
50
51

52
53 **Conclusions** Lowering medical and pharmacy costs requires weight management in older ages,
54
55 particularly for underweight and obese men and women. Medical costs were significantly
56
57
58
59
60

1
2
3 reduced, likely due to effective drug treatment and prevention. Higher pharmacy costs for certain
4
5 drugs among underweight individuals may be associated with poorer nutrition.
6
7
8
9

10 Strengths and limitations of this study

- 11 • A large cohort of employees was available for retrospective assessment of the
12 association between sex, age, and BMI with medical and pharmacy costs.
13
- 14 • The association between sex, age, and 32 specific types of medication were assessed,
15 some of which have not been previously considered.
16
- 17 • All active employees received employer-sponsored medical and pharmacy coverage,
18 and above 84% had information that allowed us to determine body mass.
19
- 20 • A few medications may have contributed to weight gain, which we were unable to
21 adjust for in the current study.
22
- 23 • The study population and patterns of prescription drug use may limit generalization of
24 the results.
25
26
27
28
29
30
31
32
33
34
35

Introduction

Many companies offer wellness-screening programs consisting of health risk assessment and biometric screening. The 2016 Employer Health Benefits Survey found that among large firms (200 or more employees) in the United States, 59% offered health risk assessment (of which 32% had an incentive component) and 53% offered biometric screening (of which 31% included an incentive component).¹ These programs are intended to promote a greater sense of personal responsibility for lifestyle choices, identify the need for health behavior change, reduce future health problems, encourage patient management of existing health problems, decrease worker absenteeism, and improve job satisfaction and worker productivity.²⁻⁷ Larger companies are also required to offer employer-sponsored medical and pharmacy coverage for their employees. Hence, information obtained on the health risk assessment and screenings can be compared with the medical and pharmacy costs.

Medical and pharmacy costs are influenced by a number of factors, including sex, age, and Body Mass Index (BMI).⁸⁻¹⁰ Although medical costs are often a response to acute and chronic health conditions, pharmaceutical costs are often used to prevent more serious health problems. For example, antihypertensive medication, or statins, are useful in preventing cardiovascular disease;¹¹⁻¹³ multivitamins or folic acid for preventing congenital abnormalities;¹⁴ aspirin and non-steroidal anti-inflammatory for preventing colorectal cancer;¹⁵ bronchodilators, steroids, and anti-inflammatories for managing asthma;¹⁶ and nonsteroidal anti-inflammatory drugs, steroids, analgesics, and immunosuppressive drugs for managing arthritis.¹⁷ Consequently, wellness screening may actually increase use of prescription medication.¹⁸

1
2
3 Although a person's body weight may be associated with increased risk for various
4 chronic health conditions and poorer health-related quality of life,^{19 20} only in the last 15 years or
5 so has its impact on healthcare expenditures been assessed.¹⁰ Further, only a small number of
6 studies have explored the association between body weight and prescription drug use. A study
7 conducted in England found that overweight and obese individuals were more likely to receive
8 medication for the cardiovascular system; gastrointestinal system; respiratory system; central
9 nervous system; endocrine system; gynecology/urinary disorders; musculoskeletal and joint
10 disorders; infections; eye, ear and oropharynx problems; and skin disorders.²¹ A study in Sweden
11 showed that use and cost of medication in general are significantly greater in obese individuals.²²
12 A study in the United States found that obesity was responsible for \$7 billion in Medicare
13 prescription drug costs in 2006.²³ Another study conducted in the United States identified
14 increased medication use during 1988 through 2012, with the increase most prominent among
15 obese individuals.²⁴ A large cross-sectional study of 9789 adults in the National Health and
16 Nutrition Examination Survey (NHANES) found that obese individuals utilize several
17 prescription drugs (e.g., hypertension, lipid-lowering, and diabetes medications) more frequently
18 than normal weight individuals.²⁵ Another study based on NHANES data found that while
19 medication use increased over time for obese individuals compared with normal weight
20 individuals ages 40 years and older, the increase was only marginal for those aged 25-39 years.²⁶
21 One study found that obese individuals used more analgesic, asthma, cardiovascular, diabetes,
22 intranasal allergic rhinitis, thyroid, and ulcer medications.²⁷
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 The purpose of the current study was to identify the extent to which sex, age, and BMI
50 weight classifications are associated with medical and pharmacy costs among a large group of
51 teachers, administrators, and other school staff. These associations are also evaluated for 32 more
52
53
54
55
56
57
58
59
60

1
2
3 commonly prescribed medications.²⁸ Although studies have previously looked at the association
4
5 between BMI and prescription medications, we evaluated some drugs that have not been
6
7 formerly considered, and the breadth of drugs covered is greater than in past studies. In addition,
8
9 evaluating the effect of being underweight on medical and pharmacy costs, and on specific drug
10
11 types, is unique to this study.
12
13
14
15

16 17 **Methods**

18 19 *Patient and Public Involvement*

20
21 A retrospective cohort study was conducted that associated sex, age, and BMI with medical and
22
23 pharmacy cost data for employees of a large school district in the western United States. Specific
24
25 patients and or the general public was not involved in this study. Body mass index was obtained
26
27 from those employees who participated in wellness screening. Employer-sponsored insurance
28
29 was available to all employees. The school district comprised six high schools, eight junior high
30
31 schools, and 31 elementary schools. Employees consisted of approximately three teachers to
32
33 every one staff member (cooks, bus drivers, grounds keepers, maintenance workers,
34
35 administrators, clerical workers, etc.). We were not provided specific job type and salary for each
36
37 employee. However, we can assume that the teachers, administrators, counselors, and nurses,
38
39 who represent almost all of the employees, had at least a college degree, that their salaries are
40
41 commensurate with other school districts, and that the employer-sponsored insurance coverage
42
43 was not strongly impacted by the employee's income or education.
44
45
46
47
48

49 The study involved the academic years 2010-11, 2011-12, 2012-13, and 2013-14.
50
51 Employees were offered wellness screenings (personal health risk assessment [HRA] and
52
53 biometric evaluation) each fall. Medical and pharmacy claims data were also obtained for the
54
55
56
57
58
59
60

1
2
3 employees in each academic year. Wellness screening and claims data were combined with a file
4
5 of eligible employees and assessed within each academic year. The eligibility file contained
6
7 information on current employment, sex, age, and year.
8
9

10 11 12 *Wellness Screening* 13

14
15 All employees were offered wellness screening. Although participation was voluntary, it
16
17 was promoted through incentives. The HRA involved 36 questions. Biometric screenings
18
19 involved measurements of body mass index (BMI kg/m²), blood pressure (mm Hg), cholesterol
20
21 (mg/dL), and glucose (mg/dL). The HRA and biometric screenings were provided at no cost to
22
23 the employees, and were made available on location or with a personal physician. A health nurse
24
25 or physician assisted the employee in interpreting their HRA and screening results, in order to
26
27 help guide their need for lifestyle changes and control measures. The current study only
28
29 considers BMI. Weight classifications are based on commonly accepted ranges of BMI, as
30
31 follows: underweight (BMI < 18.5), normal weight (BMI 18.5-24), overweight (BMI 25-29),
32
33 obese (BMI 30-39), and morbidly obese (BMI 40+).
34
35
36
37
38
39

40 41 *Medical and Pharmacy Claims Data* 42

43 All active employees received employer-sponsored medical and pharmacy coverage, for
44
45 themselves and their families. The school district is fully insured with a retained-retention
46
47 agreement that makes the plan act very much like a self-funded health plan. Each month the
48
49 district pays a health insurance premium for the cost of healthcare and a small premium for
50
51 reinsurance of catastrophic claims. Catastrophic claims greater than \$250,000 are reinsured by a
52
53 stop loss policy and are not paid for by the school district. Employee pharmacy data do not
54
55
56
57
58
59

1
2
3 include over-the-counter drugs, but only those medications requiring a prescription. In the United
4
5 States, a drug is sold over-the-counter if the Food and Drug Administration deems it as
6
7 sufficiently safe and effective. These medications are not included in the current study. Further,
8
9 medical and pharmacy cost represents the amount paid by the insurance company as well as
10
11 copays by the employee.
12
13
14
15

16 17 *Statistical Techniques*

18
19 Counts, means, standard deviations, medians, and percentages were used to describe the
20
21 study population. Pair-wise comparisons of means were evaluated for statistical significance
22
23 using the Student-Newman-Keuls Test. Risk ratios compare having a medical and pharmacy cost
24
25 above the 50th percentile (vs. below), 75th percentile (vs. below), and 90th percentile (vs. below).
26
27 Statistical significance was determined by the corresponding 95% confidence intervals. For
28
29 selected medications, the risk of medication use was compared using risk ratios and attributable
30
31 fraction percentages across the levels of sex, age, and BMI weight classifications. Statistical
32
33 significance of differences in percent use of selected medications across sex, age, and BMI
34
35 categories was based on two-sided tests of significance were based on the 0.05 level against a
36
37 null hypothesis of no association. Data was evaluated using the statistical software package PC-
38
39 SAS (version 9.4; SAS Institute, Inc., 2014).
40
41
42
43
44
45

46 47 **Results**

48
49 In 2010-11, there were 3023 eligible employees, of which 2531 (83.72%) remained employed
50
51 through the academic year 2013-14. Those more likely to remain employed over the study period
52
53 were 40-59 years of age and had lower medical and pharmacy costs (Table 1). In 2010-11, ages
54
55
56
57
58
59

1
2
3 ranged from 18-76, with mean age significantly younger for those who remained employed (46.9
4 vs. 49.2, $p < 0.0001$). Those who remained employed had significantly lower mean medical costs
5 (\$3056 vs. \$7887, $p < 0.0001$) and mean pharmacy costs (\$859 vs. \$1105, $p = 0.0387$). The
6 results of this study are based on those continuously employed over the four academic years.
7
8
9

10
11
12
13 Most employees participated in annual wellness screening (84.1% in 2010-11, 84.4% in
14 2011-12, 87.6% in 2012-13, and 80.7% in 2013-14). In 2010-11, there was no significant
15 difference in mean medical cost between those who participated in wellness screening and those
16 who did not (\$3148 vs. \$2571, $p = 0.2900$). However, median medical cost was significantly
17 greater for those who participated in wellness screening (\$588 vs. \$470, $p = 0.0454$). For all
18 academic years, women were 1.03 (95% CI 1.01- 1.06) times more likely than men to complete
19 annual wellness screenings, after adjusting for age and academic year. Participants in wellness
20 screening were significantly younger ($M = 47.8$ vs. 49.8 , $p < 0.0001$), after adjusting for sex and
21 year. Those participating in wellness screening had significantly lower mean medical cost
22 (\$3093 vs. \$4181, $p = 0.0013$), but experienced no significant difference in mean annual
23 pharmacy costs, after adjusting for age, sex, and year.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Among participants in annual wellness screening, mean BMI remained constant across
40 the academic years (Table 2). Mean BMI was greater for men than women and in ages 40 years
41 and older. Medical and pharmacy costs were highly positively skewed, with considerable
42 variability. Hence, identifying significant differences in the mean costs across the levels of sex,
43 age, and year, were less likely to occur than to find significant differences in the median costs
44 across the levels of these variables. Medical costs were higher for women than men, increased
45 with age, and were greater in morbidly obese individuals. Pharmacy costs were higher in women
46 than men, increased with age, and were lowest in those of normal weight.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The risk of medical and pharmacy costs above the 50th, 75th, and 90th percentiles are
4 shown according to sex, age, and BMI weight classification in Table 3. Higher BMI has a greater
5 impact on higher percentiles of medical and pharmacy costs. For example, morbidly obese
6 compared with normal weight are 1.13 (13%), 1.30 (30%), and 1.93 (93%) more likely to have
7 pharmacy costs above the 50th, 75th, and 90th percentiles, respectively. Medical and pharmacy
8 costs above these percentiles are greater in women than men and increase with age.
9

10
11
12 Associations between selected percentiles of medical and pharmacy costs and BMI
13 weight classifications varied according to age (Figure 1), but not sex (data not shown). Greater
14 medical and pharmacy costs with older age groups are seen in the graph. However, the
15 increasing costs with higher age are most pronounced in the underweight and morbidly obese
16 groups.
17

18
19
20 Medication use is shown across sex, age, and BMI groups in Table 4. For any
21 medication, women were 18% more likely to file a claim than men, employees 60 years of age or
22 older were 23% more likely to file a claim than those less than 40 years, and morbidly obese
23 were 6% more likely to file a claim than those of normal weight. For 22 of the 32 medications
24 considered, the percentage of annual claims was higher for women than men. For only high
25 blood pressure was the percentage of claims greater for men than women. For 24 of the
26 medications, the percentage of annual claims increased with age. For 23 of the medications, the
27 percentage of annual claims was associated with BMI (19 positively and 4 negatively). The
28 strongest positive associations involved diabetes, high cholesterol (statins), high blood pressure,
29 and edema. Negative associations involved acne, birth control, Herpes, and osteoporosis. The
30 highest annual percent of acne, antibiotic, cold/influenza/allergy, and eye infection medications
31 occurred in underweight individuals. For edema, muscle spasms, pain, and ulcers, medication
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 use was comparatively high in underweight individuals, dropped for normal weight, and then
4
5 increased in higher weight classifications.
6
7

8 We also report the attributable fraction in the population. For example, this statistic says
9
10 that 8.82% of diabetes medication is attributed to being overweight, 20.34% is attributed to being
11
12 obese, and 30.43% is attributed to being morbidly obese. Where the risk ratio is less than 1, the
13
14 preventive fraction can be estimated. For example, the risk of requiring osteoporosis medication
15
16 is lower for obese compared with normal weight employees (i.e., Risk Ratio = 0.54). The
17
18 corresponding preventive fraction is 66%, meaning in the absence of obesity there would be 66%
19
20 fewer claims for osteoporosis medication. The attributable fraction in the population and the
21
22 preventive fraction both assume a cause-and-effect association between exposure and disease.
23
24
25
26
27
28
29

30 **Discussion**

31
32 The current study identified the degree to which sex, age, and BMI are associated with medical
33
34 and pharmacy costs among employees in a large school district. Associations were also evaluated
35
36 for 32 commonly prescribed medications.²⁸ The study extends previous research by including
37
38 certain medications not previously evaluated and considering associations for all BMI weight
39
40 classifications.
41
42

43 Higher medical and pharmacy costs among women, in older age, and among those not of
44
45 normal weight is consistent with previous research.⁸⁻¹⁰ Greater medical and pharmacy costs with
46
47 older age are most pronounced in the underweight and morbidly obese groups. Hence, weight
48
49 management at older ages appears particularly important in terms of lowering medical and
50
51 pharmacy costs.
52
53
54
55
56
57
58
59
60

1
2
3 Higher medication use in women than men was primarily because of drugs involving
4 birth control, osteoporosis, thyroid disease, and urinary tract infection. Prescription costs for
5 vitamins/minerals were also noticeably higher in women than men. Family planning and prenatal
6 care may explain the greater use of birth control medications and vitamins/minerals among
7 women. Loss of estrogen in women at older ages and female reproductive hormones may
8 contribute to the higher level of osteoporosis and thyroid disease in women.^{29 30}

9
10
11 Medication use was higher in those aged 60 years and older compared with those younger
12 than 40, primarily because of diabetes, edema, high blood pressure, high cholesterol (statins),
13 and thyroid disease. Previous research has shown that the risk of these diseases increase with
14 age.³¹⁻³⁵ Medication use also noticeably increased with age for acid reflux, bowel/rectum,
15 inflammation, and stomach acid. This is consistent with older age tending to be associated with
16 more gastrointestinal problems.³⁶

17
18 Medication use was highest in those who were morbidly obese. We found positive
19 associations between body weight and higher use of medications for treating acid reflux, fungus,
20 bacterial infections, arthritis, asthma, colds, influenza, allergies, depression, diabetes, edema,
21 high blood pressure, muscle spasms, nausea/vomiting, pain, high cholesterol, stomach acid,
22 thyroid, and ulcers. Other studies have identified a similar associations.^{21 24 25 27} Morbidly obese
23 individuals were also more likely to be prescribed vitamins and minerals than normal weight
24 individuals. We did not find an association between body weight and increased use of
25 medication for the bowel/rectum, skin, or urinary tract, which was counter to that found in other
26 studies.^{21 37-39} We also assessed but did not find a significant association for medications used to
27 treat anxiety, insomnia, convulsions, or teeth and gums. The insignificant finding for
28 anticonvulsants and teeth and gums may be because of insufficient power (i.e., small numbers).

1
2
3 Finally, we assessed the association between body weight and medications for birth control,
4 herpes, and osteoporosis, wherein significant negative associations were found. We are not
5 aware of other studies that have looked at the association between body weight and medications
6 used for colds, influenza, depression, edema, birth control, herpes, or osteoporosis.
7
8
9
10
11

12 Greater use of medication to treat acid reflux or stomach acid among individuals with
13 higher BMI is consistent with previous research showing hospitalization rates for reflux disease
14 to be positively associated with BMI.^{40 41} Another study found that higher BMI was associated
15 with increased gastroesophageal reflux in both normal and overweight individuals.⁴² Heavier
16 body weight can add pressure to the stomach and diaphragm, thereby resulting in reflux. Further,
17 increased use of medication for nausea/vomiting among individuals with higher BMI weight
18 classifications is consistent with other research.⁴³
19
20
21
22
23
24
25
26
27
28

29 The positive association between higher BMI and increased use of medication for ulcers
30 is consistent with other research, particularly peptic (gastric and duodenal) ulcers.^{44 45} The
31 mechanism to explain the association between obesity and peptic ulcer disease remains unclear.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Previous research has shown that overweight and obese individuals are at greater risk for
infections.³⁷⁻⁴⁹ This is consistent with our findings that show increased use of antibiotics and
medication for acne, colds/influenza/allergy, and eye infections among obese individuals.
However, it has been shown previously that antibiotics can also weaken the immune system,⁵⁰ as
well as lead to obesity.⁵¹ Some inflammatory diseases known to be associated with obesity in
which we found a positive association between obesity and medication included influenza,^{52 53}
heart disease,⁵⁴ diabetes,⁵⁵ allergies,⁵⁶⁻⁵⁹ asthma,⁶⁰ edema,⁶¹⁻⁶³ and arthritis.⁶⁴⁻⁶⁷ A compromised

1
2
3 immune system may also trigger autoimmune diseases, including rheumatoid arthritis and
4
5 thyroid disease,⁶⁸ as indicated in the current study.
6
7

8 Overweight and obese individuals were more likely to receive cold, influenza, or allergy
9 medication. Obesity is associated with impaired immune response to influenza vaccination in
10 humans.⁶⁹ Because vaccination is less successful for obese individuals,^{70 71} a greater level of
11 medication may be sought for treating colds, influenza, and allergies.
12
13
14
15
16
17

18 Overweight and obese individuals received higher levels of pain medication. Research
19 indicates that the nature of the relationship between higher BMI and pain is likely indirect.⁷² For
20 example, greater body weight is associated with osteoarthritis, which, in turn, leads to pain.⁷³
21 Being overweight or obese may result in greater risk for back pain, joint pain, and muscle
22 spasms.⁷⁴ One study also found that obese individuals were more sensitive than those of normal
23 weight to pressure pain.⁷⁵
24
25
26
27
28
29
30
31
32

33 We found that higher BMI was associated with depression medication, as consistent with
34 previous research.⁷⁶⁻⁷⁹ In one study, the age-adjusted level of depression among adults (ages 20
35 and older) in the United States was 43.2% for those with depression compared with 33.0% for
36 those without depression.⁸⁰ It may be that higher use of prescription medication for depression
37 among those with greater BMI is partly because these people are more likely to experience other
38 conditions related to depression, such as heart disease and diabetes.⁸¹⁻⁸³
39
40
41
42
43
44
45
46

47 There was more use of vitamins/minerals among morbidly obese employees. Of the
48 prescribed vitamins/minerals only 8.0% involved vitamin B and 57.3% involved vitamin D. A
49 previous study showed an association between low vitamin B12 and being obese.⁸⁴ Another
50 study found that the prevalence of vitamin D deficiency was 35% greater in obese individuals.⁸⁵
51
52
53
54
55
56
57
58
59
60

1
2
3 Acne, antibiotic, cold/influenza/allergy, and eye infection medications were prescribed
4 more often for underweight individuals. This is consistent with underweight individuals having
5 poorer nutrition and, consequently, a weakened immune system.⁸⁶ For edema, muscle spasms,
6 pain, and ulcers, medication use showed a J-shape relationship with BMI weight classification.
7
8 Poor nutrition may also explain the higher levels of medication use among underweight
9 individuals for these medications. Despite mean medical costs being similar for those who
10 participated in wellness screening during the first year of the study, over the four academic years,
11 participants in wellness screening ended up having significantly lower mean medical costs.
12
13 However, pharmacy costs did not go down. It has been shown that wellness screening can cause
14 the number and cost of pharmaceuticals to go up, at least initially, as the need for treatment is
15 identified.⁸⁷ Identified treatment needs can then, in turn, help prevent more costly health
16 problems in the future. For example, medications used to treat high blood pressure can result in
17 lowering the risk of diabetes, heart disease, stroke and kidney disease; treatment of insomnia can
18 help lower the risk of irritability, depression or anxiety, difficulty paying attention, and accidents
19 due to increased errors; treatment of high cholesterol with statins can help lower the risk of
20 cardiovascular disease; treatment of oral infections can help reduce the risk of diabetes,
21 cardiovascular disease, and preterm birth; and vitamins/minerals can help prevent a host of
22 diseases (scurvy, rickets, anemia, neural tube defects, pellagra, etc.). High blood pressure and
23 statin medications were among the highest prescribed in our study.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 A limitation of this study involves external validity (generalizability). Specifically, the
48 study considered those individuals who remained employed over all four academic years. These
49 individuals were generally healthier. The study also focused on those who completed wellness
50 screening because they contained BMI information. These employees were more likely women
51
52
53
54
55
56
57
58
59
60

1
2
3 and younger. In addition, the causal direction between medication use and BMI could not be
4
5 determined. That is, some medications may have contributed to body mass whereas others were
6
7 in response to body mass. Finally, the current study did not have information on the use of
8
9 vitamins or minerals obtained over the counter and small numbers made it impossible to evaluate
10
11 the relationship between specific types of vitamins/minerals and sex, age, and BMI.
12
13
14
15
16
17

18 **Conclusion**

19
20
21 Weight management at older ages, particularly in underweight and morbidly obese individuals, is
22
23 most important for lowering medical and pharmacy costs. Medical costs decreased, possibly
24
25 because of effective drug treatment and prevention. Pharmacy costs remained constant, possibly
26
27 because screening identified a need for certain medications. Greater use of medication among
28
29 women than men is primarily because of drugs involving birth control, osteoporosis, thyroid
30
31 disease, and urinary tract infection. Greater medication use in older age is primarily related to
32
33 medications used to treat gastrointestinal problems. Medication use was positively associated
34
35 with BMI for most of the conditions being treated, with exceptions involving birth control,
36
37 herpes, and osteoporosis. A J-shape relationship between BMI weight classification and
38
39 medication use for acne, antibiotic, cold/influenza/allergy, eye infection, edema, muscle spasms,
40
41 pain, and ulcers may be because of poorer nutrition in underweight individuals.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. 2016 Employer Health Benefits Survey. kff.org. <http://www.kff.org/health-costs/report/2016-employer-health-benefits-survey/>. Published September 14, 2016. Accessed February 21, 2018.
2. Chen L, Hannon PA, Laing SS, Kohn MJ, Clark K, Pritchard S, Harris JR. Perceived workplace health support is associated with employee productivity. *Am J Health Promot.* 2015;29(3):139-146.
3. Centers for Disease Control and Prevention. cdc.gov. <http://www.cdc.gov/sustainability/worksitewellness/> Worksite wellness. Updated December 9, 2014. Accessed March 18, 2018.
4. Michaels CN, Greene AM. Worksite wellness: increasing adoption of workplace health promotion programs. *Health Promot Pract.* 2013;14(4):473-479.
5. Witt LB, Olsen D, Ablah E. Motivating factors for small and midsized businesses to implement worksite health promotion. *Health Promot Pract.* 2013;14(6), 876-884.
6. Niessen MA, Kraaijenhagen RA, Dijkgraaf MG, van Pelt D, van Kalken CK, Peek N. Impact of a Web-based worksite health promotion program on absenteeism. *J Occup Environ Med.* 2012;54(4):404-408.
7. Kaspin LC, Gorman KM, Miller RM. Systematic review of employer-sponsored wellness strategies and their economic and health-related outcomes. *Popul Health Manag.* 2013;16(1): 14-21.
8. Metge C, Black C, Peterson S, Kozyrskyi AL. The population's use of pharmaceuticals. *Med Care.* 1999;37(6 Suppl):JS42-JS59.

- 1
2
3 9. Bertakis K, Azari R, Helms L, Callahan E, Robbins J. Gender differences in the utilization of
4 health care services. *J Fam Pract.* 2000;49(2):147-152.
5
6
- 7
8 10. Arterburn DE, Maciejewski ML, Tsevat J. Impact of morbid obesity on medical expenditures
9 in adults. *Int J Obes.* 2005;29(3):334-339.
10
11
- 12 11. Karmali KN, Lloyd-Jones DM, Berendsen M, et al. Drugs for primary prevention of
13 atherosclerotic cardiovascular disease: an overview of systematic reviews. *JAMA Cardiol.*
14 2016;1(3):341-349.
15
16
- 17 12. Fretheim A, Odgaard-Jensen, Brørs O, Madsen S, et al. Comparative effectiveness of
18 antihypertensive medication for primary prevention of cardiovascular disease: systematic
19 review and multiple treatments meta-analysis. *BMC Med.* 2012;10:33.
20
21
- 22 13. Taylor F, Huffman MD, Macedo A, et al. Statins for the primary prevention of
23 cardiovascular disease. *Cochrane.* 2013. [http://www.cochrane.org/CD004816/VASC_statins-](http://www.cochrane.org/CD004816/VASC_statins-primary-prevention-cardiovascular-disease)
24 primary-prevention-cardiovascular-disease. Accessed February 21, 2018.
25
26
- 27 14. Czeizel AE. Birth defects are preventable. *Int J Med Sci.* 2005;2(3):91-92.
28
29
- 30 15. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. *Gastroenterology.*
31 2010;138(6):2029-2043.
32
33
- 34 16. Asthma. Mayo Clinic. [https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-](https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-treatment/drc-20369660)
35 treatment/drc-20369660. Published March 9, 2018. Accessed February 24, 2018.
36
37
- 38 17. Arthritis. Mayo Clinic. [https://www.mayoclinic.org/diseases-conditions/arthritis/diagnosis-](https://www.mayoclinic.org/diseases-conditions/arthritis/diagnosis-treatment/drc-20350777)
39 treatment/drc-20350777. Published March 7, 2018. Accessed February 24, 2018.
40
41
- 42 18. Preventive Medicine Reports Paper
43
44
- 45 19. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic
46 consequences of obesity. *Arch Intern Med.* 1999;119(18):2177-2183.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
20. Pi-Sunyer X. The medical risks of obesity. *Postgrad Med.* 2009;121(6):21-33.
21. Kinge JM, Morris S. Association between obesity and prescribed medication use in England. *Econ Hum Biol.* 2014;15:47-55.
22. Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. *Arch Intern Med.* 2002;162(18):2061-2069.
23. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. *Health Aff.* 2009;28(5):w822-31.
24. Randhawa AK, Parikh JS, Kuk JL. Trends in medication use by body mass index and age between 1988 and 2012 in the United States. *PLoS One.* 2017 Sep 20;12(9):e0184089.
25. Kit BK, Ogden CL, Flegal KM. Prescription medication use among normal weight, overweight, and obese adults, United States, 2005-2008. *Ann Epidemiol.* 2012;22(2):112-119.
26. Jarrett B, Bloch GJ, Bennett D, Bleazard B, Hedges D. The influence of body mass index, age and gender on current illness: a cross-sectional study. *Int J Obes.* 2010;34(3):429-436.
27. Raebel MA, Malone DC, Conner DA, Xu S, Porter JA, Lanty FA. Health services use and health care costs of obese and nonobese individuals. *Arch Intern Med.* 2004;164(19):2135-2140.
28. Fuentes AV, Pineda MD, Venkata KCN. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. *Pharmacy (Basel).* 2018;6(2):E43.
29. Alswat KA. Gender disparities in osteoporosis. *Clin Med Res.* 2017;9(5): 382–387.

- 1
- 2
- 3 30. Li H, Li J. Thyroid disorders in women. *Minerva Med.* 2015;106(2):109-114.
- 4
- 5 31. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. *Diabetes Care.*
- 6 2012;35(12):2650-2664.
- 7
- 8 32. Traves KP, Studdiford JS, Pickle S, Tully AS. Edema: diagnosis and management. *Am Fam*
- 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
33. Mc Donald Posso AJ, Motta Borrel JA, Fontes F, Cruz Gonzalez CE, Pachón Burgos AA, Cumbreira Ortega A. High blood pressure in Panama: Prevalence, sociodemographic and biologic profile, treatment, and control (STROBE). *Medicine (Baltimore).* 2014;93(22):e101.
34. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. *Circulation.* 1997;96(1):37-43.
35. Gesing A. The thyroid gland and the process of aging. *Thyroid Res.* 2015;8(Suppl 1):A8.
36. A L D'Souza. Ageing and the gut. *Postgrad Med J.* 2007; 83(975):44–53.
37. Ma Y, Yang Y, Wang F, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. *PLoS One.* 2013;8(1):e53916.
38. Brown J, Wimpenny P, Maughan H. Skin problems in people with obesity. *Nurs Stand.* 2004;18(35):38-42.
39. Semins MJ, Shore AD, Makary MA, Weiner J, Matlaga BR. The impact of obesity on urinary tract infection risk. *Urology.* 2012;79(2):266-269.
40. Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup

- 1
2
3 Study. First National Health and Nutrition Examination Survey. *Ann Epidemiol.*
4
5 1999;9(7):424-435.
6
7
8 41. Anggiansah R, Sweis R, Anggiansah A, Wong T, Cooper D, Fox M. The effects of obesity
9
10 on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux
11
12 disease. *Alim Pharmacol Ther.* 2013;37(5):555-563.
13
14
15 42. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Association between body
16
17 mass index and gastroesophageal reflux symptoms in both normal weight and overweight
18
19 women. *N Engl J Med.* 2006;354(22):2340-2348.
20
21
22 43. Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in
23
24 young adults: a birth cohort study. *Am J Gastroenterol* 2004;99(9):1807-1814.
25
26
27 44. Boylan MR, Khalili H, Huang ES, Chan AT. Measures of adiposity are associated with
28
29 increased risk of peptic ulcer. *Clin Gastroenterol Hepatol.* 2014 Oct;12(10):1688-1694.
30
31
32 45. Kim J, Kim KH, Lee BJ. Association of peptic ulcer disease with obesity, nutritional
33
34 components, and blood parameters in the Korean population. *PLoS One.* 2017;12(8):
35
36 e0183777.
37
38 46. Xu M, Liu L, Yuan B, Yin J, Lu Q. Association of obesity with *Helicobacter pylori* infection:
39
40 A retrospective study. *World J Gastroenterol* 2017;23(15):2750-2756.
41
42
43 47. Falagas ME, Kompoti M. Obesity and infection. *Lancet Infect Dis* 2006;6(7)438-446.
44
45
46 48. Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. *Int J Obes.*
47
48 2013;37:333-340.
49
50 49. Lübbecke A, Zingg M, Hoffmeyer P, et al. Body mass and weight thresholds for increased
51
52 prosthetic joint infection rates after primary total joint arthroplasty. *Acta Orthopaedica.*
53
54 2016;87(2):132-138
55
56
57
58
59
60

- 1
2
3 50. Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ. Antibiotic-induced
4 changes to the host metabolic environment inhibit drug efficacy and alter immune function.
5
6 Cell Host & Microbe. 2017;22(6):757-765.
7
8
9
- 10 51. Early G. Current Evidence regarding antibiotic exposure and childhood obesity: an
11 integrative review. *Ped Nurs*. 2017;43(4):169-174.
12
13
- 14 52. Bandaru P, Rajkumar H, Napanveettil G. The impact of obesity on immune response to
15 infection and vaccine: an insight into plausible mechanisms. *Endocrinol Metab Syndr*
16
17 2013;2:2.
18
19
- 20 53. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during
21 influenza seasons in Ontario, Canada: a cohort study. *Clin Infect Dis*. 2011;53(5):413-421.
22
23
- 24 54. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease.
25
26 *Mediators Inflamm*. 2010;2010:535918.
27
28
- 29 55. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent
30 advances in the relationship between obesity, inflammation, and insulin resistance. *Eur*
31
32 *Cytokine Netw*. 2006;17(1):4-12.
33
34
- 35 56. Ciprandi G, Pistorio A, Tosca M, Ferraro MR, Cirillo I. Body mass index, respiratory
36 function and bronchial hyperactivity in allergic rhinitis and asthma. *Respir Med*
37
38 2009;103(2):289-295.
39
40
- 41 57. Gorgievska-Sukarovska B, Lipozencić J, Susac A. Obesity and allergic diseases. *Acta*
42
43 *Dermatovenerol Croat*. 2008;16(4):231-235.
44
45
- 46 58. Shah R, Yang Y. Health and economic burden of obesity in elderly individuals with asthma
47
48 in the United States. *Popul Health Manag* 2015;18(3):186-191.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 59. Guo Y, Moon JY, Laurie CC, et al. Genetic Predisposition to Obesity is associated
4 with Asthma in US Hispanics/Latinos: Results from the Hispanic Community Health
5 Study/Study of Latinos. *Allergy*. 2018;doi: 10.1111/all.13450. [Epub ahead of print]
6
7
8
9
10 60. Rodriguez D. Obesity and Asthma – What’s the Connection.
11
12 <https://www.everydayhealth.com/asthma/obesity-connection.aspx>. Published August 28,
13 2013. Accessed April 12, 2018.
14
15
16
17 61. Greene, A.K., et al. Lower-Extremity Lymphedema and Elevated Body-Mass Index. *N Engl*
18 *J Med*. 2012;366:2136-2137.
19
20
21 62. Helyer, L.K., et al. Obesity is a risk factor for developing postoperative lymphedema in
22 breast cancer patients. *Breast J*. 2012;16(1):48-54.
23
24
25
26 63. Greene AK, Grant FD, Slavin SA, Maclellan RA. Obesity-induced lymphedema: clinical and
27 lymphoscintigraphic features. *Plast Reconstr Surg*. 2015;135(6):1715-1719.
28
29
30
31 64. King LK, March L, Anandacoomarasamy A. Obesity & osteoarthritis. *Indian J Med Res*.
32 2013;138(2):185-193.
33
34
35 65. Baodong Qin, Min Yang, Haitao Fu, et al. Body mass index and the risk of rheumatoid
36 arthritis: a systematic review and dose-response meta-analysis. *Arthritis Res Ther*.
37 2015;17(1):86.
38
39
40
41
42 66. Feng J, Chen Q, Yu F, et al. Body mass index and risk of rheumatoid arthritis: a meta-
43 analysis of observational studies. *Medicine*. 2016;95(8):e2859.
44
45
46
47 67. Albrecht K, Richter A, Callhoff J, et al. Body mass index distribution in rheumatoid arthritis:
48 a collaborative analysis from three large German rheumatoid arthritis databases. *Arthritis Res*
49 *Ther*. 2016;18:149.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 68. Rodriguez D. How Your Immune System Worsens Arthritis. EverydayHealth.com.
4
5 <https://www.everydayhealth.com/arthritis/understanding/the-immune-system.aspx>. Published
6
7 August 1, 2012. Accessed April 11, 2018.
8
9
- 10 69. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response
11
12 to influenza vaccination in humans. *Int J Obes*. 2012;36(8):1072-1077.
13
14
- 15 70. Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune
16
17 response to vaccination. *Vaccine*. 2015;33(36): 4422–4429.
18
19
- 20 71. Young KM, Gray CM, Bekker LG. Is Obesity a Risk Factor for Vaccine Non-
21
22 Responsiveness? *PLoS One*. 2013;8(12): e82779.
23
24
- 25 72. Okifuji A, Hare BD. The association between chronic pain and obesity. *J Pain Res*.
26
27 2015;8:399-408.
28
29
- 30 73. Erdmann J. Osteoarthritis and Obesity. www.arthritis.org. [https://www.arthritis.org/living-](https://www.arthritis.org/living-with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php)
31
32 [with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php](https://www.arthritis.org/living-with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php). Accessed April
33
34 11, 2018.
35
36
- 37 74. American Obesity Association. Health effects of obesity. AOA Fact Sheets. 2002.
38
- 39 75. Tashani OA, Asitita R, Sharp D, Johnson MI. Body mass index and distribution of body fat
40
41 can influence sensory detection and pain sensitivity. *Eur J Pain* 2017;21(7):1186-1196.
42
43
- 44 76. Rathee N. Obesity and depression: Are they related? *Indian J Health Well*. 2017;8(12):1472-
45
46 1475.
47
- 48 77. Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH. Depression and anxiety among
49
50 US adults: associations with body mass index. *Int J Obesity*. 2009;33(2):257-266.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 78. Onyike CU, Crum RM, Lee HB, Lyketsos DG, Eaton WW. Is obesity associated with major
4 depression? Results from the Third National Health and Nutrition Examination Survey. *Am J*
5
6 *Epidemiol.* 2003;158(12):1139-1147.
7
8
9
10 79. Petry NM, Barry D, Pietrzak RH, Wagner JA. Overweight and obesity are associated with
11
12 psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and
13
14 Related Conditions. *Psychosom Med.* 2008;70(3):288-297.
15
16
17 80. Pratt LA, Brody DJ. Depression and obesity in the U.S. adult household population, 2005-
18
19 2010. NCHS Data Brief, No. 167, October 2014.
20
21
22 81. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood
23
24 disorders and obesity related? A review for the mental health professional. *J Clin Psychiatry*
25
26 2004;65(5):634-651.
27
28
29 82. Ferraro KF, Su Y, Gretebeck RJ, Black DR, Badylak SF. Body mass index and disability in
30
31 adulthood: A 20-year panel study. *Am J Public Health.* 2002;92(5):834-840.
32
33
34 83. Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. *J*
35
36 *Psychosom Res.* 2002;53(4):859-863.
37
38
39 84. Baltaci D, Kutlucan A, Turker Y, et al. Association of vitamin B12 with obesity, overweight,
40
41 insulin resistance and metabolic syndrome, and body fat composition; primary care-based
42
43 study. *Med Glas.* 2013;10(2):203-210.
44
45
46 85. Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin D
47
48 deficiency: a systematic review and meta-analysis. *Obes Rev.* 2015;16(4):341-349.
49
50
51 86. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? *The*
52
53 *Lancet* 2003;361:2226-2234.
54
55
56
57
58
59
60

1
2
3 87. Merrill RM, Telford CT. Pharmaceutical use according to participation in worksite wellness
4 screening and health campaigns. *Prev Med Rep* 2018;12:158-163.
5
6
7

8 **Footnotes**

9

10
11 Contributors: RMM conceived and designed the epidemiological study, contributed to
12 acquisition of data, analyzed and interpreted the data, and drafted the manuscript. RPF
13 interpreted the data, provided a literature review, and revised the manuscript. Both authors
14 critically revised the manuscript for important intellectual content. The manuscript has been read
15 and approved by both authors.
16
17
18
19
20
21
22

23 Funding: The authors have not declared a specific grant for this research from any funding
24 agency in the public, commercial or not-for-profit sectors.
25
26
27

28 Competing interests: None declared.
29
30

31 Patient consent: Not required.
32
33

34 Ethics approval: Study approval was obtained from the institutional review board at Brigham
35 Young University (IRB E1 5259).
36
37
38

39 Provenance and peer review: Not commissioned; externally peer reviewed.
40
41

42 Data sharing statement: The data sets used and analyzed in the current study are available from
43 the corresponding author on reasonable request at: Ray_Merrill@byu.edu
44
45
46
47
48
49
50
51
52
53
54
55
56
57

Table 1 Characterization of the study group according to sex, age, medical and pharmacy costs

	No.	%	Continuously Employed %	Chi-square p value	Risk Ratio	95% CI
Sex						
Men	797	26.36	84.69	0.3884	1.00	
Women	2226	73.64	83.38		0.98	0.95-1.02
Age Group						
18-39	770	25.47	82.21	< 0.0001	1.00	
40-49	806	26.66	89.45		1.09	1.05-1.13
50-59	1088	35.99	88.24		1.07	1.03-1.12
60-76	359	11.88	60.45		0.74	0.67-0.80
Medical Cost (USD)						
0-184	755	25.0	87.55	< 0.0001	1.00	
185-604	757	25.0	85.07		0.97	0.93-1.01
605-2049	755	25.0	84.64		0.97	0.93-1.01
2050-7191	454	15.0	79.30		0.91	0.86-0.96
7192+	302	10.0	75.17		0.86	0.80-0.92
Pharmacy Cost (USD)						
0-6	759	25.0	86.92	< 0.0001	1.00	
7-194	755	25.0	85.21		0.99	0.69-1.03
195-903	755	25.0	82.59		0.96	0.92-1.00
904-2303	452	15.0	84.14		0.99	0.94-1.04
2304+	302	10.0	74.92		0.86	0.80-0.93

Sex, age, medical and pharmacy costs apply to the 2010-11 academic year.

Table 2 Medical and pharmacy costs according to sex, age, year, and body mass index

	BMI (kg/m ²)			Medical Cost (USD)			Median	Median one-way analysis	Pharmacy Cost (USD)			Median	Median one-way analysis
	Mean	SD	SNK	Mean	SD	SNK		p value	Mean	SD	SNK		p value
Sex													
Men	29.35	5.80	A	2869	10581	A	373	< 0.0001	725	2324	A	53	< 0.0001
Women	27.26	6.47	B	3447	12049	A	741		963	3550	B	238	
Age Group													
18-39	27.17	6.06	A	2236	9344	A	389	< 0.0001	660	3342	A	70	< 0.0001
40-49	27.76	6.42	B	3052	12366	B	503		750	2806	A	106	
50-59	28.05	6.55	B	3935	12579	B	845		1021	3288	B	261	
60-76	28.17	6.13	B	3749	10831	B	989		1288	3990	C	344	
Year													
2010-11	27.89	6.40	A	3188	10524	A	605	0.2313	830	2247	A	195	0.0016
2011-12	27.79	6.31	A	3621	12816	A	610		953	3180	A	189	
2012-13	27.87	6.59	A	3208	11836	A	670		934	3571	A	173	
2013-14	27.63	6.16	A	3191	11557	A	651		894	3913	A	141	
BMI (kg/m ²)													
Underweight				2191	1190	A	647	0.0003	1454	6706	A	224	0.0004
Normal weight				2826	333	A	650		779	3285	B	167	
Overweight				3174	514	A	603		926	3085	A, B	169	
Obese				3544	459	A	665		1031	3458	A, B	228	
Morbidly obese				6911	2092	B	1033		853	1493	A, B	242	

SNK: Student-Newman-Keuls Test. Different letters indicate significant difference at the 0.05 level.

Table 3 Risk of medical and pharmacy costs (USD) above the 50th, 75th, and 90th percentiles according to BMI weight classification, sex, and age

	Medical						Pharmacy					
	50 th percentile Above vs. below		75 th percentile Above vs. below		90 th percentile Above vs. below		50 th percentile Above vs. below		75 th percentile Above vs. below		90 th percentile Above vs. below	
	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI
Sex												
Men	1.00		1.00		1.00		1.00		1.00		1.00	
Women	1.43	1.36-1.51	1.47	1.35-1.60	1.42	1.24-1.64	1.58	1.50-1.66	1.59	1.46-1.74	1.14	1.00-1.29
Age Groups												
18-39	1.00		1.00		1.00		1.00		1.00		1.00	
40-49	1.16	1.08-1.23	1.15	1.03-1.29	1.08	0.90-1.28	1.14	1.07-1.22	1.45	1.29-1.64	1.72	1.37-2.15
50-59	1.50	1.42-1.59	1.65	1.50-1.82	1.36	1.16-1.58	1.48	1.39-1.56	2.28	2.05-2.55	2.82	2.30-3.46
60+	1.61	1.52-1.72	1.83	1.64-2.04	1.33	1.11-1.60	1.57	1.48-1.68	2.57	2.29-2.89	3.78	3.06-4.68
BMI (kg/m ²)												
Underweight	1.05	0.88-1.26	0.91	0.64-1.31	0.61	0.28-1.35	2.05	1.25-3.34	1.05	0.74-1.48	2.05	1.25-3.34
Normal weight	1.00		1.00		1.00		1.00		1.00		1.00	
Overweight	0.95	0.90-1.00	0.95	0.86-1.05	1.01	0.85-1.20	1.01	0.95-1.06	1.18	1.07-1.30	1.68	1.41-2.00
Obese	1.00	0.95-1.06	1.14	1.03-1.25	1.21	1.01-1.43	1.11	1.05-1.17	1.19	1.08-1.31	1.76	1.47-2.12
Morbidly obese	1.18	1.08-1.29	1.62	1.40-1.87	2.18	1.72-2.77	1.13	1.03-1.25	1.30	1.09-1.55	1.93	1.43-2.61

Shaded cells represent statistical significance at the 0.05 level.

Table 4 Medication use according to sex, age, and BMI weight classification

		Sex		Age Group				Body Mass Index (kg/m ²)				
		Men	Women	18-39	40-49	50-59	60+	Underweight	Normal weight	Over weight	Obese	Morbidly obese
Medication	%											
Acid Reflux	5.75	5.56	5.81	3.02	4.54	7.14	8.36	3.57	4.34	5.36	7.19	9.14
Risk ratio		1.00	1.04	1.00	1.50	2.36	2.77	0.82	1.00	1.24	1.66	2.11
AF _p (%)		0.00	0.26	0.00	2.81	7.27	9.23		0.00	1.33	3.64	5.98
Acne	7.17	3.15	8.62	7.15	7.03	7.16	7.40	9.82	8.81	6.64	6.34	6.18
Risk ratio		1.00	2.74	1.00	0.98	1.00	1.03	1.11	1.00	0.75	0.72	0.70
AF _p (%)		0.00	11.07	0.00	0.01	0.25	0.25	0.82	0.00			
Antibiotic	21.21	17.81	22.44	18.72	20.76	22.76	21.93	25.89	20.54	20.74	23.73	21.24
Risk ratio		1.00	1.26	1.00	1.11	1.22	1.17	1.26	1.00	1.01	1.16	1.03
AF _p (%)		0.00	5.23	0.00	2.26	4.38	3.51	5.24	0.00	0.21	3.19	0.72
Anticonvulsants	1.49	1.39	1.53	1.84	1.32	1.45	1.40	2.68	1.25	1.13	1.65	1.61
Risk ratio		1.00	1.10	1.00	0.72	0.79	0.76	2.14	1.00	0.90	1.32	1.29
AF _p (%)		0.00	0.15	0.00				1.68	0.00		0.47	0.43
Antifungal	5.29	2.61	5.81	5.64	6.03	4.24	3.87	5.36	5.83	3.81	6.24	6.18
Risk ratio		1.00	2.23	1.00	1.07	0.75	0.69	0.92	1.00	0.65	1.07	1.06
AF _p (%)		0.00	6.09	0.00	0.36				0.00		0.37	0.32
Anxiety	7.88	6.31	8.45	6.42	7.80	8.36	8.97	8.93	7.22	7.11	7.29	6.45
Risk ratio		1.00	1.34	1.00	1.21	1.30	1.40	1.24	1.00	0.98	1.01	0.89
AF _p (%)		0.00	2.60	0.00	1.67	2.33	3.03	1.83	0.00		0.08	
Arthritis	11.06	11.13	11.03	7.72	10.53	12.83	12.56	7.14	9.36	10.72	13.84	14.78
Risk ratio		1.00	0.99	1.00	1.36	1.66	1.63	0.76	1.00	1.15	1.48	1.58
AF _p (%)		0.00		0.00	3.87	6.82	6.48		0.00	1.58	5.03	6.02
Asthma	8.61	7.19	9.13	7.48	8.80	8.00	11.22	6.25	6.24	8.74	10.39	10.75

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Risk ratio		1.00	1.27	1.00	1.18	1.07	1.50	1.00	1.00	1.40	1.67	1.72
AF _p (%)		0.00	2.27	0.00	1.50	0.59	4.13	0.01	0.00	3.33	5.42	5.86
Birth Control	8.71	0.24	10.88	21.13	8.77	2.59	0.95	10.71	11.69	7.30	6.34	6.99
Risk ratio		1.00	45.33	1.00	0.42	0.12	0.04	0.92	1.00	0.62	0.54	0.60
AF _p (%)		0.00	79.43	0.00					0.00			
Bowel/Rectum	3.06	2.75	3.17	1.76	2.84	3.53	4.15	1.79	3.15	2.87	2.85	2.96
Risk ratio		1.00	1.15	1.00	1.61	2.01	2.36	0.57	1.00	0.91	0.90	0.94
AF _p (%)		0.00	0.47	0.00	1.84	2.99	3.99		0.00			
Cold/Influenza/Allergy	17.80	14.52	18.99	15.73	18.30	18.14	19.07	22.32	15.53	18.56	20.38	22.04
Risk ratio		1.00	1.31	1.00	1.16	1.15	1.21	1.44	1.00	1.20	1.31	1.42
AF _p (%)		0.00	5.20	0.00	2.83	2.65	3.64	7.22	0.00	3.36	5.27	6.94
Depression	18.24	10.28	21.14	12.51	19.30	20.75	18.84	15.18	16.20	17.59	20.83	18.55
Risk ratio		1.00	2.06	1.00	1.54	1.66	1.51	0.94	1.00	1.09	1.29	1.15
AF _p (%)		0.00	16.16	0.00	9.01	10.73	8.45		0.00	1.54	4.95	2.58
Diabetes	6.32	6.48	6.22	2.53	4.50	7.82	10.94	1.79	2.24	5.67	11.29	17.74
Risk ratio		1.00	0.96	1.00	1.78	3.09	4.32	0.80	1.00	2.53	5.04	7.92
AF _p (%)		0.00		0.00	4.69	11.67	17.36		0.00	8.82	20.34	30.43
Edema	5.14	3.12	5.87	2.04	3.64	6.48	8.86	6.25	3.08	4.66	7.29	12.90
Risk ratio		1.00	1.88	1.00	1.78	3.18	4.34	2.03	1.00	1.51	2.37	4.19
AF _p (%)		0.00	4.33	0.00	3.88	10.06	14.66	5.02	0.00	2.57	6.56	14.08
Eye Infection	12.01	9.23	12.87	11.44	13.06	11.13	12.34	14.29	11.02	12.12	13.64	9.68
Risk ratio		1.00	1.39	1.00	1.14	0.97	1.08	1.30	1.00	1.10	1.24	0.88
AF _p (%)		0.00	4.52	0.00	1.67		0.94	3.44	0.00	1.18	2.78	
Herpes	6.30	3.26	6.86	4.82	7.24	6.12	4.71	1.79	7.66	7.22	4.20	1.88
Risk ratio		1.00	2.10	1.00	1.50	1.27	0.98	0.23	1.00	0.94	0.55	0.25
AF _p (%)		0.00	6.50	0.00	3.07	1.67			0.00			
High Blood Pressure	16.49	19.95	15.60	4.58	11.05	22.78	29.39	6.25	8.54	17.44	24.68	31.99
Risk ratio		1.00	0.78	1.00	2.41	4.97	6.42	0.73	1.00	2.04	2.89	3.75
AF _p (%)		0.00		0.00	18.89	39.59	47.18		0.00	14.66	23.76	31.17
Inflammation	1.19	0.68	1.37	0.69	0.87	1.50	1.68	1.79	0.98	1.40	0.80	1.61
Risk ratio		1.00	2.01	1.00	1.26	2.17	2.43	1.83	1.00	1.43	0.82	1.64
AF _p (%)		0.00	1.19	0.00	0.31	1.38	1.68	0.97	0.00	0.51		0.76

Insomnia	4.23	2.24	4.95	2.70	3.60	5.72	4.04	8.93	4.07	3.92	3.85	4.84
Risk ratio		1.00	2.21	1.00	1.33	2.12	1.50	2.19	1.00	0.96	0.95	1.19
AF _p (%)		0.00	4.87	0.00	1.39	4.52	2.06	4.81	0.00			0.79
Muscle Spasms	4.34	3.53	4.64	3.11	4.57	4.93	4.37	5.36	3.29	4.27	5.44	6.99
Risk ratio		1.00	1.31	1.00	1.47	1.59	1.41	1.63	1.00	1.30	1.65	2.12
AF _p (%)		0.00	1.35	0.00	2.00	2.48	1.73	2.66	0.00	1.28	2.76	4.65
Nausea/Vomiting	5.01	3.77	5.47	5.44	4.85	4.83	5.10	4.46	4.14	4.50	6.19	5.65
Risk ratio		1.00	1.45	1.00	0.89	0.89	0.94	1.08	1.00	1.09	1.50	1.36
AF _p (%)		0.00	2.21	0.00				0.39	0.00	0.43	2.42	1.79
Opioids	17.04	15.98	17.42	14.14	16.29	18.62	18.73	17.86	13.39	15.77	20.28	27.69
Risk ratio		1.00	1.09	1.00	1.15	1.32	1.32	1.33	1.00	1.18	1.51	2.07
AF _p (%)		0.00	1.51	0.00	2.53	5.12	5.24	5.38	0.00	2.94	8.06	15.40
Osteoporosis	1.21	0.07	1.63	0.00	0.17	1.30	4.37	0.89	1.56	1.20	0.85	0.00
Risk ratio		1.00	23.29	1.00				0.57	1.00	0.77	0.54	0.00
AF _p (%)		0.00	21.24	0.00					0.00			
Pain – non opioid	2.19	1.63	2.39	2.78	2.15	1.98	1.91	3.57	1.73	1.67	2.55	2.96
Risk ratio		1.00	1.47	1.00	0.77	0.71	0.69	2.06	1.00	0.97	1.47	1.71
AF _p (%)		0.00	1.01	0.00				2.28	0.00		1.03	1.53
Skin	6.84	4.88	7.55	5.44	6.44	7.37	8.24	6.25	7.25	6.41	7.19	5.38
Risk ratio		1.00	1.55	1.00	1.18	1.35	1.51	0.86	1.00	0.88	0.99	0.74
AF _p (%)		0.00	3.61	0.00	1.24	2.37	3.40		0.00			
Statins	12.05	15.91	10.65	1.76	7.07	16.46	24.51	2.68	5.59	15.15	17.18	21.77
Risk ratio		1.00	0.67	1.00	4.02	9.35	13.93	0.48	1.00	2.71	3.07	3.89
AF _p (%)		0.00		0.00	26.66	50.16	60.90		0.00	17.09	19.99	25.86
Stomach Acid	1.19	1.49	1.07	0.86	1.25	0.99	1.96	0.89	0.81	1.01	1.90	1.08
Risk ratio		1.00	0.72	1.00	1.45	1.15	2.28	1.10	1.00	1.25	2.35	1.33
AF _p (%)		0.00		0.00	0.54	0.18	1.50	0.12	0.00	0.29	1.58	0.40
Teeth/Gums	0.43	0.37	0.46	0.37	0.35	0.43	0.67	0.00	0.27	0.43	0.35	0.27
Risk ratio		1.00	1.24	1.00	0.95	1.16	1.81	0.00	1.00	1.59	1.30	1.00
AF _p (%)		0.00	0.10	0.00		0.07	0.35		0.00	0.25	0.13	0.00
Thyroid	12.76	2.99	16.31	4.37	11.19	16.92	17.61	6.25	13.97	12.74	13.94	19.09
Risk ratio		1.00	5.45	1.00	2.56	3.87	4.03	0.45	1.00	0.91	1.00	1.37

AF _p (%)		0.00	36.24	0.00	16.61	26.82	27.88		0.00			4.47
Ulcers	9.38	8.55	9.69	8.30	8.28	10.19	10.88	10.71	7.59	9.90	10.99	15.32
Risk ratio		1.00	1.13	1.00	1.00	1.23	1.31	1.41	1.00	1.30	1.45	2.02
AF _p (%)		0.00	1.24	0.00		2.09	2.83	3.71	0.00	2.78	4.03	8.72
Urinary Tract Infection	3.01	0.20	4.44	3.39	3.08	3.45	3.25	6.25	3.83	2.83	3.50	3.76
Risk ratio		1.00	22.20	1.00	0.91	1.02	0.96	1.63	1.00	0.74	0.91	0.98
AF _p (%)		0.00	38.95	0.00		0.05		1.87	0.00			
Vitamins/Minerals	2.07	0.71	2.57	2.49	1.73	1.88	2.47	0.00	2.07	1.28	1.75	5.38
Risk ratio		1.00	3.62	1.00	0.69	0.76	0.99	0.00	1.00	0.62	0.85	2.60
AF _p (%)		0.00	5.14	0.00					0.00			3.20
All prescriptions	80.87	71.40	84.32	71.52	78.45	85.24	88.00	83.93	81.46	81.28	83.47	86.29
Risk ratio		1.00	1.18	1.00	1.10	1.19	1.23	1.03	1.00	1.00	1.02	1.06
AF _p (%)		0.00	12.77	0.00	7.27	13.43	15.71	2.39	0.00		1.96	4.58

AF_p: Attributable fraction in the population. Shaded cells represent statistical significance at the 0.05 level. Cells that are left blank had a negative AF_p. In these cases the preventive fraction ($[\text{Risk Ratio} - 1] \times 100$) is more appropriate.

Review only

1
2
3 Figure 1. Median medical and pharmacy cost (USD) according to Body Mass Index weight
4 classifications and age
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page/line numbers
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1/6, 2/25
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Done
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Done
Objectives	3	State specific objectives, including any prespecified hypotheses	Done
Methods			
Study design	4	Present key elements of study design early in the paper	Done
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Done
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Done
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Done
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Done
Bias	9	Describe any efforts to address potential sources of bias	Done
Study size	10	Explain how the study size was arrived at	Done
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Done
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Done
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Done
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Done
		(b) Indicate number of participants with missing data for each variable of interest	Done
		(c) Summarise follow-up time (eg, average and total amount)	Done
Outcome data	15*	Report numbers of outcome events or summary measures over time	Done
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	Done

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Done
Discussion			
Key results	18	Summarise key results with reference to study objectives	Done
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Done
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done
Generalisability	21	Discuss the generalisability (external validity) of the study results	Done
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Done

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

To what extent does sex, age, and BMI impact medical and pharmacy costs? A retrospective cohort study involving employees in a large school district

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024078.R2
Article Type:	Research
Date Submitted by the Author:	28-Jan-2019
Complete List of Authors:	Merrill, Ray; Brigham Young University, Public Health Fowers, Rylan; Brigham Young University
Primary Subject Heading:	Pharmacology and therapeutics
Secondary Subject Heading:	Public health, Epidemiology
Keywords:	health risks, screening, prescription medication, health risk appraisal, body mass index, pharmaceutical costs

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 **To what extent does sex, age, and BMI impact medical and pharmacy costs? A**
16 **retrospective cohort study involving employees in a large school district**
17
18

19
20 Ray M. Merrill, PhD, MPH, Rylan P. Fowers, BS
21

22
23 Department of Public Health, College of Life Sciences, Brigham Young University
24
25
26
27
28
29
30
31

32 Corresponding Author:
33

34 Ray M. Merrill
35

36 Department of Public Health
37

38 2063 Life Sciences Building
39

40 Provo, Utah 84602
41

42 Email: Ray_Merrill@byu.edu
43

44 Telephone: 801-422-9788
45

46 Fax: 801-422-9363
47
48
49

50 Keywords: body mass index, obesity, prevention, pharmaceuticals, screening
51

52 Word count: 3527
53
54
55
56
57
58
59
60

1
2
3 **Objective** To identify the extent that sex, age, and body mass index (BMI) is associated with
4
5 medical and pharmacy costs.
6

7
8 **Design** Retrospective cohort.
9

10 **Setting** A school district in the Western United States involving 2531 workers continuously
11
12 employed during 2011-2014.
13

14 **Main outcome measures** Medical and pharmacy costs and BMI.
15

16
17 **Results** Approximately 84% of employees participated in the wellness screening. Participants
18
19 were 1.03 (95% CI 1.01- 1.06) times more likely to be women and younger (M = 47.8 vs. 49.8, p
20
21 < 0.001). Median medical and pharmacy costs were higher for women than men, increased with
22
23 age, and were greater in morbidly obese individuals (p < 0.001). Annual pharmacy claims were
24
25 18% more likely to be filed by women than men, 23% more likely filed by those aged ≥ 60 versus
26
27 <40 years, and 6% more likely filed by morbidly obese individuals than of normal weight (p <
28
29 0.001) individuals. Greater medical and pharmacy costs in older age were most pronounced in
30
31 underweight and morbidly obese groups. Higher use of medication among women than men was
32
33 primarily because of drugs involving birth control, osteoporosis, thyroid disease, and urinary
34
35 tract infection. Higher medication use in older age was primarily related to medications used to
36
37 treat gastrointestinal problems. Medication use was positively associated with BMI weight
38
39 classifications for most of the 33 drug types considered, with exceptions involving birth control,
40
41 herpes, and osteoporosis. A J-shape relationship was observed between BMI and medication use
42
43 for acne, antibiotic, cold/influenza/allergy, eye infection, edema, muscle spasms, pain, and
44
45 ulcers.
46
47
48
49
50
51

52
53 **Conclusions** Lowering medical and pharmacy costs requires weight management in older ages,
54
55 particularly for underweight and obese men and women. Medical costs were significantly
56
57
58
59
60

1
2
3 reduced, likely due to effective drug treatment and prevention. Higher pharmacy costs for certain
4
5 drugs among underweight individuals may be associated with poorer nutrition.
6
7
8
9

10 Strengths and limitations of this study

- 11 • A large cohort of employees was available for retrospective assessment of the
12 association between sex, age, and BMI with medical and pharmacy costs.
13
- 14 • The association between sex, age, and 33 specific types of medication were assessed,
15 some of which have not been previously considered.
16
- 17 • All active employees received employer-sponsored medical and pharmacy coverage,
18 and above 84% had information that allowed us to determine body mass.
19
- 20 • A few medications may have contributed to weight gain, which we were unable to
21 adjust for in the current study.
22
- 23 • The study population and patterns of prescription drug use may limit generalization of
24 the results.
25
26
27
28
29
30
31
32
33
34
35

Introduction

Many companies offer wellness-screening programs consisting of health risk assessment and biometric screening. The 2016 Employer Health Benefits Survey found that among large firms (200 or more employees) in the United States, 59% offered health risk assessment (of which 32% had an incentive component) and 53% offered biometric screening (of which 31% included an incentive component).¹ These programs are intended to promote a greater sense of personal responsibility for lifestyle choices, identify the need for health behavior change, reduce future health problems, encourage patient management of existing health problems, decrease worker absenteeism, and improve job satisfaction and worker productivity.²⁻⁷ Larger companies are also required to offer employer-sponsored medical and pharmacy coverage for their employees. Hence, information obtained on the health risk assessment and screenings can be compared with the medical and pharmacy costs.

Medical and pharmacy costs are influenced by a number of factors, including sex, age, and Body Mass Index (BMI).⁸⁻¹⁰ Although medical costs are often a response to acute and chronic health conditions, pharmaceutical costs are often used to prevent more serious health problems. For example, antihypertensive medication, or statins, are useful in preventing cardiovascular disease;¹¹⁻¹³ multivitamins or folic acid for preventing congenital abnormalities;¹⁴ aspirin and non-steroidal anti-inflammatory for preventing colorectal cancer;¹⁵ bronchodilators, steroids, and anti-inflammatories for managing asthma;¹⁶ and nonsteroidal anti-inflammatory drugs, steroids, analgesics, and immunosuppressive drugs for managing arthritis.¹⁷ Consequently, wellness screening may actually increase use of prescription medication.¹⁸

1
2
3 Although a person's body weight may be associated with increased risk for various
4 chronic health conditions and poorer health-related quality of life,^{19 20} only in the last 15 years or
5 so has its impact on healthcare expenditures been assessed.¹⁰ Further, only a small number of
6 studies have explored the association between body weight and prescription drug use. A study
7 conducted in England found that overweight and obese individuals were more likely to receive
8 medication for the cardiovascular system; gastrointestinal system; respiratory system; central
9 nervous system; endocrine system; gynecology/urinary disorders; musculoskeletal and joint
10 disorders; infections; eye, ear and oropharynx problems; and skin disorders.²¹ A study in Sweden
11 showed that use and cost of medication in general are significantly greater in obese individuals.²²
12 A study in the United States found that obesity was responsible for \$7 billion in Medicare
13 prescription drug costs in 2006.²³ Another study conducted in the United States identified
14 increased medication use during 1988 through 2012, with the increase most prominent among
15 obese individuals.²⁴ A large cross-sectional study of 9789 adults in the National Health and
16 Nutrition Examination Survey (NHANES) found that obese individuals utilize several
17 prescription drugs (e.g., hypertension, lipid-lowering, and diabetes medications) more frequently
18 than normal weight individuals.²⁵ Another study based on NHANES data found that while
19 medication use increased over time for obese individuals compared with normal weight
20 individuals ages 40 years and older, the increase was only marginal for those aged 25-39 years.²⁶
21 One study found that obese individuals used more analgesic, asthma, cardiovascular, diabetes,
22 intranasal allergic rhinitis, thyroid, and ulcer medications.²⁷
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 The purpose of the current study was to identify the extent to which sex, age, and BMI
50 weight classifications are associated with medical and pharmacy costs among a large group of
51 teachers, administrators, and other school staff. These associations are also evaluated for 33 more
52
53
54
55
56
57
58
59
60

1
2
3 commonly prescribed medications.²⁸ Although studies have previously looked at the association
4 between BMI and prescription medications, we evaluated some drugs that have not been
5
6 formerly considered, and the breadth of drugs covered is greater than in past studies. In addition,
7
8 evaluating the effect of being underweight on medical and pharmacy costs, and on specific drug
9
10 types, is unique to this study.
11
12
13
14
15

16 **Methods**

17 *Patient and Public Involvement*

18
19 A retrospective cohort study was conducted that associated sex, age, and BMI with medical and
20
21 pharmacy cost data for employees of a large school district in the western United States. Specific
22
23 patients and or the general public was not involved in this study. Body mass index was obtained
24
25 from those employees who participated in wellness screening. Employer-sponsored insurance
26
27 was available to all employees. The school district comprised six high schools, eight junior high
28
29 schools, and 31 elementary schools. Employees consisted of approximately three teachers to
30
31 every one staff member (cooks, bus drivers, grounds keepers, maintenance workers,
32
33 administrators, clerical workers, etc.). We were not provided specific job type and salary for each
34
35 employee. However, we can assume that the teachers, administrators, counselors, and nurses,
36
37 who represent almost all of the employees, had at least a college degree, that their salaries are
38
39 commensurate with other school districts, and that the employer-sponsored insurance coverage
40
41 was not strongly impacted by the employee's income or education.
42
43
44
45
46
47
48

49 The study involved the academic years 2010-11, 2011-12, 2012-13, and 2013-14.
50
51 Employees were offered wellness screenings (personal health risk assessment [HRA] and
52
53 biometric evaluation) each fall. Medical and pharmacy claims data were also obtained for the
54
55
56
57
58
59
60

1
2
3 employees in each academic year. Wellness screening and claims data were combined with a file
4
5 of eligible employees and assessed within each academic year. The eligibility file contained
6
7 information on current employment, sex, age, and year.
8
9

10 11 12 *Wellness Screening* 13

14
15 All employees were offered wellness screening. Although participation was voluntary, it
16
17 was promoted through incentives. The HRA involved 36 questions. Biometric screenings
18
19 involved measurements of body mass index (BMI kg/m²), blood pressure (mm Hg), cholesterol
20
21 (mg/dL), and glucose (mg/dL). The HRA and biometric screenings were provided at no cost to
22
23 the employees, and were made available on location or with a personal physician. A health nurse
24
25 or physician assisted the employee in interpreting their HRA and screening results, in order to
26
27 help guide their need for lifestyle changes and control measures. The current study only
28
29 considers BMI. Weight classifications are based on commonly accepted ranges of BMI, as
30
31 follows: underweight (BMI < 18.5), normal weight (BMI 18.5-24), overweight (BMI 25-29),
32
33 obese (BMI 30-39), and morbidly obese (BMI 40+).
34
35
36
37
38
39

40 41 *Medical and Pharmacy Claims Data* 42

43 All active employees received employer-sponsored medical and pharmacy coverage, for
44
45 themselves and their families. The school district is fully insured with a retained-retention
46
47 agreement that makes the plan act very much like a self-funded health plan. Each month the
48
49 district pays a health insurance premium for the cost of healthcare and a small premium for
50
51 reinsurance of catastrophic claims. Catastrophic claims greater than \$250,000 are reinsured by a
52
53 stop loss policy and are not paid for by the school district. Employee pharmacy data do not
54
55
56
57
58
59

1
2
3 include over-the-counter drugs, but only those medications requiring a prescription. In the United
4
5 States, a drug is sold over-the-counter if the Food and Drug Administration deems it as
6
7 sufficiently safe and effective. These medications are not included in the current study. Further,
8
9 medical and pharmacy cost represents the amount paid by the insurance company as well as
10
11 copays by the employee.
12
13
14
15

16 17 *Statistical Techniques*

18
19 Counts, means, standard deviations, medians, and percentages were used to describe the
20
21 study population. Pair-wise comparisons of means were evaluated for statistical significance
22
23 using the Student-Newman-Keuls Test. Risk ratios compare having a medical and pharmacy cost
24
25 above the 50th percentile (vs. below), 75th percentile (vs. below), and 90th percentile (vs. below).
26
27 Statistical significance was determined by the corresponding 95% confidence intervals. For
28
29 selected medications, the risk of medication use was compared using risk ratios and attributable
30
31 fraction percentages across the levels of sex, age, and BMI weight classifications. Statistical
32
33 significance of differences in percent use of selected medications across sex, age, and BMI
34
35 categories was based on two-sided tests of significance were based on the 0.05 level against a
36
37 null hypothesis of no association. Data was evaluated using the statistical software package PC-
38
39 SAS (version 9.4; SAS Institute, Inc., 2014).
40
41
42
43
44
45

46 47 **Results**

48
49 In 2010-11, there were 3023 eligible employees, of which 2531 (83.72%) remained employed
50
51 through the academic year 2013-14. Those more likely to remain employed over the study period
52
53 were 40-59 years of age and had lower medical and pharmacy costs (Table 1). In 2010-11, ages
54
55
56
57
58
59

1
2
3 ranged from 18-76, with mean age significantly younger for those who remained employed (46.9
4 vs. 49.2, $p < 0.0001$). Those who remained employed had significantly lower mean medical costs
5 (\$3056 vs. \$7887, $p < 0.0001$) and mean pharmacy costs (\$859 vs. \$1105, $p = 0.0387$). The
6 results of this study are based on those continuously employed over the four academic years.
7
8
9
10
11

12
13 Most employees participated in annual wellness screening (84.1% in 2010-11, 84.4% in
14 2011-12, 87.6% in 2012-13, and 80.7% in 2013-14). In 2010-11, there was no significant
15 difference in mean medical cost between those who participated in wellness screening and those
16 who did not (\$3148 vs. \$2571, $p = 0.2900$). However, median medical cost was significantly
17 greater for those who participated in wellness screening (\$588 vs. \$470, $p = 0.0454$). For all
18 academic years, women were 1.03 (95% CI 1.01- 1.06) times more likely than men to complete
19 annual wellness screenings, after adjusting for age and academic year. Participants in wellness
20 screening were significantly younger ($M = 47.8$ vs. 49.8 , $p < 0.0001$), after adjusting for sex and
21 year. Those participating in wellness screening had significantly lower mean medical cost
22 (\$3093 vs. \$4181, $p = 0.0013$), but experienced no significant difference in mean annual
23 pharmacy costs, after adjusting for age, sex, and year.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Among participants in annual wellness screening, mean BMI remained constant across
40 the academic years (Table 2). Mean BMI was greater for men than women and in ages 40 years
41 and older. Medical and pharmacy costs were highly positively skewed, with considerable
42 variability. Hence, identifying significant differences in the mean costs across the levels of sex,
43 age, and year, were less likely to occur than to find significant differences in the median costs
44 across the levels of these variables. Medical costs were higher for women than men, increased
45 with age, and were greater in morbidly obese individuals. Pharmacy costs were higher in women
46 than men, increased with age, and were lowest in those of normal weight.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The risk of medical and pharmacy costs above the 50th, 75th, and 90th percentiles are
4 shown according to sex, age, and BMI weight classification in Table 3. Higher BMI has a greater
5 impact on higher percentiles of medical and pharmacy costs. For example, morbidly obese
6 compared with normal weight are 1.13 (13%), 1.30 (30%), and 1.93 (93%) more likely to have
7 pharmacy costs above the 50th, 75th, and 90th percentiles, respectively. Medical and pharmacy
8 costs above these percentiles are greater in women than men and increase with age.
9

10
11
12 Associations between selected percentiles of medical and pharmacy costs and BMI
13 weight classifications varied according to age (Figure 1), but not sex (data not shown). Greater
14 medical and pharmacy costs with older age groups are seen in the graph. However, the
15 increasing costs with higher age are most pronounced in the underweight and morbidly obese
16 groups.
17

18
19
20 Medication use is shown across sex, age, and BMI groups in Table 4. For any
21 medication, women were 18% more likely to file a claim than men, employees 60 years of age or
22 older were 23% more likely to file a claim than those less than 40 years, and morbidly obese
23 were 6% more likely to file a claim than those of normal weight. For 22 of the 33 medications
24 considered, the percentage of annual claims was higher for women than men. For high blood
25 pressure and statins was the percentage of claims greater for men than women. For 25 of the
26 medications, the percentage of annual claims increased with age. For 24 of the medications, the
27 percentage of annual claims was associated with BMI (20 positively and 4 negatively). The
28 strongest positive associations involved diabetes, high cholesterol (statins), blood thinners, high
29 blood pressure, and edema. Negative associations involved acne, birth control, Herpes, and
30 osteoporosis. The highest annual percent of acne, antibiotic, cold/influenza/allergy, and eye
31 infection medications occurred in underweight individuals. For edema, muscle spasms, pain, and
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ulcers, medication use was comparatively high in underweight individuals, dropped for normal
4 weight, and then increased in higher weight classifications.
5
6

7
8 We also report the attributable fraction in the population. For example, this statistic says
9 that 8.82% of diabetes medication is attributed to being overweight, 20.34% is attributed to being
10 obese, and 30.43% is attributed to being morbidly obese. Where the risk ratio is less than 1, the
11 preventive fraction can be estimated. For example, the risk of requiring osteoporosis medication
12 is lower for obese compared with normal weight employees (i.e., Risk Ratio = 0.54). The
13 corresponding preventive fraction is 66%, meaning in the absence of obesity there would be 66%
14 fewer claims for osteoporosis medication. The attributable fraction in the population and the
15 preventive fraction both assume a cause-and-effect association between exposure and disease.
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Discussion**

31
32 The current study identified the degree to which sex, age, and BMI are associated with medical
33 and pharmacy costs among employees in a large school district. Associations were also evaluated
34 for 33 commonly prescribed medications.²⁸ The study extends previous research by including
35 certain medications not previously evaluated and considering associations for all BMI weight
36 classifications.
37
38
39
40
41
42

43 Higher medical and pharmacy costs among women, in older age, and among those not of
44 normal weight is consistent with previous research.⁸⁻¹⁰ Greater medical and pharmacy costs with
45 older age are most pronounced in the underweight and morbidly obese groups. Hence, weight
46 management at older ages appears particularly important in terms of lowering medical and
47 pharmacy costs.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Higher medication use in women than men was primarily because of drugs involving
4 birth control, osteoporosis, thyroid disease, and urinary tract infection. Prescription costs for
5 vitamins/minerals were also noticeably higher in women than men. Family planning and prenatal
6 care may explain the greater use of birth control medications and vitamins/minerals among
7 women. Loss of estrogen in women at older ages and female reproductive hormones may
8 contribute to the higher level of osteoporosis and thyroid disease in women.^{29 30}

9
10 Medication use was higher in those aged 60 years and older compared with those younger
11 than 40, primarily because of diabetes, edema, high blood pressure, high cholesterol (statins),
12 and thyroid disease. Previous research has shown that the risk of these diseases increase with
13 age.³¹⁻³⁵ Medication use also noticeably increased with age for acid reflux, bowel/rectum,
14 inflammation, and stomach acid. This is consistent with older age tending to be associated with
15 more gastrointestinal problems.³⁶

16
17 Medication use was highest in those who were morbidly obese. We found positive
18 associations between body weight and higher use of medications for treating acid reflux, fungus,
19 bacterial infections, arthritis, asthma, colds, influenza, allergies, depression, diabetes, edema,
20 high blood pressure, muscle spasms, nausea/vomiting, pain, high cholesterol, stomach acid,
21 thyroid, and ulcers. Other studies have identified a similar associations.^{21 24 25 27} Morbidly obese
22 individuals were also more likely to be prescribed vitamins and minerals than normal weight
23 individuals. We did not find an association between body weight and increased use of
24 medication for the bowel/rectum, skin, or urinary tract, which was counter to that found in other
25 studies.^{21 37-39} We also assessed but did not find a significant association for medications used to
26 treat anxiety, insomnia, convulsions, or teeth and gums. The insignificant finding for
27 anticonvulsants and teeth and gums may be because of insufficient power (i.e., small numbers).

1
2
3 Finally, we assessed the association between body weight and medications for birth control,
4 herpes, and osteoporosis, wherein significant negative associations were found. We are not
5 aware of other studies that have looked at the association between body weight and medications
6 used for colds, influenza, depression, edema, birth control, herpes, or osteoporosis.
7
8
9
10

11
12 Greater use of medication to treat acid reflux or stomach acid among individuals with
13 higher BMI is consistent with previous research showing hospitalization rates for reflux disease
14 to be positively associated with BMI.^{40 41} Another study found that higher BMI was associated
15 with increased gastroesophageal reflux in both normal and overweight individuals.⁴² Heavier
16 body weight can add pressure to the stomach and diaphragm, thereby resulting in reflux. Further,
17 increased use of medication for nausea/vomiting among individuals with higher BMI weight
18 classifications is consistent with other research.⁴³
19
20
21
22
23
24
25
26
27
28

29 The positive association between higher BMI and increased use of medication for ulcers
30 is consistent with other research, particularly peptic (gastric and duodenal) ulcers.^{44 45} The
31 mechanism to explain the association between obesity and peptic ulcer disease remains unclear.
32
33 Obesity is also associated with *Helicobacter pylori*, which has been linked with gastric ulcers.⁴⁶
34
35
36
37
38

39 Previous research has shown that overweight and obese individuals are at greater risk for
40 infections.³⁷⁻⁴⁹ This is consistent with our findings that show increased use of antibiotics and
41 medication for acne, colds/influenza/allergy, and eye infections among obese individuals.
42
43 However, it has been shown previously that antibiotics can also weaken the immune system,⁵⁰ as
44 well as lead to obesity.⁵¹ Some inflammatory diseases known to be associated with obesity in
45 which we found a positive association between obesity and medication included influenza,^{52 53}
46 heart disease,⁵⁴ diabetes,⁵⁵ allergies,⁵⁶⁻⁵⁹ asthma,⁶⁰ edema,⁶¹⁻⁶³ and arthritis.⁶⁴⁻⁶⁷ A compromised
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 immune system may also trigger autoimmune diseases, including rheumatoid arthritis and
4
5 thyroid disease,⁶⁸ as indicated in the current study.
6
7

8 Overweight and obese individuals were more likely to receive cold, influenza, or allergy
9 medication. Obesity is associated with impaired immune response to influenza vaccination in
10 humans.⁶⁹ Because vaccination is less successful for obese individuals,^{70 71} a greater level of
11 medication may be sought for treating colds, influenza, and allergies.
12
13
14
15
16
17

18 Overweight and obese individuals received higher levels of pain medication. Research
19 indicates that the nature of the relationship between higher BMI and pain is likely indirect.⁷² For
20 example, greater body weight is associated with osteoarthritis, which, in turn, leads to pain.⁷³
21 Being overweight or obese may result in greater risk for back pain, joint pain, and muscle
22 spasms.⁷⁴ One study also found that obese individuals were more sensitive than those of normal
23 weight to pressure pain.⁷⁵
24
25
26
27
28
29
30
31
32

33 We found that higher BMI was associated with depression medication, as consistent with
34 previous research.⁷⁶⁻⁷⁹ In one study, the age-adjusted level of depression among adults (ages 20
35 and older) in the United States was 43.2% for those with depression compared with 33.0% for
36 those without depression.⁸⁰ It may be that higher use of prescription medication for depression
37 among those with greater BMI is partly because these people are more likely to experience other
38 conditions related to depression, such as heart disease and diabetes.⁸¹⁻⁸³
39
40
41
42
43
44
45
46

47 There was more use of vitamins/minerals among morbidly obese employees. Of the
48 prescribed vitamins/minerals only 8.0% involved vitamin B and 57.3% involved vitamin D. A
49 previous study showed an association between low vitamin B12 and being obese.⁸⁴ Another
50 study found that the prevalence of vitamin D deficiency was 35% greater in obese individuals.⁸⁵
51
52
53
54
55
56
57
58
59
60

1
2
3 Acne, antibiotic, cold/influenza/allergy, and eye infection medications were prescribed
4 more often for underweight individuals. This is consistent with underweight individuals having
5 poorer nutrition and, consequently, a weakened immune system.⁸⁶ For edema, muscle spasms,
6 pain, and ulcers, medication use showed a J-shape relationship with BMI weight classification.
7
8 Poor nutrition may also explain the higher levels of medication use among underweight
9 individuals for these medications. Despite mean medical costs being similar for those who
10 participated in wellness screening during the first year of the study, over the four academic years,
11 participants in wellness screening ended up having significantly lower mean medical costs.
12
13 However, pharmacy costs did not go down. It has been shown that wellness screening can cause
14 the number and cost of pharmaceuticals to go up, at least initially, as the need for treatment is
15 identified.⁸⁷ Identified treatment needs can then, in turn, help prevent more costly health
16 problems in the future. For example, medications used to treat high blood pressure can result in
17 lowering the risk of diabetes, heart disease, stroke and kidney disease; treatment of insomnia can
18 help lower the risk of irritability, depression or anxiety, difficulty paying attention, and accidents
19 due to increased errors; treatment of high cholesterol with statins can help lower the risk of
20 cardiovascular disease; treatment of oral infections can help reduce the risk of diabetes,
21 cardiovascular disease, and preterm birth; and vitamins/minerals can help prevent a host of
22 diseases (scurvy, rickets, anemia, neural tube defects, pellagra, etc.). High blood pressure and
23 statin medications were among the highest prescribed in our study.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 A limitation of this study involves external validity (generalizability). Specifically, the
48 study only considered those individuals who remained employed over all four academic years.
49
50 These people were generally healthier and in the age range 40-59. The study also focused on
51 those who completed wellness screening because they contained BMI information. These
52
53
54
55
56
57
58
59
60

1
2
3 employees were more likely women and younger. In addition, the causal direction between
4 medication use and BMI could not be determined. That is, some medications may have
5 contributed to body mass whereas others were in response to body mass. Finally, the current
6 study did not have information on the use of vitamins or minerals obtained over the counter and
7 small numbers made it impossible to evaluate the relationship between specific types of
8 vitamins/minerals and sex, age, and BMI.
9
10
11
12
13
14
15
16
17
18
19
20

21 **Conclusion**

22
23 Weight management at older ages, particularly in underweight and morbidly obese individuals, is
24 most important for lowering medical and pharmacy costs. Medical costs decreased, possibly
25 because of effective drug treatment and prevention. Pharmacy costs remained constant, possibly
26 because screening identified a need for certain medications. Greater use of medication among
27 women than men is primarily because of drugs involving birth control, osteoporosis, thyroid
28 disease, and urinary tract infection. Greater medication use in older age is primarily related to
29 medications used to treat gastrointestinal problems. Medication use was positively associated
30 with BMI for most of the conditions being treated, with exceptions involving birth control,
31 herpes, and osteoporosis. A J-shape relationship between BMI weight classification and
32 medication use for acne, antibiotic, cold/influenza/allergy, eye infection, edema, muscle spasms,
33 pain, and ulcers may be because of poorer nutrition in underweight individuals.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. 2016 Employer Health Benefits Survey. kff.org. <http://www.kff.org/health-costs/report/2016-employer-health-benefits-survey/>. Published September 14, 2016. Accessed February 21, 2018.
2. Chen L, Hannon PA, Laing SS, Kohn MJ, Clark K, Pritchard S, Harris JR. Perceived workplace health support is associated with employee productivity. *Am J Health Promot.* 2015;29(3):139-146.
3. Centers for Disease Control and Prevention. cdc.gov. <http://www.cdc.gov/sustainability/worksitewellness/> Worksite wellness. Updated December 9, 2014. Accessed March 18, 2018.
4. Michaels CN, Greene AM. Worksite wellness: increasing adoption of workplace health promotion programs. *Health Promot Pract.* 2013;14(4):473-479.
5. Witt LB, Olsen D, Ablah E. Motivating factors for small and midsized businesses to implement worksite health promotion. *Health Promot Pract.* 2013;14(6), 876-884.
6. Niessen MA, Kraaijenhagen RA, Dijkgraaf MG, van Pelt D, van Kalken CK, Peek N. Impact of a Web-based worksite health promotion program on absenteeism. *J Occup Environ Med.* 2012;54(4):404-408.
7. Kaspin LC, Gorman KM, Miller RM. Systematic review of employer-sponsored wellness strategies and their economic and health-related outcomes. *Popul Health Manag.* 2013;16(1): 14-21.
8. Metge C, Black C, Peterson S, Kozyrskyi AL. The population's use of pharmaceuticals. *Med Care.* 1999;37(6 Suppl):JS42-JS59.

- 1
2
3 9. Bertakis K, Azari R, Helms L, Callahan E, Robbins J. Gender differences in the utilization of
4 health care services. *J Fam Pract.* 2000;49(2):147-152.
5
6
- 7
8 10. Arterburn DE, Maciejewski ML, Tsevat J. Impact of morbid obesity on medical expenditures
9 in adults. *Int J Obes.* 2005;29(3):334-339.
10
11
- 12 11. Karmali KN, Lloyd-Jones DM, Berendsen M, et al. Drugs for primary prevention of
13 atherosclerotic cardiovascular disease: an overview of systematic reviews. *JAMA Cardiol.*
14 2016;1(3):341-349.
15
16
- 17 12. Fretheim A, Odgaard-Jensen, Brørs O, Madsen S, et al. Comparative effectiveness of
18 antihypertensive medication for primary prevention of cardiovascular disease: systematic
19 review and multiple treatments meta-analysis. *BMC Med.* 2012;10:33.
20
21
- 22 13. Taylor F, Huffman MD, Macedo A, et al. Statins for the primary prevention of
23 cardiovascular disease. *Cochrane.* 2013. [http://www.cochrane.org/CD004816/VASC_statins-](http://www.cochrane.org/CD004816/VASC_statins-primary-prevention-cardiovascular-disease)
24 primary-prevention-cardiovascular-disease. Accessed February 21, 2018.
25
26
- 27 14. Czeizel AE. Birth defects are preventable. *Int J Med Sci.* 2005;2(3):91-92.
28
29
- 30 15. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. *Gastroenterology.*
31 2010;138(6):2029-2043.
32
33
- 34 16. Asthma. Mayo Clinic. [https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-](https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-treatment/drc-20369660)
35 treatment/drc-20369660. Published March 9, 2018. Accessed February 24, 2018.
36
37
- 38 17. Arthritis. Mayo Clinic. [https://www.mayoclinic.org/diseases-conditions/arthritis/diagnosis-](https://www.mayoclinic.org/diseases-conditions/arthritis/diagnosis-treatment/drc-20350777)
39 treatment/drc-20350777. Published March 7, 2018. Accessed February 24, 2018.
40
41
- 42 18. Preventive Medicine Reports Paper
43
44
- 45 19. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic
46 consequences of obesity. *Arch Intern Med.* 1999;119(18):2177-2183.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 20. Pi-Sunyer X. The medical risks of obesity. *Postgrad Med.* 2009;121(6):21-33.
4
- 5 21. Kinge JM, Morris S. Association between obesity and prescribed medication use in England.
6
7 *Econ Hum Biol.* 2014;15:47-55.
8
- 9 22. Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison
10
11 with a randomly selected population sample and long-term changes after conventional and
12
13 surgical treatment: the SOS intervention study. *Arch Intern Med.* 2002;162(18):2061-2069.
14
- 15 23. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to
16
17 obesity: payer-and service-specific estimates. *Health Aff.* 2009;28(5):w822-31.
18
- 19 24. Randhawa AK, Parikh JS, Kuk JL. Trends in medication use by body mass index and age
20
21 between 1988 and 2012 in the United States. *PLoS One.* 2017 Sep 20;12(9):e0184089.
22
- 23 25. Kit BK, Ogden CL, Flegal KM. Prescription medication use among normal weight,
24
25 overweight, and obese adults, United States, 2005-2008. *Ann Epidemiol.* 2012;22(2):112-
26
27 119.
28
- 29 26. Jarrett B, Bloch GJ, Bennett D, Bleazard B, Hedges D. The influence of body mass
30
31 index, age and gender on current illness: a cross-sectional study. *Int J Obes.* 2010;34(3):429-
32
33 436.
34
- 35 27. Raebel MA, Malone DC, Conner DA, Xu S, Porter JA, Lanty FA. Health services use
36
37 and health care costs of obese and nonobese individuals. *Arch Intern*
38
39 *Med.* 2004;164(19):2135-2140.
40
- 41 28. Fuentes AV, Pineda MD, Venkata KCN. Comprehension of top 200 prescribed drugs in
42
43 the US as a resource for pharmacy teaching, training and practice. *Pharmacy (Basel).*
44
45 2018;6(2):E43.
46
- 47 29. Alswat KA. Gender disparities in osteoporosis. *Clin Med Res.* 2017;9(5): 382–387.
48
49
50
51
52
53

- 1
- 2
- 3 30. Li H, Li J. Thyroid disorders in women. *Minerva Med.* 2015;106(2):109-114.
- 4
- 5 31. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. *Diabetes Care.*
- 6
- 7 2012;35(12):2650-2664.
- 8
- 9
- 10 32. Traves KP, Studdiford JS, Pickle S, Tully AS. Edema: diagnosis and management. *Am Fam*
- 11
- 12 *Physician.* 2013;88(2):102-110.
- 13
- 14 33. Mc Donald Posso AJ, Motta Borrel JA, Fontes F, Cruz Gonzalez CE, Pachón Burgos
- 15
- 16 AA, Cumbreira Ortega A. High blood pressure in Panama: Prevalence, sociodemographic and
- 17
- 18 biologic profile, treatment, and control (STROBE). *Medicine (Baltimore).* 2014;93(22):
- 19
- 20 e101.
- 21
- 22
- 23 34. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in
- 24
- 25 older men and women. The Rancho Bernardo Study 1984-1994. *Circulation.* 1997;96(1):37-
- 26
- 27 43.
- 28
- 29
- 30 35. Gesing A. The thyroid gland and the process of aging. *Thyroid Res.* 2015;8(Suppl 1):A8.
- 31
- 32
- 33 36. A L D'Souza. Ageing and the gut. *Postgrad Med J.* 2007; 83(975):44–53.
- 34
- 35 37. Ma Y, Yang Y, Wang F, et al. Obesity and risk of colorectal cancer: a systematic review of
- 36
- 37 prospective studies. *PLoS One.* 2013;8(1):e53916.
- 38
- 39
- 40 38. Brown J, Wimpenny P, Maughan H. Skin problems in people with obesity. *Nurs Stand.*
- 41
- 42 2004;18(35):38-42.
- 43
- 44 39. Semins MJ, Shore AD, Makary MA, Weiner J, Matlaga BR. The impact
- 45
- 46 of obesity on urinary tract infection risk. *Urology.* 2012;79(2):266-269.
- 47
- 48
- 49 40. Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of
- 50
- 51 gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 Study. First National Health and Nutrition Examination Survey. *Ann Epidemiol.*
4
5 1999;9(7):424-435.
6
7
8 41. Anggiansah R, Sweis R, Anggiansah A, Wong T, Cooper D, Fox M. The effects of obesity
9
10 on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux
11
12 disease. *Alim Pharmacol Ther.* 2013;37(5):555-563.
13
14
15 42. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Association between body
16
17 mass index and gastroesophageal reflux symptoms in both normal weight and overweight
18
19 women. *N Engl J Med.* 2006;354(22):2340-2348.
20
21
22 43. Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in
23
24 young adults: a birth cohort study. *Am J Gastroenterol* 2004;99(9):1807-1814.
25
26
27 44. Boylan MR, Khalili H, Huang ES, Chan AT. Measures of adiposity are associated with
28
29 increased risk of peptic ulcer. *Clin Gastroenterol Hepatol.* 2014 Oct;12(10):1688-1694.
30
31
32 45. Kim J, Kim KH, Lee BJ. Association of peptic ulcer disease with obesity, nutritional
33
34 components, and blood parameters in the Korean population. *PLoS One.* 2017;12(8):
35
36 e0183777.
37
38 46. Xu M, Liu L, Yuan B, Yin J, Lu Q. Association of obesity with *Helicobacter pylori* infection:
39
40 A retrospective study. *World J Gastroenterol* 2017;23(15):2750-2756.
41
42
43 47. Falagas ME, Kompoti M. Obesity and infection. *Lancet Infect Dis* 2006;6(7)438-446.
44
45
46 48. Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. *Int J Obes.*
47
48 2013;37:333-340.
49
50 49. Lübbecke A, Zingg M, Hoffmeyer P, et al. Body mass and weight thresholds for increased
51
52 prosthetic joint infection rates after primary total joint arthroplasty. *Acta Orthopaedica.*
53
54 2016;87(2):132-138
55
56
57
58
59
60

- 1
2
3 50. Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ. Antibiotic-induced
4 changes to the host metabolic environment inhibit drug efficacy and alter immune function.
5
6 Cell Host & Microbe. 2017;22(6):757-765.
7
8
9
- 10 51. Early G. Current Evidence regarding antibiotic exposure and childhood obesity: an
11 integrative review. *Ped Nurs*. 2017;43(4):169-174.
12
13
- 14 52. Bandaru P, Rajkumar H, Napanveettil G. The impact of obesity on immune response to
15 infection and vaccine: an insight into plausible mechanisms. *Endocrinol Metab Syndr*
16
17 2013;2:2.
18
19
- 20 53. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during
21 influenza seasons in Ontario, Canada: a cohort study. *Clin Infect Dis*. 2011;53(5):413-421.
22
23
- 24 54. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease.
25
26 *Mediators Inflamm*. 2010;2010:535918.
27
28
- 29 55. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent
30 advances in the relationship between obesity, inflammation, and insulin resistance. *Eur*
31
32 *Cytokine Netw*. 2006;17(1):4-12.
33
34
- 35 56. Ciprandi G, Pistorio A, Tosca M, Ferraro MR, Cirillo I. Body mass index, respiratory
36 function and bronchial hyperactivity in allergic rhinitis and asthma. *Respir Med*
37
38 2009;103(2):289-295.
39
40
- 41 57. Gorgievska-Sukarovska B, Lipozencić J, Susac A. Obesity and allergic diseases. *Acta*
42
43 *Dermatovenerol Croat*. 2008;16(4):231-235.
44
45
- 46 58. Shah R, Yang Y. Health and economic burden of obesity in elderly individuals with asthma
47
48 in the United States. *Popul Health Manag* 2015;18(3):186-191.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 59. Guo Y, Moon JY, Laurie CC, et al. Genetic Predisposition to Obesity is associated
4 with Asthma in US Hispanics/Latinos: Results from the Hispanic Community Health
5 Study/Study of Latinos. *Allergy*. 2018;doi: 10.1111/all.13450. [Epub ahead of print]
6
7
8
9
10 60. Rodriguez D. Obesity and Asthma – What’s the Connection.
11
12 <https://www.everydayhealth.com/asthma/obesity-connection.aspx>. Published August 28,
13 2013. Accessed April 12, 2018.
14
15
16
17 61. Greene, A.K., et al. Lower-Extremity Lymphedema and Elevated Body-Mass Index. *N Engl*
18 *J Med*. 2012;366:2136-2137.
19
20
21 62. Helyer, L.K., et al. Obesity is a risk factor for developing postoperative lymphedema in
22 breast cancer patients. *Breast J*. 2012;16(1):48-54.
23
24
25
26 63. Greene AK, Grant FD, Slavin SA, Maclellan RA. Obesity-induced lymphedema: clinical and
27 lymphoscintigraphic features. *Plast Reconstr Surg*. 2015;135(6):1715-1719.
28
29
30
31 64. King LK, March L, Anandacoomarasamy A. Obesity & osteoarthritis. *Indian J Med Res*.
32 2013;138(2):185-193.
33
34
35 65. Baodong Qin, Min Yang, Haitao Fu, et al. Body mass index and the risk of rheumatoid
36 arthritis: a systematic review and dose-response meta-analysis. *Arthritis Res Ther*.
37 2015;17(1):86.
38
39
40
41
42 66. Feng J, Chen Q, Yu F, et al. Body mass index and risk of rheumatoid arthritis: a meta-
43 analysis of observational studies. *Medicine*. 2016;95(8):e2859.
44
45
46
47 67. Albrecht K, Richter A, Callhoff J, et al. Body mass index distribution in rheumatoid arthritis:
48 a collaborative analysis from three large German rheumatoid arthritis databases. *Arthritis Res*
49 *Ther*. 2016;18:149.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 68. Rodriguez D. How Your Immune System Worsens Arthritis. EverydayHealth.com.
4
5 <https://www.everydayhealth.com/arthritis/understanding/the-immune-system.aspx>. Published
6
7 August 1, 2012. Accessed April 11, 2018.
8
9
- 10 69. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response
11
12 to influenza vaccination in humans. *Int J Obes*. 2012;36(8):1072-1077.
13
14
- 15 70. Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune
16
17 response to vaccination. *Vaccine*. 2015;33(36): 4422–4429.
18
19
- 20 71. Young KM, Gray CM, Bekker LG. Is Obesity a Risk Factor for Vaccine Non-
21
22 Responsiveness? *PLoS One*. 2013;8(12): e82779.
23
24
- 25 72. Okifuji A, Hare BD. The association between chronic pain and obesity. *J Pain Res*.
26
27 2015;8:399-408.
28
29
- 30 73. Erdmann J. Osteoarthritis and Obesity. www.arthritis.org. [https://www.arthritis.org/living-](https://www.arthritis.org/living-with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php)
31
32 [with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php](https://www.arthritis.org/living-with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php). Accessed April
33
34 11, 2018.
35
36
- 37 74. American Obesity Association. Health effects of obesity. AOA Fact Sheets. 2002.
38
- 39 75. Tashani OA, Asitita R, Sharp D, Johnson MI. Body mass index and distribution of body fat
40
41 can influence sensory detection and pain sensitivity. *Eur J Pain* 2017;21(7):1186-1196.
42
43
- 44 76. Rathee N. Obesity and depression: Are they related? *Indian J Health Well*. 2017;8(12):1472-
45
46 1475.
47
- 48 77. Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH. Depression and anxiety among
49
50 US adults: associations with body mass index. *Int J Obesity*. 2009;33(2):257-266.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 78. Onyike CU, Crum RM, Lee HB, Lyketsos DG, Eaton WW. Is obesity associated with major
4 depression? Results from the Third National Health and Nutrition Examination Survey. *Am J*
5
6 *Epidemiol.* 2003;158(12):1139-1147.
7
8
9
10 79. Petry NM, Barry D, Pietrzak RH, Wagner JA. Overweight and obesity are associated with
11
12 psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and
13
14 Related Conditions. *Psychosom Med.* 2008;70(3):288-297.
15
16
17 80. Pratt LA, Brody DJ. Depression and obesity in the U.S. adult household population, 2005-
18
19 2010. NCHS Data Brief, No. 167, October 2014.
20
21
22 81. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood
23
24 disorders and obesity related? A review for the mental health professional. *J Clin Psychiatry*
25
26 2004;65(5):634-651.
27
28
29 82. Ferraro KF, Su Y, Gretebeck RJ, Black DR, Badylak SF. Body mass index and disability in
30
31 adulthood: A 20-year panel study. *Am J Public Health.* 2002;92(5):834-840.
32
33
34 83. Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. *J*
35
36 *Psychosom Res.* 2002;53(4):859-863.
37
38
39 84. Baltaci D, Kutlucan A, Turker Y, et al. Association of vitamin B12 with obesity, overweight,
40
41 insulin resistance and metabolic syndrome, and body fat composition; primary care-based
42
43 study. *Med Glas.* 2013;10(2):203-210.
44
45
46 85. Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin D
47
48 deficiency: a systematic review and meta-analysis. *Obes Rev.* 2015;16(4):341-349.
49
50
51 86. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? *The*
52
53 *Lancet* 2003;361:2226-2234.
54
55
56
57
58
59
60

1
2
3 87. Merrill RM, Telford CT. Pharmaceutical use according to participation in worksite wellness
4 screening and health campaigns. *Prev Med Rep* 2018;12:158-163.
5
6
7

8 **Footnotes**

9

10
11 Contributors: RMM conceived and designed the epidemiological study, contributed to
12 acquisition of data, analyzed and interpreted the data, and drafted the manuscript. RPF
13 interpreted the data, provided a literature review, and revised the manuscript. Both authors
14 critically revised the manuscript for important intellectual content. The manuscript has been read
15 and approved by both authors.
16
17
18
19
20
21
22

23 Funding: The authors have not declared a specific grant for this research from any funding
24 agency in the public, commercial or not-for-profit sectors.
25
26
27

28 Competing interests: None declared.
29
30

31 Patient consent: Not required.
32
33

34 Ethics approval: Study approval was obtained from the institutional review board at Brigham
35 Young University (IRB E1 5259).
36
37
38

39 Provenance and peer review: Not commissioned; externally peer reviewed.
40
41

42 Data sharing statement: The data sets used and analyzed in the current study are available from
43 the corresponding author on reasonable request at: Ray_Merrill@byu.edu
44
45
46
47
48
49
50
51
52
53
54
55
56
57

Table 1 Characterization of the study group according to sex, age, medical and pharmacy costs

	No.	%	Continuously Employed %	Chi-square p value	Risk Ratio	95% CI
Sex						
Men	797	26.36	84.69	0.3884	1.00	
Women	2226	73.64	83.38		0.98	0.95-1.02
Age Group						
18-39	770	25.47	82.21	< 0.0001	1.00	
40-49	806	26.66	89.45		1.09	1.05-1.13
50-59	1088	35.99	88.24		1.07	1.03-1.12
60-76	359	11.88	60.45		0.74	0.67-0.80
Medical Cost (USD)						
0-184	755	25.0	87.55	< 0.0001	1.00	
185-604	757	25.0	85.07		0.97	0.93-1.01
605-2049	755	25.0	84.64		0.97	0.93-1.01
2050-7191	454	15.0	79.30		0.91	0.86-0.96
7192+	302	10.0	75.17		0.86	0.80-0.92
Pharmacy Cost (USD)						
0-6	759	25.0	86.92	< 0.0001	1.00	
7-194	755	25.0	85.21		0.99	0.69-1.03
195-903	755	25.0	82.59		0.96	0.92-1.00
904-2303	452	15.0	84.14		0.99	0.94-1.04
2304+	302	10.0	74.92		0.86	0.80-0.93

Sex, age, medical and pharmacy costs apply to the 2010-11 academic year.

Table 2 Medical and pharmacy costs according to sex, age, year, and body mass index

	BMI (kg/m ²)			Medical Cost (USD)			Median	Median one-way analysis	Pharmacy Cost (USD)			Median	Median one-way analysis
	Mean	SD	SNK	Mean	SD	SNK		p value	Mean	SD	SNK		p value
Sex													
Men	29.35	5.80	A	2869	10581	A	373	< 0.0001	725	2324	A	53	< 0.0001
Women	27.26	6.47	B	3447	12049	A	741		963	3550	B	238	
Age Group													
18-39	27.17	6.06	A	2236	9344	A	389	< 0.0001	660	3342	A	70	< 0.0001
40-49	27.76	6.42	B	3052	12366	B	503		750	2806	A	106	
50-59	28.05	6.55	B	3935	12579	B	845		1021	3288	B	261	
60-76	28.17	6.13	B	3749	10831	B	989		1288	3990	C	344	
Year													
2010-11	27.89	6.40	A	3188	10524	A	605	0.2313	830	2247	A	195	0.0016
2011-12	27.79	6.31	A	3621	12816	A	610		953	3180	A	189	
2012-13	27.87	6.59	A	3208	11836	A	670		934	3571	A	173	
2013-14	27.63	6.16	A	3191	11557	A	651		894	3913	A	141	
BMI (kg/m ²)													
Underweight				2191	1190	A	647	0.0003	1454	6706	A	224	0.0004
Normal weight				2826	333	A	650		779	3285	B	167	
Overweight				3174	514	A	603		926	3085	A, B	169	
Obese				3544	459	A	665		1031	3458	A, B	228	
Morbidly obese				6911	2092	B	1033		853	1493	A, B	242	

SNK: Student-Newman-Keuls Test. Different letters in the SNK columns indicate significant difference among the levels of the variables at the 0.05 level.

Table 3 Risk of medical and pharmacy costs (USD) above the 50th, 75th, and 90th percentiles according to BMI weight classification, sex, and age

	Medical						Pharmacy					
	50 th percentile Above vs. below		75 th percentile Above vs. below		90 th percentile Above vs. below		50 th percentile Above vs. below		75 th percentile Above vs. below		90 th percentile Above vs. below	
	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI
Sex												
Men	1.00		1.00		1.00		1.00		1.00		1.00	
Women	1.43	1.36-1.51	1.47	1.35-1.60	1.42	1.24-1.64	1.58	1.50-1.66	1.59	1.46-1.74	1.14	1.00-1.29
Age Groups												
18-39	1.00		1.00		1.00		1.00		1.00		1.00	
40-49	1.16	1.08-1.23	1.15	1.03-1.29	1.08	0.90-1.28	1.14	1.07-1.22	1.45	1.29-1.64	1.72	1.37-2.15
50-59	1.50	1.42-1.59	1.65	1.50-1.82	1.36	1.16-1.58	1.48	1.39-1.56	2.28	2.05-2.55	2.82	2.30-3.46
60+	1.61	1.52-1.72	1.83	1.64-2.04	1.33	1.11-1.60	1.57	1.48-1.68	2.57	2.29-2.89	3.78	3.06-4.68
BMI (kg/m ²)												
Underweight	1.05	0.88-1.26	0.91	0.64-1.31	0.61	0.28-1.35	2.05	1.25-3.34	1.05	0.74-1.48	2.05	1.25-3.34
Normal weight	1.00		1.00		1.00		1.00		1.00		1.00	
Overweight	0.95	0.90-1.00	0.95	0.86-1.05	1.01	0.85-1.20	1.01	0.95-1.06	1.18	1.07-1.30	1.68	1.41-2.00
Obese	1.00	0.95-1.06	1.14	1.03-1.25	1.21	1.01-1.43	1.11	1.05-1.17	1.19	1.08-1.31	1.76	1.47-2.12
Morbidly obese	1.18	1.08-1.29	1.62	1.40-1.87	2.18	1.72-2.77	1.13	1.03-1.25	1.30	1.09-1.55	1.93	1.43-2.61

Shaded cells represent statistical significance at the 0.05 level.

Table 4 Medication use according to sex, age, and BMI weight classification

		Sex		Age Group				Body Mass Index (kg/m ²)				
		Men	Women	18-39	40-49	50-59	60+	Underweight	Normal weight	Over weight	Obese	Morbidly obese
Medication	%											
Acid Reflux	5.75	5.56	5.81	3.02	4.54	7.14	8.36	3.57	4.34	5.36	7.19	9.14
Risk ratio		1.00	1.04	1.00	1.50	2.36	2.77	0.82	1.00	1.24	1.66	2.11
AF _p (%)		0.00	0.26	0.00	2.81	7.27	9.23		0.00	1.33	3.64	5.98
Acne	7.17	3.15	8.62	7.15	7.03	7.16	7.40	9.82	8.81	6.64	6.34	6.18
Risk ratio		1.00	2.74	1.00	0.98	1.00	1.03	1.11	1.00	0.75	0.72	0.70
AF _p (%)		0.00	11.07	0.00	0.01	0.25	0.25	0.82	0.00			
Antibiotic	21.21	17.81	22.44	18.72	20.76	22.76	21.93	25.89	20.54	20.74	23.73	21.24
Risk ratio		1.00	1.26	1.00	1.11	1.22	1.17	1.26	1.00	1.01	1.16	1.03
AF _p (%)		0.00	5.23	0.00	2.26	4.38	3.51	5.24	0.00	0.21	3.19	0.72
Anticonvulsants	1.49	1.39	1.53	1.84	1.32	1.45	1.40	2.68	1.25	1.13	1.65	1.61
Risk ratio		1.00	1.10	1.00	0.72	0.79	0.76	2.14	1.00	0.90	1.32	1.29
AF _p (%)		0.00	0.15	0.00				1.68	0.00		0.47	0.43
Antifungal	5.29	2.61	5.81	5.64	6.03	4.24	3.87	5.36	5.83	3.81	6.24	6.18
Risk ratio		1.00	2.23	1.00	1.07	0.75	0.69	0.92	1.00	0.65	1.07	1.06
AF _p (%)		0.00	6.09	0.00	0.36				0.00		0.37	0.32
Anxiety	7.88	6.31	8.45	6.42	7.80	8.36	8.97	8.93	7.22	7.11	7.29	6.45
Risk ratio		1.00	1.34	1.00	1.21	1.30	1.40	1.24	1.00	0.98	1.01	0.89
AF _p (%)		0.00	2.60	0.00	1.67	2.33	3.03	1.83	0.00		0.08	
Arthritis	11.06	11.13	11.03	7.72	10.53	12.83	12.56	7.14	9.36	10.72	13.84	14.78
Risk ratio		1.00	0.99	1.00	1.36	1.66	1.63	0.76	1.00	1.15	1.48	1.58
AF _p (%)		0.00		0.00	3.87	6.82	6.48		0.00	1.58	5.03	6.02
Asthma	8.61	7.19	9.13	7.48	8.80	8.00	11.22	6.25	6.24	8.74	10.39	10.75

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Risk ratio		1.00	1.27	1.00	1.18	1.07	1.50	1.00	1.00	1.40	1.67	1.72
AF _p (%)		0.00	2.27	0.00	1.50	0.59	4.13	0.01	0.00	3.33	5.42	5.86
Birth Control	8.71	0.24	10.88	21.13	8.77	2.59	0.95	10.71	11.69	7.30	6.34	6.99
Risk ratio		1.00	45.33	1.00	0.42	0.12	0.04	0.92	1.00	0.62	0.54	0.60
AF _p (%)		0.00	79.43	0.00					0.00			
Blood Thinner	1.26	1.85	1.05	3.91	18.75	45.31	32.03	0.95	0.52	1.15	2.08	5.22
Risk ratio		1.00	0.57	1.00	4.80	11.59	8.19	1.83	1.00	2.21	4.00	10.04
AF _p (%)		0.00		0	4.56	11.77	8.31	1.03	0	1.50	3.64	10.22
Bowel/Rectum	3.06	2.75	3.17	1.76	2.84	3.53	4.15	1.79	3.15	2.87	2.85	2.96
Risk ratio		1.00	1.15	1.00	1.61	2.01	2.36	0.57	1.00	0.91	0.90	0.94
AF _p (%)		0.00	0.47	0.00	1.84	2.99	3.99		0.00			
Cold/Influenza/Allergy	17.80	14.52	18.99	15.73	18.30	18.14	19.07	22.32	15.53	18.56	20.38	22.04
Risk ratio		1.00	1.31	1.00	1.16	1.15	1.21	1.44	1.00	1.20	1.31	1.42
AF _p (%)		0.00	5.20	0.00	2.83	2.65	3.64	7.22	0.00	3.36	5.27	6.94
Depression	18.24	10.28	21.14	12.51	19.30	20.75	18.84	15.18	16.20	17.59	20.83	18.55
Risk ratio		1.00	2.06	1.00	1.54	1.66	1.51	0.94	1.00	1.09	1.29	1.15
AF _p (%)		0.00	16.16	0.00	9.01	10.73	8.45		0.00	1.54	4.95	2.58
Diabetes	6.32	6.48	6.22	2.53	4.50	7.82	10.94	1.79	2.24	5.67	11.29	17.74
Risk ratio		1.00	0.96	1.00	1.78	3.09	4.32	0.80	1.00	2.53	5.04	7.92
AF _p (%)		0.00		0.00	4.69	11.67	17.36		0.00	8.82	20.34	30.43
Edema	5.14	3.12	5.87	2.04	3.64	6.48	8.86	6.25	3.08	4.66	7.29	12.90
Risk ratio		1.00	1.88	1.00	1.78	3.18	4.34	2.03	1.00	1.51	2.37	4.19
AF _p (%)		0.00	4.33	0.00	3.88	10.06	14.66	5.02	0.00	2.57	6.56	14.08
Eye Infection	12.01	9.23	12.87	11.44	13.06	11.13	12.34	14.29	11.02	12.12	13.64	9.68
Risk ratio		1.00	1.39	1.00	1.14	0.97	1.08	1.30	1.00	1.10	1.24	0.88
AF _p (%)		0.00	4.52	0.00	1.67		0.94	3.44	0.00	1.18	2.78	
Herpes	6.30	3.26	6.86	4.82	7.24	6.12	4.71	1.79	7.66	7.22	4.20	1.88
Risk ratio		1.00	2.10	1.00	1.50	1.27	0.98	0.23	1.00	0.94	0.55	0.25
AF _p (%)		0.00	6.50	0.00	3.07	1.67			0.00			
High Blood Pressure	16.49	19.95	15.60	4.58	11.05	22.78	29.39	6.25	8.54	17.44	24.68	31.99
Risk ratio		1.00	0.78	1.00	2.41	4.97	6.42	0.73	1.00	2.04	2.89	3.75
AF _p (%)		0.00		0.00	18.89	39.59	47.18		0.00	14.66	23.76	31.17

Inflammation	1.19	0.68	1.37	0.69	0.87	1.50	1.68	1.79	0.98	1.40	0.80	1.61
Risk ratio		1.00	2.01	1.00	1.26	2.17	2.43	1.83	1.00	1.43	0.82	1.64
AF _p (%)		0.00	1.19	0.00	0.31	1.38	1.68	0.97	0.00	0.51		0.76
Insomnia	4.23	2.24	4.95	2.70	3.60	5.72	4.04	8.93	4.07	3.92	3.85	4.84
Risk ratio		1.00	2.21	1.00	1.33	2.12	1.50	2.19	1.00	0.96	0.95	1.19
AF _p (%)		0.00	4.87	0.00	1.39	4.52	2.06	4.81	0.00			0.79
Muscle Spasms	4.34	3.53	4.64	3.11	4.57	4.93	4.37	5.36	3.29	4.27	5.44	6.99
Risk ratio		1.00	1.31	1.00	1.47	1.59	1.41	1.63	1.00	1.30	1.65	2.12
AF _p (%)		0.00	1.35	0.00	2.00	2.48	1.73	2.66	0.00	1.28	2.76	4.65
Nausea/Vomiting	5.01	3.77	5.47	5.44	4.85	4.83	5.10	4.46	4.14	4.50	6.19	5.65
Risk ratio		1.00	1.45	1.00	0.89	0.89	0.94	1.08	1.00	1.09	1.50	1.36
AF _p (%)		0.00	2.21	0.00				0.39	0.00	0.43	2.42	1.79
Opioids	17.04	15.98	17.42	14.14	16.29	18.62	18.73	17.86	13.39	15.77	20.28	27.69
Risk ratio		1.00	1.09	1.00	1.15	1.32	1.32	1.33	1.00	1.18	1.51	2.07
AF _p (%)		0.00	1.51	0.00	2.53	5.12	5.24	5.38	0.00	2.94	8.06	15.40
Osteoporosis	1.21	0.07	1.63	0.00	0.17	1.30	4.37	0.89	1.56	1.20	0.85	0.00
Risk ratio		1.00	23.29	1.00				0.57	1.00	0.77	0.54	0.00
AF _p (%)		0.00	21.24	0.00					0.00			
Pain – non opioid	2.19	1.63	2.39	2.78	2.15	1.98	1.91	3.57	1.73	1.67	2.55	2.96
Risk ratio		1.00	1.47	1.00	0.77	0.71	0.69	2.06	1.00	0.97	1.47	1.71
AF _p (%)		0.00	1.01	0.00				2.28	0.00		1.03	1.53
Skin	6.84	4.88	7.55	5.44	6.44	7.37	8.24	6.25	7.25	6.41	7.19	5.38
Risk ratio		1.00	1.55	1.00	1.18	1.35	1.51	0.86	1.00	0.88	0.99	0.74
AF _p (%)		0.00	3.61	0.00	1.24	2.37	3.40		0.00			
Statins	14.49	17.93	13.24	2.31	8.53	20.58	28.4	3.81	7.02	17.95	19.89	27.47
Risk ratio		1.00	0.74	1.00	3.69	8.91	12.29	0.54	1.00	2.56	2.83	3.91
AF _p (%)		0.00		0.00	28.07	53.40	62.07		0.00	18.41	20.99	29.68
Stomach Acid	1.19	1.49	1.07	0.86	1.25	0.99	1.96	0.89	0.81	1.01	1.90	1.08
Risk ratio		1.00	0.72	1.00	1.45	1.15	2.28	1.10	1.00	1.25	2.35	1.33
AF _p (%)		0.00		0.00	0.54	0.18	1.50	0.12	0.00	0.29	1.58	0.40
Teeth/Gums	0.43	0.37	0.46	0.37	0.35	0.43	0.67	0.00	0.27	0.43	0.35	0.27
Risk ratio		1.00	1.24	1.00	0.95	1.16	1.81	0.00	1.00	1.59	1.30	1.00

AF _p (%)		0.00	0.10	0.00		0.07	0.35		0.00	0.25	0.13	0.00
Thyroid	12.76	2.99	16.31	4.37	11.19	16.92	17.61	6.25	13.97	12.74	13.94	19.09
Risk ratio		1.00	5.45	1.00	2.56	3.87	4.03	0.45	1.00	0.91	1.00	1.37
AF _p (%)		0.00	36.24	0.00	16.61	26.82	27.88		0.00			4.47
Ulcers	9.38	8.55	9.69	8.30	8.28	10.19	10.88	10.71	7.59	9.90	10.99	15.32
Risk ratio		1.00	1.13	1.00	1.00	1.23	1.31	1.41	1.00	1.30	1.45	2.02
AF _p (%)		0.00	1.24	0.00		2.09	2.83	3.71	0.00	2.78	4.03	8.72
Urinary Tract Infection	3.01	0.20	4.44	3.39	3.08	3.45	3.25	6.25	3.83	2.83	3.50	3.76
Risk ratio		1.00	22.20	1.00	0.91	1.02	0.96	1.63	1.00	0.74	0.91	0.98
AF _p (%)		0.00	38.95	0.00		0.05		1.87	0.00			
Vitamins/Minerals	2.07	0.71	2.57	2.49	1.73	1.88	2.47	0.00	2.07	1.28	1.75	5.38
Risk ratio		1.00	3.62	1.00	0.69	0.76	0.99	0.00	1.00	0.62	0.85	2.60
AF _p (%)		0.00	5.14	0.00					0.00			3.20
All prescriptions	80.87	71.40	84.32	71.52	78.45	85.24	88.00	83.93	81.46	81.28	83.47	86.29
Risk ratio		1.00	1.18	1.00	1.10	1.19	1.23	1.03	1.00	1.00	1.02	1.06
AF _p (%)		0.00	12.77	0.00	7.27	13.43	15.71	2.39	0.00		1.96	4.58


AF_p: Attributable fraction in the population. Shaded cells represent statistical significance at the 0.05 level. Cells that are left blank had a negative AF_p. In these cases the preventive fraction ($[\text{Risk Ratio} - 1] \times 100$) is more appropriate.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Figure 1. Median medical and pharmacy cost (USD) according to Body Mass Index weight classifications and age

For peer review only



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page/line numbers
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1/6, 2/25
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Done
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Done
Objectives	3	State specific objectives, including any prespecified hypotheses	Done
Methods			
Study design	4	Present key elements of study design early in the paper	Done
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Done
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Done
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Done
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Done
Bias	9	Describe any efforts to address potential sources of bias	Done
Study size	10	Explain how the study size was arrived at	Done
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Done
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Done
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Done
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Done
		(b) Indicate number of participants with missing data for each variable of interest	Done
		(c) Summarise follow-up time (eg, average and total amount)	Done
Outcome data	15*	Report numbers of outcome events or summary measures over time	Done
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	Done

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Done
Discussion			
Key results	18	Summarise key results with reference to study objectives	Done
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Done
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done
Generalisability	21	Discuss the generalisability (external validity) of the study results	Done
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Done

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

To what extent does sex, age, and BMI impact medical and pharmacy costs? A retrospective cohort study involving employees in a large school district in the United States

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024078.R3
Article Type:	Research
Date Submitted by the Author:	13-Mar-2019
Complete List of Authors:	Merrill, Ray; Brigham Young University, Public Health Fowers, Rylan; Brigham Young University
Primary Subject Heading:	Pharmacology and therapeutics
Secondary Subject Heading:	Public health, Epidemiology
Keywords:	health risks, screening, prescription medication, health risk appraisal, body mass index, pharmaceutical costs

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 **To what extent does sex, age, and BMI impact medical and pharmacy costs? A**
16 **retrospective cohort study involving employees in a large school district in the United**
17 **States**
18
19
20
21

22 Ray M. Merrill, PhD, MPH, Rylan P. Fowers, BS
23
24

25 Department of Public Health, College of Life Sciences, Brigham Young University
26
27
28
29
30
31
32
33
34

35 Corresponding Author:

36 Ray M. Merrill

37 Department of Public Health

38 2063 Life Sciences Building

39 Provo, Utah 84602

40 Email: Ray_Merrill@byu.edu

41 Telephone: 801-422-9788

42 Fax: 801-422-9363
43
44
45
46
47
48
49
50
51

52 Keywords: body mass index, obesity, prevention, pharmaceuticals, screening
53

54 Word count: 3527
55
56
57
58
59
60

1
2
3 **Objective** To identify the extent that sex, age, and body mass index (BMI) is associated with
4 medical and pharmacy costs.
5
6

7
8 **Design** Retrospective cohort.
9

10 **Setting** A school district in the Western United States involving 2531 workers continuously
11 employed during 2011-2014.
12
13

14 **Main outcome measures** Medical and pharmacy costs and BMI.
15

16
17 **Results** Approximately 84% of employees participated in wellness screening. Participants were
18 1.03 (95% CI 1.01- 1.06) times more likely to be women and younger ($M = 47.8$ vs. 49.8 , $p <$
19 0.001). Median medical and pharmacy costs were higher for women than men, increased with
20 age, and were greater in morbidly obese individuals ($p < 0.001$). Annual pharmacy claims were
21 18% more likely to be filed by women than men, 23% more likely filed by those aged ≥ 60 versus
22 < 40 years, and 6% more likely filed by morbidly obese individuals than of normal weight ($p <$
23 0.001) individuals. Greater medical and pharmacy costs in older age were most pronounced in
24 underweight and morbidly obese groups. Higher use of medication among women than men was
25 primarily because of drugs involving birth control, osteoporosis, thyroid disease, and urinary
26 tract infection. Higher medication use in older age was primarily related to medications used to
27 treat gastrointestinal problems. Medication use was positively associated with BMI weight
28 classifications for most of the 33 drug types considered, with exceptions involving birth control,
29 herpes, and osteoporosis. A J-shape relationship was observed between BMI and medication use
30 for acne, antibiotic, cold/influenza/allergy, eye infection, edema, muscle spasms, pain, and
31 ulcers.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 **Conclusions** Medications associated with higher medical and pharmacy costs among women,
53 older age, and underweight or obese individuals are identified. Lowering medical and pharmacy
54
55
56
57
58
59
60

1
2
3 costs requires weight management in older ages, particularly for underweight and obese. Higher
4
5 pharmacy costs for certain drugs among underweight individuals may be associated with poorer
6
7 nutrition.
8
9
10
11

12 Strengths and limitations of this study

- 13
14
15 • A large cohort of employees was available for retrospective assessment of the
16 association between sex, age, and BMI with medical and pharmacy costs.
17
18 • The association between sex, age, and 33 specific types of medication were assessed,
19 some of which have not been previously considered.
20
21 • All active employees received employer-sponsored medical and pharmacy coverage,
22 and above 84% had information that allowed us to determine body mass.
23
24 • A few medications may have contributed to weight gain, which we were unable to
25 adjust for in the current study.
26
27 • The study population and patterns of prescription drug use may limit generalization of
28 the results.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Many companies offer wellness-screening programs consisting of health risk assessment and biometric screening. The 2016 Employer Health Benefits Survey found that among large firms (200 or more employees) in the United States, 59% offered health risk assessment (of which 32% had an incentive component) and 53% offered biometric screening (of which 31% included an incentive component).¹ These programs are intended to promote a greater sense of personal responsibility for lifestyle choices, identify the need for health behavior change, reduce future health problems, encourage patient management of existing health problems, decrease worker absenteeism, and improve job satisfaction and worker productivity.²⁻⁷ Larger companies are also required to offer employer-sponsored medical and pharmacy coverage for their employees. Hence, information obtained on the health risk assessment and screenings can be compared with the medical and pharmacy costs.

Medical and pharmacy costs are influenced by a number of factors, including sex, age, and Body Mass Index (BMI).⁸⁻¹⁰ Although medical costs are often a response to acute and chronic health conditions, pharmaceutical costs are often used to prevent more serious health problems. For example, antihypertensive medication, or statins, are useful in preventing cardiovascular disease;¹¹⁻¹³ multivitamins or folic acid for preventing congenital abnormalities;¹⁴ aspirin and non-steroidal anti-inflammatory for preventing colorectal cancer;¹⁵ bronchodilators, steroids, and anti-inflammatories for managing asthma;¹⁶ and nonsteroidal anti-inflammatory drugs, steroids, analgesics, and immunosuppressive drugs for managing arthritis.¹⁷ Consequently, wellness screening may actually increase use of prescription medication.¹⁸

1
2
3 Although a person's body weight may be associated with increased risk for various
4 chronic health conditions and poorer health-related quality of life,^{19 20} only in the last 15 years or
5 so has its impact on healthcare expenditures been assessed.¹⁰ Further, only a small number of
6 studies have explored the association between body weight and prescription drug use. A study
7 conducted in England found that overweight and obese individuals were more likely to receive
8 medication for the cardiovascular system; gastrointestinal system; respiratory system; central
9 nervous system; endocrine system; gynecology/urinary disorders; musculoskeletal and joint
10 disorders; infections; eye, ear and oropharynx problems; and skin disorders.²¹ A study in Sweden
11 showed that use and cost of medication in general are significantly greater in obese individuals.²²
12 A study in the United States found that obesity was responsible for \$7 billion in Medicare
13 prescription drug costs in 2006.²³ Another study conducted in the United States identified
14 increased medication use during 1988 through 2012, with the increase most prominent among
15 obese individuals.²⁴ A large cross-sectional study of 9789 adults in the National Health and
16 Nutrition Examination Survey (NHANES) found that obese individuals utilize several
17 prescription drugs (e.g., hypertension, lipid-lowering, and diabetes medications) more frequently
18 than normal weight individuals.²⁵ Another study based on NHANES data found that while
19 medication use increased over time for obese individuals compared with normal weight
20 individuals ages 40 years and older, the increase was only marginal for those aged 25-39 years.²⁶
21 One study found that obese individuals used more analgesic, asthma, cardiovascular, diabetes,
22 intranasal allergic rhinitis, thyroid, and ulcer medications.²⁷
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 The purpose of the current study was to identify the extent to which sex, age, and BMI
50 weight classifications are associated with medical and pharmacy costs among a large group of
51 teachers, administrators, and other school staff. These associations are also evaluated for 33 more
52
53
54
55
56
57
58
59
60

1
2
3 commonly prescribed medications.²⁸ Although studies have previously looked at the association
4 between BMI and prescription medications, we evaluated some drugs that have not been
5
6 formerly considered, and the breadth of drugs covered is greater than in past studies. In addition,
7
8 evaluating the effect of being underweight on medical and pharmacy costs, and on specific drug
9
10 types, is unique to this study.
11
12
13
14
15

16 **Methods**

17 *Patient and Public Involvement*

18
19 A retrospective cohort study was conducted that associated sex, age, and BMI with medical and
20
21 pharmacy cost data for employees of a large school district in the western United States. Specific
22
23 patients and or the general public was not involved in this study. Body mass index was obtained
24
25 from those employees who participated in wellness screening. Employer-sponsored insurance
26
27 was available to all employees. The school district comprised six high schools, eight junior high
28
29 schools, and 31 elementary schools. Employees consisted of approximately three teachers to
30
31 every one staff member (cooks, bus drivers, grounds keepers, maintenance workers,
32
33 administrators, clerical workers, etc.). We were not provided specific job type and salary for each
34
35 employee. However, we can assume that the teachers, administrators, counselors, and nurses,
36
37 who represent almost all of the employees, had at least a college degree, that their salaries are
38
39 commensurate with other school districts, and that the employer-sponsored insurance coverage
40
41 was not strongly impacted by the employee's income or education.
42
43
44
45
46
47
48

49 The study involved the academic years 2010-11, 2011-12, 2012-13, and 2013-14.
50
51 Employees were offered wellness screenings (personal health risk assessment [HRA] and
52
53 biometric evaluation) each fall. Medical and pharmacy claims data were also obtained for the
54
55
56
57
58
59
60

1
2
3 employees in each academic year. Wellness screening and claims data were combined with a file
4
5 of eligible employees and assessed within each academic year. The eligibility file contained
6
7 information on current employment, sex, age, and year.
8
9

10 11 12 *Wellness Screening* 13

14
15 All employees were offered wellness screening. Although participation was voluntary, it
16
17 was promoted through incentives. The HRA involved 36 questions. Biometric screenings
18
19 involved measurements of body mass index (BMI kg/m²), blood pressure (mm Hg), cholesterol
20
21 (mg/dL), and glucose (mg/dL). The HRA and biometric screenings were provided at no cost to
22
23 the employees, and were made available on location or with a personal physician. A health nurse
24
25 or physician assisted the employee in interpreting their HRA and screening results, in order to
26
27 help guide their need for lifestyle changes and control measures. The current study only
28
29 considers BMI. Weight classifications are based on commonly accepted ranges of BMI, as
30
31 follows: underweight (BMI < 18.5), normal weight (BMI 18.5-24), overweight (BMI 25-29),
32
33 obese (BMI 30-39), and morbidly obese (BMI 40+).
34
35
36
37
38
39

40 41 *Medical and Pharmacy Claims Data* 42

43 All active employees received employer-sponsored medical and pharmacy coverage, for
44
45 themselves and their families. The school district is fully insured with a retained-retention
46
47 agreement that makes the plan act very much like a self-funded health plan. Each month the
48
49 district pays a health insurance premium for the cost of healthcare and a small premium for
50
51 reinsurance of catastrophic claims. Catastrophic claims greater than \$250,000 are reinsured by a
52
53 stop loss policy and are not paid for by the school district. Employee pharmacy data do not
54
55
56
57
58
59

1
2
3 include over-the-counter drugs, but only those medications requiring a prescription. In the United
4
5 States, a drug is sold over-the-counter if the Food and Drug Administration deems it as
6
7 sufficiently safe and effective. These medications are not included in the current study. Further,
8
9 medical and pharmacy cost represents the amount paid by the insurance company as well as
10
11 copays by the employee.
12
13
14
15
16

17 *Statistical Techniques*

18
19 Counts, means, standard deviations, medians, and percentages were used to describe the
20
21 study population. Pair-wise comparisons of means were evaluated for statistical significance
22
23 using the Student-Newman-Keuls Test. Risk ratios compare having a medical and pharmacy cost
24
25 above the 50th percentile (vs. below), 75th percentile (vs. below), and 90th percentile (vs. below).
26
27 Statistical significance was determined by the corresponding 95% confidence intervals. For
28
29 selected medications, the risk of medication use was compared using risk ratios and attributable
30
31 fraction percentages across the levels of sex, age, and BMI weight classifications. Statistical
32
33 significance of differences in percent use of selected medications across sex, age, and BMI
34
35 categories was based on two-sided tests of significance were based on the 0.05 level against a
36
37 null hypothesis of no association. Data was evaluated using the statistical software package PC-
38
39 SAS (version 9.4; SAS Institute, Inc., 2014).
40
41
42
43
44
45
46

47 **Results**

48
49 In 2010-11, there were 3023 eligible employees, of which 2531 (83.72%) remained employed
50
51 through the academic year 2013-14. Those more likely to remain employed over the study period
52
53 were 40-59 years of age and had lower medical and pharmacy costs (Table 1). In 2010-11, ages
54
55
56
57
58
59
60

1
2
3 ranged from 18-76, with mean age significantly younger for those who remained employed (46.9
4 vs. 49.2, $p < 0.0001$). Those who stayed with the school district had significantly lower mean
5 medical costs (\$3056 vs. \$7887, $p < 0.0001$) and mean pharmacy costs (\$859 vs. \$1105, p
6 =0.0387). The results of this study are based on those continuously employed over the four
7 academic years.
8
9
10
11
12
13
14

15 Most employees participated in annual wellness screening (84.1% in 2010-11, 84.4% in
16 2011-12, 87.6% in 2012-13, and 80.7% in 2013-14). In 2010-11, there was no significant
17 difference in mean medical cost between those who participated in wellness screening and those
18 who did not (\$3148 vs. \$2571, $p = 0.2900$). However, median medical cost was significantly
19 greater for those who participated in wellness screening (\$588 vs. \$470, $p = 0.0454$). For all
20 academic years, women were 1.03 (95% CI 1.01- 1.06) times more likely than men to complete
21 annual wellness screenings, after adjusting for age and academic year. Participants in wellness
22 screening were significantly younger ($M = 47.8$ vs. 49.8, $p < 0.0001$), after adjusting for sex and
23 year. Those participating in wellness screening had significantly lower mean medical cost
24 (\$3093 vs. \$4181, $p = 0.0013$), but experienced no significant difference in mean annual
25 pharmacy costs, after adjusting for age, sex, and year.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 Among participants in annual wellness screening, mean BMI remained constant across
42 the academic years (Table 2). Mean BMI was greater for men than women and in ages 40 years
43 and older. Medical and pharmacy costs were highly positively skewed, with considerable
44 variability. Hence, identifying significant differences in the mean costs across the levels of sex,
45 age, and year, were less likely to occur than to find significant differences in the median costs
46 across the levels of these variables. Medical costs were higher for women than men, increased
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with age, and were greater in morbidly obese individuals. Pharmacy costs were higher in women
4
5 than men, increased with age, and were lowest in those of normal weight.
6
7

8
9 The risk of medical and pharmacy costs above the 50th, 75th, and 90th percentiles are
10 shown according to sex, age, and BMI weight classification in Table 3. Higher BMI has a greater
11 impact on higher percentiles of medical and pharmacy costs. For example, morbidly obese
12 compared with normal weight are 1.13 (13%), 1.30 (30%), and 1.93 (93%) more likely to have
13 pharmacy costs above the 50th, 75th, and 90th percentiles, respectively. Medical and pharmacy
14 costs above these percentiles are greater in women than men and increase with age.
15
16
17
18
19
20
21
22

23 Associations between selected percentiles of medical and pharmacy costs and BMI
24 weight classifications varied according to age (Figure 1), but not sex (data not shown). Greater
25 medical and pharmacy costs with older age groups are seen in the graph. However, the
26 increasing costs with higher age are most pronounced in the underweight and morbidly obese
27 groups.
28
29
30
31
32
33
34

35 Medication use is shown across sex, age, and BMI groups in Table 4. For any
36 medication, women were 18% more likely to file a claim than men, employees 60 years of age or
37 older were 23% more likely to file a claim than those less than 40 years, and morbidly obese
38 were 6% more likely to file a claim than those of normal weight. For 22 of the 33 medications
39 considered, the percentage of annual claims was higher for women than men. For high blood
40 pressure and statins was the percentage of claims greater for men than women. For 25 of the
41 medications, the percentage of annual claims increased with age. For 24 of the medications, the
42 percentage of annual claims was associated with BMI (20 positively and 4 negatively). The
43 strongest positive associations involved diabetes, high cholesterol (statins), blood thinners, high
44 blood pressure, and edema. Negative associations involved acne, birth control, Herpes, and
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 osteoporosis. The highest annual percent of acne, antibiotic, cold/influenza/allergy, and eye
4
5 infection medications occurred in underweight individuals. For edema, muscle spasms, pain, and
6
7 ulcers, medication use was comparatively high in underweight individuals, dropped for normal
8
9 weight, and then increased in higher weight classifications.
10
11
12

13 We also report the attributable fraction in the population. For example, this statistic says
14
15 that 8.82% of diabetes medication is attributed to being overweight, 20.34% is attributed to being
16
17 obese, and 30.43% is attributed to being morbidly obese. Where the risk ratio is less than 1, the
18
19 preventive fraction can be estimated. For example, the risk of requiring osteoporosis medication
20
21 is lower for obese compared with normal weight employees (i.e., Risk Ratio = 0.54). The
22
23 corresponding preventive fraction is 66%, meaning in the absence of obesity there would be 66%
24
25 fewer claims for osteoporosis medication. The attributable fraction in the population and the
26
27 preventive fraction both assume a cause-and-effect association between exposure and disease.
28
29
30
31
32
33

34 **Discussion**

35
36 The current study identified the degree to which sex, age, and BMI are associated with medical
37
38 and pharmacy costs among employees in a large school district. Associations were also evaluated
39
40 for 33 commonly prescribed medications.²⁸ The study extends previous research by including
41
42 certain medications not previously evaluated and considering associations for all BMI weight
43
44 classifications.
45
46
47

48 Higher medical and pharmacy costs among women, in older age, and among those not of
49
50 normal weight is consistent with previous research.⁸⁻¹⁰ Greater medical and pharmacy costs with
51
52 older age are most pronounced in the underweight and morbidly obese groups. Hence, weight
53
54
55
56
57
58
59
60

1
2
3 management at older ages appears particularly important in terms of lowering medical and
4
5 pharmacy costs.
6
7

8 Higher medication use in women than men was primarily because of drugs involving
9
10 birth control, osteoporosis, thyroid disease, and urinary tract infection. Prescription costs for
11
12 vitamins/minerals were also noticeably higher in women than men. Family planning and prenatal
13
14 care may explain the greater use of birth control medications and vitamins/minerals among
15
16 women. Loss of estrogen in women at older ages and female reproductive hormones may
17
18 contribute to the higher level of osteoporosis and thyroid disease in women.^{29 30}
19
20
21
22

23 Medication use was higher in those aged 60 years and older compared with those younger
24
25 than 40, primarily because of diabetes, edema, high blood pressure, high cholesterol (statins),
26
27 and thyroid disease. Previous research has shown that the risk of these diseases increase with
28
29 age.³¹⁻³⁵ Medication use also noticeably increased with age for acid reflux, bowel/rectum,
30
31 inflammation, and stomach acid. This is consistent with older age tending to be associated with
32
33 more gastrointestinal problems.³⁶
34
35
36

37 Medication use was highest in those who were morbidly obese. We found positive
38
39 associations between body weight and higher use of medications for treating acid reflux, fungus,
40
41 bacterial infections, arthritis, asthma, colds, influenza, allergies, depression, diabetes, edema,
42
43 high blood pressure, muscle spasms, nausea/vomiting, pain, high cholesterol, stomach acid,
44
45 thyroid, and ulcers. Other studies have identified a similar associations.^{21 24 25 27} Morbidly obese
46
47 individuals were also more likely to be prescribed vitamins and minerals than normal weight
48
49 individuals. We did not find an association between body weight and increased use of
50
51 medication for the bowel/rectum, skin, or urinary tract, which was counter to that found in other
52
53 studies.^{21 37-39} We also assessed but did not find a significant association for medications used to
54
55
56
57
58
59
60

1
2
3 treat anxiety, insomnia, convulsions, or teeth and gums. The insignificant finding for
4 anticonvulsants and teeth and gums may be because of insufficient power (i.e., small numbers).
5
6 Finally, we assessed the association between body weight and medications for birth control,
7 herpes, and osteoporosis, wherein significant negative associations were found. We are not
8 aware of other studies that have looked at the association between body weight and medications
9 used for colds, influenza, depression, edema, birth control, herpes, or osteoporosis.

10
11
12
13
14
15
16
17 Greater use of medication to treat acid reflux or stomach acid among individuals with
18 higher BMI is consistent with previous research showing hospitalization rates for reflux disease
19 to be positively associated with BMI.^{40 41} Another study found that higher BMI was associated
20 with increased gastroesophageal reflux in both normal and overweight individuals.⁴² Heavier
21 body weight can add pressure to the stomach and diaphragm, thereby resulting in reflux. Further,
22 increased use of medication for nausea/vomiting among individuals with higher BMI weight
23 classifications is consistent with other research.⁴³

24
25
26
27
28
29
30
31
32
33
34 The positive association between higher BMI and increased use of medication for ulcers
35 is consistent with other research, particularly peptic (gastric and duodenal) ulcers.^{44 45} The
36 mechanism to explain the association between obesity and peptic ulcer disease remains unclear.
37
38 Obesity is also associated with *Helicobacter pylori*, which has been linked with gastric ulcers.⁴⁶

39
40
41
42
43
44 Previous research has shown that overweight and obese individuals are at greater risk for
45 infections.³⁷⁻⁴⁹ This is consistent with our findings that show increased use of antibiotics and
46 medication for acne, colds/influenza/allergy, and eye infections among obese individuals.
47
48 However, it has been shown previously that antibiotics can also weaken the immune system,⁵⁰ as
49 well as lead to obesity.⁵¹ Some inflammatory diseases known to be associated with obesity in
50 which we found a positive association between obesity and medication included influenza,^{52 53}

1
2
3 heart disease,⁵⁴ diabetes,⁵⁵ allergies,⁵⁶⁻⁵⁹ asthma,⁶⁰ edema,⁶¹⁻⁶³ and arthritis.⁶⁴⁻⁶⁷ A compromised
4
5 immune system may also trigger autoimmune diseases, including rheumatoid arthritis and
6
7 thyroid disease,⁶⁸ as indicated in the current study.

10
11 Overweight and obese individuals were more likely to receive cold, influenza, or allergy
12
13 medication. Obesity is associated with impaired immune response to influenza vaccination in
14
15 humans.⁶⁹ Because vaccination is less successful for obese individuals,^{70 71} a greater level of
16
17 medication may be sought for treating colds, influenza, and allergies.

20
21 Overweight and obese individuals received higher levels of pain medication. Research
22
23 indicates that the nature of the relationship between higher BMI and pain is likely indirect.⁷² For
24
25 example, greater body weight is associated with osteoarthritis, which, in turn, leads to pain.⁷³
26
27 Being overweight or obese may result in greater risk for back pain, joint pain, and muscle
28
29 spasms.⁷⁴ One study also found that obese individuals were more sensitive than those of normal
30
31 weight to pressure pain.⁷⁵

34
35 We found that higher BMI was associated with depression medication, as consistent with
36
37 previous research.⁷⁶⁻⁷⁹ In one study, the age-adjusted level of depression among adults (ages 20
38
39 and older) in the United States was 43.2% for those with depression compared with 33.0% for
40
41 those without depression.⁸⁰ It may be that higher use of prescription medication for depression
42
43 among those with greater BMI is partly because these people are more likely to experience other
44
45 conditions related to depression, such as heart disease and diabetes.⁸¹⁻⁸³

48
49 There was more use of vitamins/minerals among morbidly obese employees. Of the
50
51 prescribed vitamins/minerals only 8.0% involved vitamin B and 57.3% involved vitamin D. A
52
53

1
2
3 previous study showed an association between low vitamin B12 and being obese.⁸⁴ Another
4
5 study found that the prevalence of vitamin D deficiency was 35% greater in obese individuals.⁸⁵
6
7

8
9 Acne, antibiotic, cold/influenza/allergy, and eye infection medications were prescribed
10 more often for underweight individuals. This is consistent with underweight individuals having
11 poorer nutrition and, consequently, a weakened immune system.⁸⁶ For edema, muscle spasms,
12 pain, and ulcers, medication use showed a J-shape relationship with BMI weight classification.
13 Poor nutrition may also explain the higher levels of medication use among underweight
14 individuals for these medications. Despite mean medical costs being similar for those who
15 participated in wellness screening during the first year of the study, over the four academic years,
16 participants in wellness screening ended up having significantly lower mean medical costs.
17 However, pharmacy costs did not go down. It has been shown that wellness screening can cause
18 the number and cost of pharmaceuticals to go up, at least initially, as the need for treatment is
19 identified.⁸⁷ Identified treatment needs can then, in turn, help prevent more costly health
20 problems in the future. For example, medications used to treat high blood pressure can result in
21 lowering the risk of diabetes, heart disease, stroke and kidney disease; treatment of insomnia can
22 help lower the risk of irritability, depression or anxiety, difficulty paying attention, and accidents
23 due to increased errors; treatment of high cholesterol with statins can help lower the risk of
24 cardiovascular disease; treatment of oral infections can help reduce the risk of diabetes,
25 cardiovascular disease, and preterm birth; and vitamins/minerals can help prevent a host of
26 diseases (scurvy, rickets, anemia, neural tube defects, pellagra, etc.). High blood pressure and
27 statin medications were among the highest prescribed in our study.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 A limitation of this study involves external validity (generalizability). Specifically, the
53 study only considered those individuals who remained employed over all four academic years.
54
55
56
57
58
59
60

1
2
3 These people were generally healthier and in the age range 40-59. The study also focused on
4 those who completed wellness screening because they contained BMI information. These
5 employees were more likely women and younger. In addition, the causal direction between
6 medication use and BMI could not be determined. That is, some medications may have
7 contributed to body mass whereas others were in response to body mass. Finally, the current
8 study did not have information on the use of vitamins or minerals obtained over the counter and
9 small numbers made it impossible to evaluate the relationship between specific types of
10 vitamins/minerals and sex, age, and BMI.
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **Conclusion**

26
27
28 Weight management at older ages, particularly in underweight and morbidly obese individuals, is
29 most important for lowering medical and pharmacy costs. Medical costs decreased, possibly
30 because of effective drug treatment and prevention. Pharmacy costs remained constant, possibly
31 because screening identified a need for certain medications. Greater use of medication among
32 women than men is primarily because of drugs involving birth control, osteoporosis, thyroid
33 disease, and urinary tract infection. Greater medication use in older age is primarily related to
34 medications used to treat gastrointestinal problems. Medication use was positively associated
35 with BMI for most of the conditions being treated, with exceptions involving birth control,
36 herpes, and osteoporosis. A J-shape relationship between BMI weight classification and
37 medication use for acne, antibiotic, cold/influenza/allergy, eye infection, edema, muscle spasms,
38 pain, and ulcers may be because of poorer nutrition in underweight individuals.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. 2016 Employer Health Benefits Survey. kff.org. <http://www.kff.org/health-costs/report/2016-employer-health-benefits-survey/>. Published September 14, 2016. Accessed February 21, 2018.
2. Chen L, Hannon PA, Laing SS, Kohn MJ, Clark K, Pritchard S, Harris JR. Perceived workplace health support is associated with employee productivity. *Am J Health Promot.* 2015;29(3):139-146.
3. Centers for Disease Control and Prevention. cdc.gov. <http://www.cdc.gov/sustainability/worksitewellness/> Worksite wellness. Updated December 9, 2014. Accessed March 18, 2018.
4. Michaels CN, Greene AM. Worksite wellness: increasing adoption of workplace health promotion programs. *Health Promot Pract.* 2013;14(4):473-479.
5. Witt LB, Olsen D, Ablah E. Motivating factors for small and midsized businesses to implement worksite health promotion. *Health Promot Pract.* 2013;14(6), 876-884.
6. Niessen MA, Kraaijenhagen RA, Dijkgraaf MG, van Pelt D, van Kalken CK, Peek N. Impact of a Web-based worksite health promotion program on absenteeism. *J Occup Environ Med.* 2012;54(4):404-408.
7. Kaspin LC, Gorman KM, Miller RM. Systematic review of employer-sponsored wellness strategies and their economic and health-related outcomes. *Popul Health Manag.* 2013;16(1): 14-21.
8. Metge C, Black C, Peterson S, Kozyrskyi AL. The population's use of pharmaceuticals. *Med Care.* 1999;37(6 Suppl):JS42-JS59.

- 1
2
3 9. Bertakis K, Azari R, Helms L, Callahan E, Robbins J. Gender differences in the utilization of
4 health care services. *J Fam Pract.* 2000;49(2):147-152.
5
6
- 7
8 10. Arterburn DE, Maciejewski ML, Tsevat J. Impact of morbid obesity on medical expenditures
9 in adults. *Int J Obes.* 2005;29(3):334-339.
10
11
- 12 11. Karmali KN, Lloyd-Jones DM, Berendsen M, et al. Drugs for primary prevention of
13 atherosclerotic cardiovascular disease: an overview of systematic reviews. *JAMA Cardiol.*
14 2016;1(3):341-349.
15
16
- 17 12. Fretheim A, Odgaard-Jensen, Brørs O, Madsen S, et al. Comparative effectiveness of
18 antihypertensive medication for primary prevention of cardiovascular disease: systematic
19 review and multiple treatments meta-analysis. *BMC Med.* 2012;10:33.
20
21
- 22 13. Taylor F, Huffman MD, Macedo A, et al. Statins for the primary prevention of
23 cardiovascular disease. *Cochrane.* 2013. [http://www.cochrane.org/CD004816/VASC_statins-](http://www.cochrane.org/CD004816/VASC_statins-primary-prevention-cardiovascular-disease)
24 primary-prevention-cardiovascular-disease. Accessed February 21, 2018.
25
26
- 27 14. Czeizel AE. Birth defects are preventable. *Int J Med Sci.* 2005;2(3):91-92.
28
29
- 30 15. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. *Gastroenterology.*
31 2010;138(6):2029-2043.
32
33
- 34 16. Asthma. Mayo Clinic. [https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-](https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-treatment/drc-20369660)
35 treatment/drc-20369660. Published March 9, 2018. Accessed February 24, 2018.
36
37
- 38 17. Arthritis. Mayo Clinic. [https://www.mayoclinic.org/diseases-conditions/arthritis/diagnosis-](https://www.mayoclinic.org/diseases-conditions/arthritis/diagnosis-treatment/drc-20350777)
39 treatment/drc-20350777. Published March 7, 2018. Accessed February 24, 2018.
40
41
- 42 18. Preventive Medicine Reports Paper
43
44
- 45 19. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic
46 consequences of obesity. *Arch Intern Med.* 1999;119(18):2177-2183.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
- 2
- 3 20. Pi-Sunyer X. The medical risks of obesity. *Postgrad Med.* 2009;121(6):21-33.
- 4
- 5 21. Kinge JM, Morris S. Association between obesity and prescribed medication use in England.
- 6
- 7 *Econ Hum Biol.* 2014;15:47-55.
- 8
- 9
- 10 22. Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison
- 11
- 12 with a randomly selected population sample and long-term changes after conventional and
- 13
- 14 surgical treatment: the SOS intervention study. *Arch Intern Med.* 2002;162(18):2061-2069.
- 15
- 16 23. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to
- 17
- 18 obesity: payer-and service-specific estimates. *Health Aff.* 2009;28(5):w822-31.
- 19
- 20 24. Randhawa AK, Parikh JS, Kuk JL. Trends in medication use by body mass index and age
- 21
- 22 between 1988 and 2012 in the United States. *PLoS One.* 2017 Sep 20;12(9):e0184089.
- 23
- 24 25. Kit BK, Ogden CL, Flegal KM. Prescription medication use among normal weight,
- 25
- 26 overweight, and obese adults, United States, 2005-2008. *Ann Epidemiol.* 2012;22(2):112-
- 27
- 28 119.
- 29
- 30 26. Jarrett B, Bloch GJ, Bennett D, Bleazard B, Hedges D. The influence of body mass
- 31
- 32 index, age and gender on current illness: a cross-sectional study. *Int J Obes.* 2010;34(3):429-
- 33
- 34 436.
- 35
- 36 27. Raebel MA, Malone DC, Conner DA, Xu S, Porter JA, Lanty FA. Health services use
- 37
- 38 and health care costs of obese and nonobese individuals. *Arch Intern*
- 39
- 40 *Med.* 2004;164(19):2135-2140.
- 41
- 42 28. Fuentes AV, Pineda MD, Venkata KCN. Comprehension of top 200 prescribed drugs in
- 43
- 44 the US as a resource for pharmacy teaching, training and practice. *Pharmacy (Basel).*
- 45
- 46 2018;6(2):E43.
- 47
- 48 29. Alswat KA. Gender disparities in osteoporosis. *Clin Med Res.* 2017;9(5): 382–387.
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 30. Li H, Li J. Thyroid disorders in women. *Minerva Med.* 2015;106(2):109-114.
4
5 31. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. *Diabetes Care.*
6
7 2012;35(12):2650-2664.
8
9 32. Traves KP, Studdiford JS, Pickle S, Tully AS. Edema: diagnosis and management. *Am Fam*
10
11 *Physician.* 2013;88(2):102-110.
12
13 33. Mc Donald Posso AJ, Motta Borrel JA, Fontes F, Cruz Gonzalez CE, Pachón Burgos
14
15 AA, Cumbreira Ortega A. High blood pressure in Panama: Prevalence, sociodemographic and
16
17 biologic profile, treatment, and control (STROBE). *Medicine (Baltimore).* 2014;93(22):
18
19 e101.
20
21 34. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in
22
23 older men and women. The Rancho Bernardo Study 1984-1994. *Circulation.* 1997;96(1):37-
24
25 43.
26
27 35. Gesing A. The thyroid gland and the process of aging. *Thyroid Res.* 2015;8(Suppl 1):A8.
28
29 36. A L D'Souza. Ageing and the gut. *Postgrad Med J.* 2007; 83(975):44–53.
30
31 37. Ma Y, Yang Y, Wang F, et al. Obesity and risk of colorectal cancer: a systematic review of
32
33 prospective studies. *PLoS One.* 2013;8(1):e53916.
34
35 38. Brown J, Wimpenny P, Maughan H. Skin problems in people with obesity. *Nurs Stand.*
36
37 2004;18(35):38-42.
38
39 39. Semins MJ, Shore AD, Makary MA, Weiner J, Matlaga BR. The impact
40
41 of obesity on urinary tract infection risk. *Urology.* 2012;79(2):266-269.
42
43 40. Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of
44
45 gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Study. First National Health and Nutrition Examination Survey. *Ann Epidemiol.*
4
5 1999;9(7):424-435.
6
7
8 41. Anggiansah R, Sweis R, Anggiansah A, Wong T, Cooper D, Fox M. The effects of obesity
9
10 on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux
11
12 disease. *Alim Pharmacol Ther.* 2013;37(5):555-563.
13
14
15 42. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Association between body
16
17 mass index and gastroesophageal reflux symptoms in both normal weight and overweight
18
19 women. *N Engl J Med.* 2006;354(22):2340-2348.
20
21
22 43. Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in
23
24 young adults: a birth cohort study. *Am J Gastroenterol* 2004;99(9):1807-1814.
25
26
27 44. Boylan MR, Khalili H, Huang ES, Chan AT. Measures of adiposity are associated with
28
29 increased risk of peptic ulcer. *Clin Gastroenterol Hepatol.* 2014 Oct;12(10):1688-1694.
30
31
32 45. Kim J, Kim KH, Lee BJ. Association of peptic ulcer disease with obesity, nutritional
33
34 components, and blood parameters in the Korean population. *PLoS One.* 2017;12(8):
35
36 e0183777.
37
38 46. Xu M, Liu L, Yuan B, Yin J, Lu Q. Association of obesity with *Helicobacter pylori* infection:
39
40 A retrospective study. *World J Gastroenterol* 2017;23(15):2750-2756.
41
42
43 47. Falagas ME, Kompoti M. Obesity and infection. *Lancet Infect Dis* 2006;6(7)438-446.
44
45
46 48. Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. *Int J Obes.*
47
48 2013;37:333-340.
49
50 49. Lübbecke A, Zingg M, Hoffmeyer P, et al. Body mass and weight thresholds for increased
51
52 prosthetic joint infection rates after primary total joint arthroplasty. *Acta Orthopaedica.*
53
54 2016;87(2):132-138
55
56
57
58
59
60

- 1
2
3 50. Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ. Antibiotic-induced
4 changes to the host metabolic environment inhibit drug efficacy and alter immune function.
5
6 Cell Host & Microbe. 2017;22(6):757-765.
7
8
9
- 10 51. Early G. Current Evidence regarding antibiotic exposure and childhood obesity: an
11 integrative review. *Ped Nurs*. 2017;43(4):169-174.
12
13
- 14 52. Bandaru P, Rajkumar H, Napanveettil G. The impact of obesity on immune response to
15 infection and vaccine: an insight into plausible mechanisms. *Endocrinol Metab Syndr*
16
17 2013;2:2.
18
19
- 20 53. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during
21 influenza seasons in Ontario, Canada: a cohort study. *Clin Infect Dis*. 2011;53(5):413-421.
22
23
- 24 54. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease.
25
26 *Mediators Inflamm*. 2010;2010:535918.
27
28
- 29 55. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent
30 advances in the relationship between obesity, inflammation, and insulin resistance. *Eur*
31
32 *Cytokine Netw*. 2006;17(1):4-12.
33
34
- 35 56. Ciprandi G, Pistorio A, Tosca M, Ferraro MR, Cirillo I. Body mass index, respiratory
36 function and bronchial hyperactivity in allergic rhinitis and asthma. *Respir Med*
37
38 2009;103(2):289-295.
39
40
- 41 57. Gorgievska-Sukarowska B, Lipozencić J, Susac A. Obesity and allergic diseases. *Acta*
42
43 *Dermatovenerol Croat*. 2008;16(4):231-235.
44
45
- 46 58. Shah R, Yang Y. Health and economic burden of obesity in elderly individuals with asthma
47
48 in the United States. *Popul Health Manag* 2015;18(3):186-191.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 59. Guo Y, Moon JY, Laurie CC, et al. Genetic Predisposition to Obesity is associated
4 with Asthma in US Hispanics/Latinos: Results from the Hispanic Community Health
5 Study/Study of Latinos. *Allergy*. 2018;doi: 10.1111/all.13450. [Epub ahead of print]
6
7
8
9
10 60. Rodriguez D. Obesity and Asthma – What’s the Connection.
11
12 <https://www.everydayhealth.com/asthma/obesity-connection.aspx>. Published August 28,
13 2013. Accessed April 12, 2018.
14
15
16
17 61. Greene, A.K., et al. Lower-Extremity Lymphedema and Elevated Body-Mass Index. *N Engl*
18 *J Med*. 2012;366:2136-2137.
19
20
21 62. Helyer, L.K., et al. Obesity is a risk factor for developing postoperative lymphedema in
22 breast cancer patients. *Breast J*. 2012;16(1):48-54.
23
24
25
26 63. Greene AK, Grant FD, Slavin SA, Maclellan RA. Obesity-induced lymphedema: clinical and
27 lymphoscintigraphic features. *Plast Reconstr Surg*. 2015;135(6):1715-1719.
28
29
30
31 64. King LK, March L, Anandacoomarasamy A. Obesity & osteoarthritis. *Indian J Med Res*.
32 2013;138(2):185-193.
33
34
35 65. Baodong Qin, Min Yang, Haitao Fu, et al. Body mass index and the risk of rheumatoid
36 arthritis: a systematic review and dose-response meta-analysis. *Arthritis Res Ther*.
37 2015;17(1):86.
38
39
40
41
42 66. Feng J, Chen Q, Yu F, et al. Body mass index and risk of rheumatoid arthritis: a meta-
43 analysis of observational studies. *Medicine*. 2016;95(8):e2859.
44
45
46
47 67. Albrecht K, Richter A, Callhoff J, et al. Body mass index distribution in rheumatoid arthritis:
48 a collaborative analysis from three large German rheumatoid arthritis databases. *Arthritis Res*
49 *Ther*. 2016;18:149.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 68. Rodriguez D. How Your Immune System Worsens Arthritis. EverydayHealth.com.
4
5 <https://www.everydayhealth.com/arthritis/understanding/the-immune-system.aspx>. Published
6
7 August 1, 2012. Accessed April 11, 2018.
8
9
- 10 69. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response
11
12 to influenza vaccination in humans. *Int J Obes*. 2012;36(8):1072-1077.
13
- 14 70. Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune
15
16 response to vaccination. *Vaccine*. 2015;33(36): 4422–4429.
17
18
- 19 71. Young KM, Gray CM, Bekker LG. Is Obesity a Risk Factor for Vaccine Non-
20
21 Responsiveness? *PLoS One*. 2013;8(12): e82779.
22
23
- 24 72. Okifuji A, Hare BD. The association between chronic pain and obesity. *J Pain Res*.
25
26 2015;8:399-408.
27
28
- 29 73. Erdmann J. Osteoarthritis and Obesity. www.arthritis.org. [https://www.arthritis.org/living-](https://www.arthritis.org/living-with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php)
30
31 [with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php](https://www.arthritis.org/living-with-arthritis/comorbidities/obesity-arthritis/osteoarthritis-and-obesity.php). Accessed April
32
33 11, 2018.
34
35
- 36 74. American Obesity Association. Health effects of obesity. AOA Fact Sheets. 2002.
37
38
- 39 75. Tashani OA, Asitita R, Sharp D, Johnson MI. Body mass index and distribution of body fat
40
41 can influence sensory detection and pain sensitivity. *Eur J Pain* 2017;21(7):1186-1196.
42
43
- 44 76. Rathee N. Obesity and depression: Are they related? *Indian J Health Well*. 2017;8(12):1472-
45
46 1475.
47
- 48 77. Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH. Depression and anxiety among
49
50 US adults: associations with body mass index. *Int J Obesity*. 2009;33(2):257-266.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 78. Onyike CU, Crum RM, Lee HB, Lyketsos DG, Eaton WW. Is obesity associated with major
4 depression? Results from the Third National Health and Nutrition Examination Survey. *Am J*
5
6 *Epidemiol.* 2003;158(12):1139-1147.
7
8
9
10 79. Petry NM, Barry D, Pietrzak RH, Wagner JA. Overweight and obesity are associated with
11
12 psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and
13
14 Related Conditions. *Psychosom Med.* 2008;70(3):288-297.
15
16
17 80. Pratt LA, Brody DJ. Depression and obesity in the U.S. adult household population, 2005-
18
19 2010. NCHS Data Brief, No. 167, October 2014.
20
21
22 81. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood
23
24 disorders and obesity related? A review for the mental health professional. *J Clin Psychiatry*
25
26 2004;65(5):634-651.
27
28
29 82. Ferraro KF, Su Y, Gretebeck RJ, Black DR, Badylak SF. Body mass index and disability in
30
31 adulthood: A 20-year panel study. *Am J Public Health.* 2002;92(5):834-840.
32
33
34 83. Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. *J*
35
36 *Psychosom Res.* 2002;53(4):859-863.
37
38
39 84. Baltaci D, Kutlucan A, Turker Y, et al. Association of vitamin B12 with obesity, overweight,
40
41 insulin resistance and metabolic syndrome, and body fat composition; primary care-based
42
43 study. *Med Glas.* 2013;10(2):203-210.
44
45
46 85. Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin D
47
48 deficiency: a systematic review and meta-analysis. *Obes Rev.* 2015;16(4):341-349.
49
50
51 86. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? *The*
52
53 *Lancet* 2003;361:2226-2234.
54
55
56
57
58
59
60

1
2
3 87. Merrill RM, Telford CT. Pharmaceutical use according to participation in worksite wellness
4 screening and health campaigns. *Prev Med Rep* 2018;12:158-163.
5
6
7

8 **Footnotes**

9

10
11 Contributors: RMM conceived and designed the epidemiological study, contributed to
12 acquisition of data, analyzed and interpreted the data, and drafted the manuscript. RPF
13 interpreted the data, provided a literature review, and revised the manuscript. Both authors
14 critically revised the manuscript for important intellectual content. The manuscript has been read
15 and approved by both authors.
16
17
18
19
20
21
22

23 Funding: The authors have not declared a specific grant for this research from any funding
24 agency in the public, commercial or not-for-profit sectors.
25
26
27

28 Competing interests: None declared.
29
30

31 Patient consent: Not required.
32
33

34 Ethics approval: Study approval was obtained from the institutional review board at Brigham
35 Young University (IRB E1 5259).
36
37
38

39 Provenance and peer review: Not commissioned; externally peer reviewed.
40
41

42 Data sharing statement: The data sets used and analyzed in the current study are available from
43 the corresponding author on reasonable request.
44
45
46

47 Patient and Public Involvement statement: Employee data consisted of sex, age, and BMI, which
48 was linked to medical and pharmacy claims data. No personal identifying information was
49 retained in the linked data set.
50
51
52
53
54
55
56
57
58
59
60

Table 1 Characterization of the study group according to sex, age, medical and pharmacy costs

	No.	%	Continuously Employed %	Chi-square p value	Risk Ratio	95% CI
Sex						
Men	797	26.36	84.69	0.3884	1.00	
Women	2226	73.64	83.38		0.98	0.95-1.02
Age Group						
18-39	770	25.47	82.21	< 0.0001	1.00	
40-49	806	26.66	89.45		1.09	1.05-1.13
50-59	1088	35.99	88.24		1.07	1.03-1.12
60-76	359	11.88	60.45		0.74	0.67-0.80
Medical Cost (USD)						
0-184	755	25.0	87.55	< 0.0001	1.00	
185-604	757	25.0	85.07		0.97	0.93-1.01
605-2049	755	25.0	84.64		0.97	0.93-1.01
2050-7191	454	15.0	79.30		0.91	0.86-0.96
7192+	302	10.0	75.17		0.86	0.80-0.92
Pharmacy Cost (USD)						
0-6	759	25.0	86.92	< 0.0001	1.00	
7-194	755	25.0	85.21		0.99	0.69-1.03
195-903	755	25.0	82.59		0.96	0.92-1.00
904-2303	452	15.0	84.14		0.99	0.94-1.04
2304+	302	10.0	74.92		0.86	0.80-0.93

Sex, age, medical and pharmacy costs apply to the 2010-11 academic year.

Table 2 Medical and pharmacy costs according to sex, age, year, and body mass index

	BMI (kg/m ²)			Medical Cost (USD)			Median	Median one-way analysis	Pharmacy Cost (USD)			Median	Median one-way analysis
	Mean	SD	SNK	Mean	SD	SNK		p value	Mean	SD	SNK		p value
Sex													
Men	29.35	5.80	A	2869	10581	A	373	< 0.0001	725	2324	A	53	< 0.0001
Women	27.26	6.47	B	3447	12049	A	741		963	3550	B	238	
Age Group													
18-39	27.17	6.06	A	2236	9344	A	389	< 0.0001	660	3342	A	70	< 0.0001
40-49	27.76	6.42	B	3052	12366	B	503		750	2806	A	106	
50-59	28.05	6.55	B	3935	12579	B	845		1021	3288	B	261	
60-76	28.17	6.13	B	3749	10831	B	989		1288	3990	C	344	
Year													
2010-11	27.89	6.40	A	3188	10524	A	605	0.2313	830	2247	A	195	0.0016
2011-12	27.79	6.31	A	3621	12816	A	610		953	3180	A	189	
2012-13	27.87	6.59	A	3208	11836	A	670		934	3571	A	173	
2013-14	27.63	6.16	A	3191	11557	A	651		894	3913	A	141	
BMI (kg/m ²)													
Underweight				2191	1190	A	647	0.0003	1454	6706	A	224	0.0004
Normal weight				2826	333	A	650		779	3285	B	167	
Overweight				3174	514	A	603		926	3085	A, B	169	
Obese				3544	459	A	665		1031	3458	A, B	228	
Morbidly obese				6911	2092	B	1033		853	1493	A, B	242	

SNK: Student-Newman-Keuls Test. Different letters in the SNK columns indicate significant difference among the levels of the variables at the 0.05 level.

Table 3 Risk of medical and pharmacy costs (USD) above the 50th, 75th, and 90th percentiles according to BMI weight classification, sex, and age

	Medical						Pharmacy					
	50 th percentile Above vs. below		75 th percentile Above vs. below		90 th percentile Above vs. below		50 th percentile Above vs. below		75 th percentile Above vs. below		90 th percentile Above vs. below	
	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI	Risk Ratio	95% CI
Sex												
Men	1.00		1.00		1.00		1.00		1.00		1.00	
Women	1.43	1.36-1.51	1.47	1.35-1.60	1.42	1.24-1.64	1.58	1.50-1.66	1.59	1.46-1.74	1.14	1.00-1.29
Age Groups												
18-39	1.00		1.00		1.00		1.00		1.00		1.00	
40-49	1.16	1.08-1.23	1.15	1.03-1.29	1.08	0.90-1.28	1.14	1.07-1.22	1.45	1.29-1.64	1.72	1.37-2.15
50-59	1.50	1.42-1.59	1.65	1.50-1.82	1.36	1.16-1.58	1.48	1.39-1.56	2.28	2.05-2.55	2.82	2.30-3.46
60+	1.61	1.52-1.72	1.83	1.64-2.04	1.33	1.11-1.60	1.57	1.48-1.68	2.57	2.29-2.89	3.78	3.06-4.68
BMI (kg/m ²)												
Underweight	1.05	0.88-1.26	0.91	0.64-1.31	0.61	0.28-1.35	2.05	1.25-3.34	1.05	0.74-1.48	2.05	1.25-3.34
Normal weight	1.00		1.00		1.00		1.00		1.00		1.00	
Overweight	0.95	0.90-1.00	0.95	0.86-1.05	1.01	0.85-1.20	1.01	0.95-1.06	1.18	1.07-1.30	1.68	1.41-2.00
Obese	1.00	0.95-1.06	1.14	1.03-1.25	1.21	1.01-1.43	1.11	1.05-1.17	1.19	1.08-1.31	1.76	1.47-2.12
Morbidly obese	1.18	1.08-1.29	1.62	1.40-1.87	2.18	1.72-2.77	1.13	1.03-1.25	1.30	1.09-1.55	1.93	1.43-2.61

Shaded cells represent statistical significance at the 0.05 level.

Table 4 Medication use according to sex, age, and BMI weight classification

		Sex		Age Group				Body Mass Index (kg/m ²)				
		Men	Women	18-39	40-49	50-59	60+	Underweight	Normal weight	Over weight	Obese	Morbidly obese
Medication	%											
Acid Reflux	5.75	5.56	5.81	3.02	4.54	7.14	8.36	3.57	4.34	5.36	7.19	9.14
Risk ratio		1.00	1.04	1.00	1.50	2.36	2.77	0.82	1.00	1.24	1.66	2.11
AF _p (%)		0.00	0.26	0.00	2.81	7.27	9.23		0.00	1.33	3.64	5.98
Acne	7.17	3.15	8.62	7.15	7.03	7.16	7.40	9.82	8.81	6.64	6.34	6.18
Risk ratio		1.00	2.74	1.00	0.98	1.00	1.03	1.11	1.00	0.75	0.72	0.70
AF _p (%)		0.00	11.07	0.00	0.01	0.25	0.25	0.82	0.00			
Antibiotic	21.21	17.81	22.44	18.72	20.76	22.76	21.93	25.89	20.54	20.74	23.73	21.24
Risk ratio		1.00	1.26	1.00	1.11	1.22	1.17	1.26	1.00	1.01	1.16	1.03
AF _p (%)		0.00	5.23	0.00	2.26	4.38	3.51	5.24	0.00	0.21	3.19	0.72
Anticonvulsants	1.49	1.39	1.53	1.84	1.32	1.45	1.40	2.68	1.25	1.13	1.65	1.61
Risk ratio		1.00	1.10	1.00	0.72	0.79	0.76	2.14	1.00	0.90	1.32	1.29
AF _p (%)		0.00	0.15	0.00				1.68	0.00		0.47	0.43
Antifungal	5.29	2.61	5.81	5.64	6.03	4.24	3.87	5.36	5.83	3.81	6.24	6.18
Risk ratio		1.00	2.23	1.00	1.07	0.75	0.69	0.92	1.00	0.65	1.07	1.06
AF _p (%)		0.00	6.09	0.00	0.36				0.00		0.37	0.32
Anxiety	7.88	6.31	8.45	6.42	7.80	8.36	8.97	8.93	7.22	7.11	7.29	6.45
Risk ratio		1.00	1.34	1.00	1.21	1.30	1.40	1.24	1.00	0.98	1.01	0.89
AF _p (%)		0.00	2.60	0.00	1.67	2.33	3.03	1.83	0.00		0.08	
Arthritis	11.06	11.13	11.03	7.72	10.53	12.83	12.56	7.14	9.36	10.72	13.84	14.78
Risk ratio		1.00	0.99	1.00	1.36	1.66	1.63	0.76	1.00	1.15	1.48	1.58
AF _p (%)		0.00		0.00	3.87	6.82	6.48		0.00	1.58	5.03	6.02
Asthma	8.61	7.19	9.13	7.48	8.80	8.00	11.22	6.25	6.24	8.74	10.39	10.75

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Risk ratio		1.00	1.27	1.00	1.18	1.07	1.50	1.00	1.00	1.40	1.67	1.72
AF _p (%)		0.00	2.27	0.00	1.50	0.59	4.13	0.01	0.00	3.33	5.42	5.86
Birth Control	8.71	0.24	10.88	21.13	8.77	2.59	0.95	10.71	11.69	7.30	6.34	6.99
Risk ratio		1.00	45.33	1.00	0.42	0.12	0.04	0.92	1.00	0.62	0.54	0.60
AF _p (%)		0.00	79.43	0.00					0.00			
Blood Thinner	1.26	1.85	1.05	3.91	18.75	45.31	32.03	0.95	0.52	1.15	2.08	5.22
Risk ratio		1.00	0.57	1.00	4.80	11.59	8.19	1.83	1.00	2.21	4.00	10.04
AF _p (%)		0.00		0	4.56	11.77	8.31	1.03	0	1.50	3.64	10.22
Bowel/Rectum	3.06	2.75	3.17	1.76	2.84	3.53	4.15	1.79	3.15	2.87	2.85	2.96
Risk ratio		1.00	1.15	1.00	1.61	2.01	2.36	0.57	1.00	0.91	0.90	0.94
AF _p (%)		0.00	0.47	0.00	1.84	2.99	3.99		0.00			
Cold/Influenza/Allergy	17.80	14.52	18.99	15.73	18.30	18.14	19.07	22.32	15.53	18.56	20.38	22.04
Risk ratio		1.00	1.31	1.00	1.16	1.15	1.21	1.44	1.00	1.20	1.31	1.42
AF _p (%)		0.00	5.20	0.00	2.83	2.65	3.64	7.22	0.00	3.36	5.27	6.94
Depression	18.24	10.28	21.14	12.51	19.30	20.75	18.84	15.18	16.20	17.59	20.83	18.55
Risk ratio		1.00	2.06	1.00	1.54	1.66	1.51	0.94	1.00	1.09	1.29	1.15
AF _p (%)		0.00	16.16	0.00	9.01	10.73	8.45		0.00	1.54	4.95	2.58
Diabetes	6.32	6.48	6.22	2.53	4.50	7.82	10.94	1.79	2.24	5.67	11.29	17.74
Risk ratio		1.00	0.96	1.00	1.78	3.09	4.32	0.80	1.00	2.53	5.04	7.92
AF _p (%)		0.00		0.00	4.69	11.67	17.36		0.00	8.82	20.34	30.43
Edema	5.14	3.12	5.87	2.04	3.64	6.48	8.86	6.25	3.08	4.66	7.29	12.90
Risk ratio		1.00	1.88	1.00	1.78	3.18	4.34	2.03	1.00	1.51	2.37	4.19
AF _p (%)		0.00	4.33	0.00	3.88	10.06	14.66	5.02	0.00	2.57	6.56	14.08
Eye Infection	12.01	9.23	12.87	11.44	13.06	11.13	12.34	14.29	11.02	12.12	13.64	9.68
Risk ratio		1.00	1.39	1.00	1.14	0.97	1.08	1.30	1.00	1.10	1.24	0.88
AF _p (%)		0.00	4.52	0.00	1.67		0.94	3.44	0.00	1.18	2.78	
Herpes	6.30	3.26	6.86	4.82	7.24	6.12	4.71	1.79	7.66	7.22	4.20	1.88
Risk ratio		1.00	2.10	1.00	1.50	1.27	0.98	0.23	1.00	0.94	0.55	0.25
AF _p (%)		0.00	6.50	0.00	3.07	1.67			0.00			
High Blood Pressure	16.49	19.95	15.60	4.58	11.05	22.78	29.39	6.25	8.54	17.44	24.68	31.99
Risk ratio		1.00	0.78	1.00	2.41	4.97	6.42	0.73	1.00	2.04	2.89	3.75
AF _p (%)		0.00		0.00	18.89	39.59	47.18		0.00	14.66	23.76	31.17

Inflammation	1.19	0.68	1.37	0.69	0.87	1.50	1.68	1.79	0.98	1.40	0.80	1.61
Risk ratio		1.00	2.01	1.00	1.26	2.17	2.43	1.83	1.00	1.43	0.82	1.64
AF _p (%)		0.00	1.19	0.00	0.31	1.38	1.68	0.97	0.00	0.51		0.76
Insomnia	4.23	2.24	4.95	2.70	3.60	5.72	4.04	8.93	4.07	3.92	3.85	4.84
Risk ratio		1.00	2.21	1.00	1.33	2.12	1.50	2.19	1.00	0.96	0.95	1.19
AF _p (%)		0.00	4.87	0.00	1.39	4.52	2.06	4.81	0.00			0.79
Muscle Spasms	4.34	3.53	4.64	3.11	4.57	4.93	4.37	5.36	3.29	4.27	5.44	6.99
Risk ratio		1.00	1.31	1.00	1.47	1.59	1.41	1.63	1.00	1.30	1.65	2.12
AF _p (%)		0.00	1.35	0.00	2.00	2.48	1.73	2.66	0.00	1.28	2.76	4.65
Nausea/Vomiting	5.01	3.77	5.47	5.44	4.85	4.83	5.10	4.46	4.14	4.50	6.19	5.65
Risk ratio		1.00	1.45	1.00	0.89	0.89	0.94	1.08	1.00	1.09	1.50	1.36
AF _p (%)		0.00	2.21	0.00				0.39	0.00	0.43	2.42	1.79
Opioids	17.04	15.98	17.42	14.14	16.29	18.62	18.73	17.86	13.39	15.77	20.28	27.69
Risk ratio		1.00	1.09	1.00	1.15	1.32	1.32	1.33	1.00	1.18	1.51	2.07
AF _p (%)		0.00	1.51	0.00	2.53	5.12	5.24	5.38	0.00	2.94	8.06	15.40
Osteoporosis	1.21	0.07	1.63	0.00	0.17	1.30	4.37	0.89	1.56	1.20	0.85	0.00
Risk ratio		1.00	23.29	1.00				0.57	1.00	0.77	0.54	0.00
AF _p (%)		0.00	21.24	0.00					0.00			
Pain – non opioid	2.19	1.63	2.39	2.78	2.15	1.98	1.91	3.57	1.73	1.67	2.55	2.96
Risk ratio		1.00	1.47	1.00	0.77	0.71	0.69	2.06	1.00	0.97	1.47	1.71
AF _p (%)		0.00	1.01	0.00				2.28	0.00		1.03	1.53
Skin	6.84	4.88	7.55	5.44	6.44	7.37	8.24	6.25	7.25	6.41	7.19	5.38
Risk ratio		1.00	1.55	1.00	1.18	1.35	1.51	0.86	1.00	0.88	0.99	0.74
AF _p (%)		0.00	3.61	0.00	1.24	2.37	3.40		0.00			
Statins	14.49	17.93	13.24	2.31	8.53	20.58	28.4	3.81	7.02	17.95	19.89	27.47
Risk ratio		1.00	0.74	1.00	3.69	8.91	12.29	0.54	1.00	2.56	2.83	3.91
AF _p (%)		0.00		0.00	28.07	53.40	62.07		0.00	18.41	20.99	29.68
Stomach Acid	1.19	1.49	1.07	0.86	1.25	0.99	1.96	0.89	0.81	1.01	1.90	1.08
Risk ratio		1.00	0.72	1.00	1.45	1.15	2.28	1.10	1.00	1.25	2.35	1.33
AF _p (%)		0.00		0.00	0.54	0.18	1.50	0.12	0.00	0.29	1.58	0.40
Teeth/Gums	0.43	0.37	0.46	0.37	0.35	0.43	0.67	0.00	0.27	0.43	0.35	0.27
Risk ratio		1.00	1.24	1.00	0.95	1.16	1.81	0.00	1.00	1.59	1.30	1.00

AF _p (%)		0.00	0.10	0.00		0.07	0.35		0.00	0.25	0.13	0.00
Thyroid	12.76	2.99	16.31	4.37	11.19	16.92	17.61	6.25	13.97	12.74	13.94	19.09
Risk ratio		1.00	5.45	1.00	2.56	3.87	4.03	0.45	1.00	0.91	1.00	1.37
AF _p (%)		0.00	36.24	0.00	16.61	26.82	27.88		0.00			4.47
Ulcers	9.38	8.55	9.69	8.30	8.28	10.19	10.88	10.71	7.59	9.90	10.99	15.32
Risk ratio		1.00	1.13	1.00	1.00	1.23	1.31	1.41	1.00	1.30	1.45	2.02
AF _p (%)		0.00	1.24	0.00		2.09	2.83	3.71	0.00	2.78	4.03	8.72
Urinary Tract Infection	3.01	0.20	4.44	3.39	3.08	3.45	3.25	6.25	3.83	2.83	3.50	3.76
Risk ratio		1.00	22.20	1.00	0.91	1.02	0.96	1.63	1.00	0.74	0.91	0.98
AF _p (%)		0.00	38.95	0.00		0.05		1.87	0.00			
Vitamins/Minerals	2.07	0.71	2.57	2.49	1.73	1.88	2.47	0.00	2.07	1.28	1.75	5.38
Risk ratio		1.00	3.62	1.00	0.69	0.76	0.99	0.00	1.00	0.62	0.85	2.60
AF _p (%)		0.00	5.14	0.00					0.00			3.20
All prescriptions	80.87	71.40	84.32	71.52	78.45	85.24	88.00	83.93	81.46	81.28	83.47	86.29
Risk ratio		1.00	1.18	1.00	1.10	1.19	1.23	1.03	1.00	1.00	1.02	1.06
AF _p (%)		0.00	12.77	0.00	7.27	13.43	15.71	2.39	0.00		1.96	4.58


AF_p: Attributable fraction in the population. Shaded cells represent statistical significance at the 0.05 level. Cells that are left blank had a negative AF_p. In these cases the preventive fraction ($[\text{Risk Ratio} - 1] \times 100$) is more appropriate.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Figure 1. Median medical and pharmacy cost (USD) according to Body Mass Index weight classifications and age

For peer review only



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page/line numbers
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1/6, 2/25
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Done
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Done
Objectives	3	State specific objectives, including any prespecified hypotheses	Done
Methods			
Study design	4	Present key elements of study design early in the paper	Done
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Done
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Done
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Done
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Done
Bias	9	Describe any efforts to address potential sources of bias	Done
Study size	10	Explain how the study size was arrived at	Done
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Done
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Done
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Done
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Done
		(b) Indicate number of participants with missing data for each variable of interest	Done
		(c) Summarise follow-up time (eg, average and total amount)	Done
Outcome data	15*	Report numbers of outcome events or summary measures over time	Done
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear	Done

		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Done
Discussion			
Key results	18	Summarise key results with reference to study objectives	Done
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Done
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done
Generalisability	21	Discuss the generalisability (external validity) of the study results	Done
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Done

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.